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ABSTRACT 
 
Absorption of gases into a liquid is of crucial importance to multiphase reactions because 
diffusion of a sparingly soluble gas across a gas-liquid interface generally limits the 
relevant reaction rates.  Pertinent examples of multiphase reactions that have found 
application in the chemical and biochemical industries include fermentation, water 
treatment, and hydrogenation reactions.  Gas-liquid mass transfer is of particular 
importance in fermentation because productivity increases in aerobic cultures are often 
constrained by transport of oxygen, which is only slightly soluble in water.  Previous 
approaches to enhance oxygen transfer consisted in adding emulsified organic phases in 
which oxygen has a greater solubility.  However, these approaches have several 
limitations, the most important of which is the difficult recovery of the organic phase 
after the fermentation.   
 
The research presented in this thesis focuses on the use of functionalized magnetic 
nanoparticles to enhance gas-liquid oxygen transfer.  The nanoparticles have a magnetic 
core and an organic coating.  The magnetic core makes it possible to easily recover the 
fluid by passing it through a magnetic field, and the coating confers colloidal stability to 
the particle. 
 
Oxygen transfer enhancement has been observed in the presence of nanoparticles coated 
with oleic acid and a polymerizable surfactant.  In cell-free media, nanoparticles improve 
gas-liquid oxygen mass transfer up to 6-fold (600%) in an agitated, sparged reactor.  
Furthermore, they show remarkable stability in high-ionic strength media over a wide pH 
range.  In a fermentation of Escherichia coli, a nanoparticle weight fraction of 0.6% 
increases oxygen uptake rate and cell growth by 40%.  
 
Through a combination of experiments using both physical and chemical methods to 
characterize mass transfer, it has been shown that both the mass transfer coefficient (kL) 
and the gas-liquid interfacial area are enhanced in the presence of nanoparticles, the latter 
accounting for a larger fraction of the total enhancement.  This insight has been used to 
propose a model of the enhancement that involves two separate mechanisms: one of area 
enhancement and the other of kL enhancement.  It has been proposed that (i) the 
nanoparticles increase interfacial area by adsorbing on the gas bubble interface and 
stabilizing it against coalescence and (ii) the nanoparticles increase the mass transfer 
coefficient by causing microconvection in the surrounding fluid through Brownian 
motion. 
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The methodology developed in this thesis shows several-fold gas-liquid mass transfer 
enhancements and at the same time allows for easier separation over previous 
approaches.  In addition, the modeling effort resulted in correlations that can allow for 
extension of this methodology from laboratory-scale to industrial scale reactions across 
the variable space considered 
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1 INTRODUCTION 
1.1 Motivation 
Maintaining an adequate oxygen supply to aerobic cell cultures has been a long-standing 
problem in fermentation technology.  This problem is particularly amplified in high cell 
density cultures and in large scale operations, in which insufficient oxygen transfer rates 
limit cell growth and ultimately process productivity.   
Oxygen has a much lower solubility in water than most common nutrients used in 
fermentation media formulation.  For instance, while sugars can be dissolved to 
concentrations greater than 500 g/L in water, the solubility of oxygen at ambient 
conditions is less than 10 mg/L.  This amount can be consumed in several seconds by a 
dense microbial broth and therefore a constant gas supply is necessary.  Cells can grow at 
a maximum rate as long as the oxygen supply is sufficient, but when it becomes limiting, 
cell growth is reduced.   
Many approaches have been tried to alleviate oxygen transfer limitations.  In the past, 
research has focused on (i) influencing process conditions by designing more efficient 
agitation and aeration systems or by enriching air with pure oxygen, (ii) modifying the 
physical properties of the medium by adding organic compounds capable of solubilizing 
oxygen more effectively than water (iii) generating oxygen in situ with a chemical 
reaction, and (iv) introducing genetic modifications in the cells to alter oxygen 
metabolism.  The application of most of these remedies has drawbacks and at best, the 
proposed solutions alleviate, but do not eliminate mass transfer limitations altogether.  
An incremental enhancement in oxygen transfer rates allows for an extended period of 
exponential cell growth but, at sufficiently high cell densities, limitations reappear.  
Therefore, research in new approaches to enhance oxygen mass transfer is necessary.   
This thesis investigates the potential for using functionalized solutions of magnetic 
nanoparticles for enhancing oxygen transfer.  These fluids consist of colloidal aqueous 
solutions of nanoparticles formed by a core of magnetite to which one or more layers of 
paraffin and polymer can be attached.  This technology shows potential for significant 
mass transfer enhancement while addressing the limitations of former approaches based 
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on the addition of an organic phase to aqueous media.  In particular it allows for the 
recovery of the dispersed phase after use.   
1.2 Specific Aims and Method of Approach 
The overall goal of this thesis is to establish the feasibility of using magnetic 
nanoparticles as a means to enhance solute mass transfer between a gas phase and a 
liquid phase, with particular emphasis on the application of oxygen transfer in 
fermentation.  In addition, this study will attempt to provide a theoretical explanation of 
the physical mechanism of enhancement. 
The specific aims and proposed method of approach are: 
1.  To characterize the capability for oxygen transfer enhancement of hydrocarbon-coated 
magnetic nanoparticles in cell-free systems: experiments are performed by two well-
defined methods for the study of mass transfer between a gas phase and a liquid phase.  
These are (i) a physical method: oxygen is absorbed across the free liquid surface of a 
stirred beaker exposed to air, and (ii) a chemical method: oxygen is absorbed into a 
sodium sulfite solution and reacts with the sulfite ions; this reaction mimics oxygen 
consumption by cells, and is carried out in a laboratory scale bioreactor.  Experiments in 
this model system have the advantage of allowing an accurate measurement of oxygen 
transfer rates while being less labor-intensive than a fermentation.   
2.  To establish the potential for oxygen transfer enhancement of nanoparticles in 
fermentation media: first, the biocompatibility of a typical Escherichia coli strain with 
nanoparticle solutions is verified through shake flask experiments; second, fermentations 
at a 5.5 L scale under an oxygen limited regime are run and oxygen transfer rates and dry 
cell weight are measured.  This establishes the mass transfer enhancement and its 
connection with increased cell growth. 
3.  To identify and model the physical mechanism of oxygen transfer enhancement: since 
enhancement can be caused by an increase in interfacial gas-liquid area and by an 
increase in the oxygen flux, experiments are designed to discriminate between these two 
phenomena.  Subsequently, attention is given to conceivable mechanisms of flux and area 
enhancement and an enhancement model is proposed. 
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1.3 Overview 
This thesis is organized in six chapters; Chapter 2 reviews the literature on several topics 
relevant to the thesis, including fermentation technology, gas-liquid mass transfer, 
magnetic fluids, and nanoparticles as a means of improving transfer properties of 
solutions, therefore providing the basis for the discussion to follow.  Chapter 3 describes 
in detail the chemical synthesis and characterization of nanoparticles and the 
experimental methods used to quantify mass transfer in cell-free model systems and in 
fermentation.  Chapter 4 presents experimental results of enhanced mass transfer rates 
obtained in cell-free systems and in fermentation.  In Chapter 5, a mechanism of 
interfacial area enhancement and a mechanism of mass transfer coefficient enhancement 
are presented.  The main contributions of the thesis are summarized in Chapter 6. 
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2 LITERATURE REVIEW 
This thesis studies the application of colloidal magnetic nanoparticles to a classic 
problem in fermentation technology, namely oxygen mass transfer.  As many of the 
emerging applications at the interface of nanotechnology and biotechnology, this work 
exploits the unique properties of materials with particle size in the range of 1 to 100 nm.  
These include, but are not restricted to, very large surface area and interactions at length 
scales where wave phenomena and structural phenomena have similar features  
(Roco, 1999).  Therefore this is a multidisciplinary problem.  In order to put this thesis in 
context it is necessary to discuss a number of subjects ranging from classical mass 
transfer studies of gas-liquid absorption, hydrodynamics, and fermentation technology 
fundamentals to emerging disciplines that have developed due to a renewed interest in 
colloidal science fueled by recent advances in organometallic chemistry. 
In the framework of this thesis, nanotechnology provides a tool to manipulate gas-liquid 
mass transfer.  While this technological concept can have repercussions in virtually any 
process limited by mass transfer of a solute between a gas phase and a liquid phase, 
ranging from waste treatment to blood oxygenation and hydrogenation reactions, special 
emphasis is given only to its application to oxygen mass transfer in fermentation.  Use of 
nanoparticles with the purpose of modifying the transport properties of a medium is an 
uncommon concept in the mainstream of research at the interface of biotechnology and 
nanotechnology, since most current applications are concerned with exploiting 
nanoparticles as investigative tools to probe ever smaller scales in biological systems and 
as drug delivery vehicles.  However, nanoparticles have been used for over a decade to 
increase heat transfer properties of solutions.  The term nanofluid (Choi, 1995) has been 
coined to describe a new kind of fluids used in a wide range of heat transfer applications.  
This thesis presents original work on the application of nanoparticles to oxygen mass 
transfer enhancement. 
2.1 Fermentation Technology 
Fermentation is defined as the anaerobic metabolism of a molecule into simpler 
molecules.  However, the term is commonly used in microbiology to refer to the making 
of a product by growth, either aerobic or anaerobic, of a microorganism.  This product 
can be the microorganism itself, a metabolite naturally generated by the microorganism, 
      18 
or a foreign product that the microorganism is designed to produce through genetic 
engineering techniques. 
Fermentation products such as cheese, wine, and beer have been produced for many 
centuries, but it is generally considered that fermentation technology in its modern form 
starts with the pioneering studies of conversion of sugar to alcohol by Louis Pasteur in 
the 19th century.  In the 1940s, a process to produce penicillin by aerobic cell culture 
became an extraordinary commercial success.  Spurred by this achievement, the 
bioprocess industry grew rapidly.  Today, many fine chemicals (antibiotics, vitamins, 
enzymes, monoclonal antibodies) and bulk chemicals (organic acids, amino acids) are 
produced by fermentation processes, and the advent of recombinant DNA technology has 
opened the door to the development of many new products. 
2.1.1 A Note on Fermentation Economics 
Fermentation processes can be broadly classified into fermentation cost-intensive or 
recovery cost-intensive, depending on whether most of the operating cost corresponds to 
the fermentation step or to the downstream processing steps (Bartholomew et al., 1979).  
Although many factors influence whether a given process falls into one of these 
categories, generally large-scale production of bulk chemicals is fermentation cost-
intensive while production of fine chemicals such as therapeutics is recovery cost-
intensive.   
Better oxygen transfer permits to achieve higher cell densities in oxygen-transfer limited 
processes, reduces fermentation cycle time, and increases the titer of the product.  
Therefore, as a technology aimed at increasing oxygen mass transfer, use of magnetic 
nanoparticles can have a larger impact when applied to a fermentation cost-intensive 
process.  Specifically, large scale and high-cell density fermentations are the best 
candidates for its application because they are the most severely limited by oxygen 
transfer.   
Integration of fermentation and purification steps is also a critical aspect in bioprocess 
economics.  While an increased titer of the fermentation product generally reduces the 
costs of the downstream processing steps, the profits can be offset when this comes at the 
expense of complicating the medium by adding chemicals that will be difficult to 
      19 
recover.  This is not the case for magnetic nanoparticles.  High-Gradient Magnetic 
Separation (HGMS) can be used to capture nanoparticles larger than 50 nm with an 
efficiency above 99.9% at high flow rates (Moeser et al., 2004; Ditsch et al., 2005b).  
Furthermore, magnetic nanoparticles can be used as a replacement for traditional column 
chromatography for recovery and purification of proteins (Ditsch et al., 2004).  This 
potentially allows integration of fermentation and separation steps in a bioprocess.   
2.1.2 Relevance of Oxygen Transfer 
At high cell densities it becomes very difficult to maintain dissolved oxygen at a level 
that allows cells to grow at their maximum rate.  When oxygen supply becomes limiting, 
cell viability and product formation decline; furthermore, cells start producing acetate 
and lactate, which inhibit cell growth.  Therefore, it is highly desirable to maintain a 
growing culture under conditions in which oxygen limitations do not exist.  If the rate of 
oxygen transfer to a culture is higher than the metabolic oxygen demand and no other 
nutrients are limiting the growth, cells can grow at their maximum rate.  Under these 
conditions, the metabolic oxygen consumption of a culture can be expressed as:  
X
Y
µOUR
2X/O
=           (1) 
Where OUR is the oxygen uptake rate, µ is the growth rate of the organism, YX/O2 is a 
stoichiometric coefficient that represents the yield of biomass on oxygen, and X is the 
concentration of biomass.  At the onset of a fermentation process, dissolved oxygen 
concentrations are typically high and cells can consume oxygen at a rate given by Eq. 1.  
If no control actions are taken to maintain high dissolved oxygen concentrations, as 
fermentation proceeds the oxygen levels fall to approximately zero.  At some point 
during the fermentation, the biological demand of the culture exceeds the oxygen mass 
transfer rate and the culture enters an oxygen-limited regime in which the growth rate can 
no longer be exponential; instead, the growth slows down and becomes linear.  Under 
these conditions, the amount of oxygen that the cells consume is expressed as 
( )bulk*L CCakOUR −=         (2) 
Where kLa is a volumetric mass transfer coefficient, which is the product of a gas-liquid 
mass transfer coefficient and a specific interfacial area between the gas phase and the 
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liquid phase; C* is the oxygen concentration at the interface and Cbulk is the oxygen 
concentration in the bulk of the liquid.   
2.1.3 Strategies for Oxygen Transfer Enhancement 
Numerous approaches have been tried to improve oxygen mass transfer between gas 
bubbles and the liquid phase.  Inspection of Eq. 2 shows that oxygen uptake rates can be 
modified by altering the mass transfer coefficient, the specific interfacial area, or the 
concentration driving force.  Classical engineering approaches have focused on 
modifying these three quantities.  Alternative approaches involving generation of oxygen 
by a reaction or genetic engineering of the host have also been explored. 
2.1.3.1 Increasing Agitation Rate and Aeration Rate  
Many investigations have studied the effect of agitation and aeration on oxygen transfer 
and as a result, numerous empirical formulations have been proposed.  Increasing the 
agitation rate has an effect on both the specific interfacial area – it increases it by 
breaking up bubbles – and the mass transfer coefficient – it reduces the thickness of the 
liquid boundary layer around a gas bubble (Section 2.2.2).  In large scale fermentations, 
energy costs from power consumption are a major contributor to operating costs, and 
therefore, agitation rates cannot be maintained arbitrarily higher.  Additionally, higher 
agitation rates are not an option in shear-sensitive organisms.  Increasing the aeration rate 
enhances the interfacial area but the rate must be maintained below the flooding limit of 
the fermentor.  In addition, various impeller types and fermentor geometric 
configurations have been suggested to optimize oxygen mass transfer (Hu et al., 1986; 
Junker et al., 1998).   
2.1.3.2 Increasing Oxygen Partial Pressure 
Increasing the partial pressure of oxygen increases the driving force for mass transfer 
This can be done by pressurizing the headspace of the bioreactor (Bauer et al., 1974).  
Pressures of up to 3 bars can be used in conventional fermentors without need for 
mechanical modifications (Yang et al., 1992), and therefore, 3-fold enhancements in 
OUR can be obtained.  The driving force can also be increased by using pure oxygen or 
air enriched with oxygen (Flickinger et al., 1977b, 1977a; Yamada et al., 1978; 
Flickinger et al., 1979); a maximum 5-fold enhancement can be obtained if pure oxygen 
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is used since the partial pressure of oxygen is 1 atm rather than 0.21 atm in air.  Both 
approaches have several limitations; gas costs become significant when sparging with 
oxygen-enriched gas mixtures, pure oxygen is explosive and poses a safety concern, 
increased pressure of the carbon dioxide generated by cells is detrimental to cell growth, 
and recently it has been found that elevated oxygen pressure or rapid increases in oxygen 
levels cause oxidative stress in some organisms.  Some of the mechanisms causing 
oxidative stress have been reviewed (Konz et al., 1998).   
2.1.3.3 Increasing Interfacial Area 
Interfacial area can be increased by reducing the average gas bubble size.  Micro-bubble 
dispersions (Kaster et al., 1990; Bredwell et al., 1998; Weber et al., 2005; Zhang et al., 
2005), also referred to as colloidal gas aphrons (Srivastava et al., 2000), are dispersions 
of small gas bubbles stabilized with a surfactant film that prevents bubble coalescence.  
Despite a reduction in the mass transfer coefficient (kL) caused by the surfactants, smaller 
bubble sizes have orders-of-magnitude larger interfacial area and an extended residence 
time in the fermentor.  Although the application of micro-bubble dispersions is attractive 
given the large increases in kLa that can be obtained (3 to 6-fold enhancements have been 
reported), no serious consideration has been given to their recovery from the 
fermentation broth. 
2.1.3.4 Generation of Oxygen by a Chemical Reaction 
Oxygen generation via a chemical reaction has also been used to enhance oxygen supply.  
Oxygen can be generated by the cleaving of hydrogen peroxide by a catalase (Schlegel, 
1977; Ibrahim et al., 1980; Holst et al., 1982; Nies et al., 1984; Pardieck et al., 1992; 
Rosenberg et al., 1992; Sonnleitner et al., 1997) or by oxygen-producing algae 
(Adlercreutz et al., 1982a; Adlercreutz et al., 1982b, 1982c; Nies et al., 1984).  These can 
be attractive approaches when the organism being cultivated is shear sensitive, e.g.  
mammalian cells.  The primary disadvantages are the low flux of oxygen generated by 
algae and the rapid deactivation of the catalases that cleave peroxides.  In addition, the in 
situ generation of oxygen by hydrogen peroxide is difficult to control; if the rate of 
oxygen production is greater than its consumption, bubble coalescence is inevitable and 
defeats the original purpose.   
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2.1.3.5 Use of Hemoglobin 
Several researchers have exploited the high affinity for binding oxygen to hemoglobin 
and myoglobin as a means of increasing oxygen transfer.  Enhancement of oxygen 
transfer dependent on hemoglobin loading to the fermentation media was observed 
(Adlercreutz et al., 1982d), but high oxygen binding affinity and deactivation of 
hemoglobin made this approach impractical.  A bacterial heme protein was discovered in 
Vitreoscilla (Wakabayashi et al., 1986) that had an amino acid sequence similar to the 
globin proteins of mammals.  Building on this finding, an elegant approach consisting of 
cloning the hemoglobin gene from Vitreoscilla and expressing it in Escherichia coli was 
proposed (Khosla et al., 1988b, 1988a).  It was found that cells with the Vistreoscilla 
hemoglobin grew faster under oxygen limitations and could attain higher densities than 
the control strain.  Subsequent studies showed that the interplay of the Vitreoscilla 
hemoglobin with the terminal oxidases was responsible for enhanced respiratory activity 
(Kallio et al., 1996).  This approach was attempted successfully in other industrially 
relevant organisms such as Streptomyces and Saccharomyces.  A foreseeable limitation 
of this approach is that it does not affect the physical oxygen transfer from the gas 
bubbles to the liquid.  A comprehensive review on the subject has been published (Frey 
et al., 2003).   
2.1.3.6 Use of Dispersed Organic Phases 
Dispersion into the fermentation media of an organic phase in which oxygen has a higher 
solubility than in water is another approach to increase oxygen transfer; a great deal of 
attention has been given to the use of aqueous emulsions of hydrocarbons and 
perfluorocarbons to increase oxygen transfer.  In the literature, these systems have often 
been referred to as “oil-in-water” systems, “oxygen carriers”, or “oxygen vectors”.  
These dispersions can be created by agitation, in which case the emulsions are unstable, 
or by use of surfactants, in which case the solutions remain stable without agitation.  
Kerosine was found to increase oxygen transfer using the sodium sulfite oxidation 
method (Mimura et al., 1969).  These findings where subsequently extended to oleic acid 
and toluene (Yoshida et al., 1970).  Subsequently the mechanism of gas transfer 
enhancement into oil-in-water solutions was explored and different mechanisms were 
identified depending on the spreading coefficient of the emulsion (Linek et al., 1976).  
Interest quickly extended to PFCs (Mattiasson et al., 1983, 1987; Lowe, 1991) because of 
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their high oxygen solubilities (15 to 20 times higher than water), the higher diffusivities 
of oxygen in PFCs as compared to water, and their remarkable biocompatibility.  
Spraying of a PFC through fermentation media and subsequent recycling was used in 
microbial systems to achieve oxygen uptake rates up to six times higher than in water 
(Damiano et al., 1985).  Emulsification of a PFC into micron-sized droplets by 
mechanical agitation was used to attain oxygen transfer rates 2.5-fold higher on a total 
liquid volume basis (per liter of water + PFC) in the presence of 40% PFC (McMillan et 
al., 1987; Junker et al., 1990; McMillan et al., 1990b).  An ample review of the 
applications of PFCs in biotechnology and biomedicine has been presented by Lowe 
(Lowe et al., 1998).  A review of the mechanisms of the mass transfer enhancement in 
the presence of dispersed organic phases will be presented in Section 2.2.4.   
Only a few of the outlined strategies for oxygen transfer enhancement have been applied 
in industry with success.  Traditionally, industrial focus has been placed on increasing 
power input, increasing aeration, and enriching the gas feed with oxygen.  Judging from 
the number of publications to date, use of dispersed organic phases of oxygen carriers has 
been the most attractive alternative to these standard practices.  However, its industrial 
application has several limitations, the most important being that PFCs and hydrocarbons 
cannot be easily recovered after a fermentation cycle.  Other limitations include 
formation of foams, inefficient use of the bulk liquid (e.g., 40% of the liquid phase is 
taken up by PFC for a 2.5-fold enhancement in oxygen transfer (McMillan, 1990)), and 
entrainment and evaporation of the organic phase, which in turn leads to serious 
environmental concerns in the case of PFCs.   
Use of hydrocarbon- or PFC-coated magnetic nanoparticle dispersions offers a solution 
to the limitations previously listed.  Recovery of the dispersed phase can be accomplished 
readily through HGMS (Moeser et al., 2004; Ditsch et al., 2005b); significant mass 
transfer enhancements can be obtained at particle loadings lower than 1% mass fraction 
(Section 4.2).  In addition, the nanoparticles are non-volatile and are synthesized with 
benign, low-cost chemicals, which makes their application attractive from an 
environmental and an economic standpoint.  The application of PFC-coated magnetic 
nanoparticles to oxygen transfer enhancement in biological processes is covered by an 
international patent (Olle et al., 2005); a continuation-in-part of the patent also covers 
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hydrocarbon-coated magnetic nanoparticles.  This will be discussed in more detail in 
Section 2.3. 
2.2 Gas-Liquid Mass Transfer 
Absorption of gases into a liquid or a slurry is of crucial importance to multiphase 
reactions, because diffusion of a sparingly soluble gas species across a thin liquid film at 
the gas-liquid interface generally limits the reaction rates.  Many instances of multiphase 
reactions in 3-phase fluidized bed processes (gas-liquid-solid or liquid-liquid-solid) that 
have found application in the petrochemical, chemical, and biochemical industries have 
been listed (Kim et al., 1997).  Typical applications include hydrogenation and 
hydrodesulfurization of oil, water treatment, the Fischer-Tropsch process, coal 
liquefaction, methanation of CO, and fermentation.   
This section introduces first the typical mass transfer steps in a fermentation process.  
Next, the basic film theories to model interfacial gas-liquid mass transfer are introduced.  
The section subsequently reviews several theoretical models that have been proposed to 
explain enhanced mass transfer in gas-liquid-solid or gas-liquid-liquid systems.  These 
models are of relevance to this thesis because the underlying gas-liquid mass transfer 
phenomena are the same that are encountered in fermentation. 
2.2.1 Mass Transfer Steps in Fermentation 
Oxygenation in a fermentation process is generally achieved by sparging air while 
applying mechanical agitation to break up the air bubbles and maintain good mixing.  
The transport of oxygen from the gas bubbles to the cells has three major steps, as shown 
in Figure 2-1: 1) diffusion of oxygen from the bulk of the gas bubble to the gas-liquid 
interface; 2) diffusion through the liquid layer around the bubble; and 3) transfer by 
convection or turbulence to the cell.  Three additional steps can be considered for a 
broader description, which include transport through the liquid film surrounding a cell, 
diffusive transport through a cellular cluster or mycelia, and transport across the cell 
envelope (Bailey et al., 1986).  Mixing inside the gas bubble is typically good and the 
rate at which gas molecules travel to the interface is high.  The diffusivity of oxygen in 
the gas phase is roughly 4 orders of magnitude larger than in water and therefore step 1 
seldom poses a limitation to mass transfer.  Similarly, good mixing in the bulk liquid 
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phase is usually guaranteed by sufficient agitation and step 3 rarely limits the mass 
transfer process.  It is widely accepted that the transfer of oxygen through the liquid film 
around the gas bubble (step 2) controls the overall oxygen transfer rate; therefore, the 
liquid film mass transfer coefficient (kL) is a good approximation of the overall 
coefficient.  Most of the studies presented in the literature have taken a single bubble as 
the representative unit of the mass transfer system and ignored bubble size distributions 
and effects of poor mixing in the bulk liquid phase.  Another common assumption has 
been to neglect the curvature of the bubble; this assumption is justified because the size 
of a bubble is generally 2 orders of magnitude larger than the thickness of the gas-liquid 
interface.  This latter consideration yields a 1-D mass transfer problem, with diffusion 
occurring only in the normal direction to the gas-liquid interface. 
 
 
 
 
 
 
 
 
 
Figure 2-1.  Steps in Mass Transfer from a Gas Bubble to a Cell 
 
2.2.2 Film Theories 
Several models for mass transfer at the gas-liquid interfacial region have been proposed.  
These models are commonly taken as a basis for modeling mass transfer in 3-phase 
systems.  These are models that do not incorporate the hydrodynamic features of the 
flows at the vicinity of the gas-liquid interface. 
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      26 
Lewis and Whitman’s film theory (Lewis et al., 1924) assumes Fickian diffusion of a 
solute through a stagnant liquid film at the gas-liquid interface.  Convective mass transfer 
is neglected and steady state diffusion assumed.  This film theory predicts a dependence 
of the mass transfer coefficient on the diffusivity of the gas solute in the liquid phase, 
DA,L, of 
δ/Dk L,AL =           (3) 
 that is not consistent with experimental results.  At liquid-solid boundaries, the typical 
relationship is given by 32 /L,AL Dk ∝  and at gas-liquid boundaries, given by 21 /L,AL Dk ∝ .  
The parameter δ introduced in the expression represents the thickness of the 
concentration boundary layer around a gas bubble.  Despite its apparent limitations, 
Whitman’s theory has been applied to a range of complex mathematical problems for 
which only a simple film diffusion model yields analytical solutions. 
Higbie’s penetration theory (Higbie, 1935), assumes that turbulence brings fluid 
elements from the bulk to the gas-liquid interface.  The elements are stagnant and the 
initial solute content is equal to the bulk concentration when the element first contacts the 
interface.  Subsequently, unsteady diffusion occurs for a fixed residence time.  The 
dependency of kL on diffusivity and the residence time of the fluid elements is given by  
tDk π/2 LA,L =          (4) 
Danckwerts’ surface renewal theory (Danckwerts, 1951) proposes that not all liquid 
elements stay at the interface for an equal amount of time; instead, there is an age-
distribution function ( ) stset −=ψ  where s is the inverse of an element’s residence time at 
the interface (or a rate of surface renewal).  The expression for kL is 
sDk LA,L =           (5) 
In both Higbie’s and Danckwerts’ models, the residence time at the interface determines 
the mass transfer rate.  Therefore, this residence time must be shorter than the time scale 
for molecular diffusion through the liquid film.  Both theories provide more accurate 
predictions of experimental data than Whitman’s theory; however, none of the 3 models 
proposes physical arguments on which to calculate the value of the quantities t – given by 
Eq. 4 – or s – given by Eq. 5.   
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2.2.3 Hydrodynamic Models 
Turbulence affects the rate at which liquid elements are renewed at a gas-liquid interface.  
Film theories fail to provide a model for the calculation of the residence time (or renewal 
rate) of fluid elements and therefore cannot be used to predict sets of experimental data 
that have been obtained at different conditions of turbulence.  Several models to estimate 
this parameter have been proposed. 
Eddy models assume that the renewal of the interface is caused by small turbulent eddies.  
Isotropic turbulence theory states that at high wave numbers turbulence depends only on 
power input per unit mass ε (which can be measured directly or calculated) and kinematic 
viscosity ν; the length scale and time scale characteristic of the smallest eddies at which 
energy dissipation occurs are given by ( ) 413 //vl ε=  and ( ) 21 //v ετ =  respectively.  
Under the assumption that mass transfer is determined by the smallest eddies, which have 
smaller scales than the gas bubbles, a relation has been proposed (Lamont et al., 1970) 
( ) n
v
D
ck ⎟⎟⎠
⎞⎜⎜⎝
⎛= LA,4/1L εν          (6) 
where c is a constant, and the exponent n has a value of 1/2 for a fluid surface and 2/3 for 
a solid surface (the presence of surfactants can rigidify a gas-liquid interface and make it 
behave as a solid).  Lamont proposed a value of 0.4 for the constant c.  A value of c of 
0.448 was reported for experiments in sodium sulfite solutions (Linek et al., 2005).   
Slip velocity models assume that the relative motion of a bubble in a liquid determines the 
surface renewal.  Slip velocities are typically equated to single bubble terminal rise 
velocities.  Bubbles are generally classified into small (bubble diameter dB below 1 mm) 
or large (dB above 2 mm) (Calderbank et al., 1995).  The former behave as rigid spheres, 
the latter have mobile interfaces.  If a gas-liquid slip velocity is known for a given 
system, boundary layer theory can be used to estimate a mass transfer coefficient.  
Equations to describe mass transfer around spherical bodies have been proposed 
(Lochiel, 1964); for Re>>1, the Sherwood number ( L,ABL D/dkSh = ) is 
312170 // ScRe.Sh =  (immobile interface)      (7a) 
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where Sc, Pe, and Re, are the Schmidt, Peclet, and Reynolds numbers, and the subscripts 
G  and L refer to the gas and liquid phases respectively. 
While eddy models predict an increase of kL with turbulence as a function of ε1/4, slip 
velocity models predict a decrease because turbulence creates smaller bubbles, which rise 
at a slower velocity.  The application of both types of model to extensive literature data 
has been reviewed (Linek et al., 2005); it has been concluded that only eddy models give 
reliable predictions in mechanically agitated systems, which is consistent with the results 
of this thesis (Section 4.2.2), while in non-agitated systems both types of models are 
appropriate. 
2.2.4 Models of Mass Transfer in the Presence of a Dispersed Phase  
The presence of a dispersed phase, either liquid or solid, in which the solubility of the 
solute of interest is higher than in the base medium, poses an interesting theoretical mass 
transfer problem.  Dispersions of small particles or liquid droplets have frequently been 
modeled by means of effective property models.  Such models are appropriate when the 
typical dimension of a dispersed phase element is much smaller than the dimension of the 
domain through which mass transfer occurs.  Typically, this domain is the liquid film 
around a gas bubble.  If this requirement is satisfied, the dispersion can be considered 
macroscopically homogeneous in spite of its biphasic nature, and the transport and 
equilibrium properties of the medium, e.g.  diffusivity and solubility, can be expressed as 
effective properties of the two components of the dispersion.  Maxwell lead the way in 
the study of transport properties of 2-component mixtures by deriving a theoretical form 
for the effective thermal conductivity of a dilute suspension of spheres (Maxwell, 1873).  
An extension of Maxwell’s approach that includes interactions between pairs of spheres 
was later presented (Jeffrey, 1973).  Jeffrey’s expression for the effective thermal 
conductivity of a dispersion can be adapted to mass transfer to obtain an analogous form 
for effective diffusivity of a solute A in a medium L 
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The values for the coefficient F(β) are given in the original paper by Jeffrey (1973).   
It has been shown that Eq. 8 underpredicts the enhancement experimentally determined 
in PFC-water systems (McMillan, 1990).  This is because Jeffrey’s analysis is based on 
steady state, while mass transfer from bubbles in an agitated, sparged vessel is a transient 
process; enhancement is largest at short times, when the dispersed phase is still not 
loaded with solute, and decreases with time.  Different definitions of enhancement have 
been used in the literature; a commonly used form is the ratio of solute fluxes in the 
presence and absence of a dispersed phase 
mediumbasesolute,
particleswithsolute,
N
N
E =          (12) 
Since experiments are generally performed at a fixed driving force, enhancement as 
expressed in Eq. 12 is also the ratio of volumetric mass transfer coefficients in the 
presence and absence of dispersed phase.  For a proper comparison with experimental 
results of gas absorption, it is necessary to express the solute fluxes as a function of time 
and integrate them over a typical exposure (or surface renewal) time.   
Film theories (Section 2.2.2) have been used as the starting point for most modeling 
approaches for mass transfer in dispersions because the mathematical problems that arise 
from their use can be solved analytically.  Early experimental observations of enhanced 
gas absorption in the presence of dispersed active carbon (Kars et al., 1979; Alper et al., 
1980) instigated the development of film models for mass transfer in the presence of a 
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dispersed phase.  Alper et al.  used carbon and quartz particles of average size 5 µm; 
carbon enhanced mass transfer, and quartz did not; enhancement was attributed to the 
highly porous structure of activated carbon.  Many theoretical studies followed.  Models 
proposed to date have been classified as homogeneous and heterogeneous (Brilman et al., 
2000).  Homogenous models assume a homogeneous distribution of the dispersed phase 
in the bulk and in the film and generally do not account for concentration gradients inside 
the dispersed phase.  Heterogeneous models account for diffusion of the solute 
alternately through bulk and particle phase; some have considered additional effects such 
as particle-particle interactions, adsorption of the dispersed phase at the gas-liquid 
interface, and curved geometry of the interfaces.  In both types of models, it is generally 
argued that gas absorption enhancement occurs because the dispersed phase interacts 
with the solute at the gas-liquid interface by removing it from the interface and 
transporting it to the bulk medium.  The main assumptions underlying the models 
presented in the literature have been summarized (Mehra, 1988).  These are (i) no fluid 
flow in the film; (ii) diffusivity of the solute is not affected by the dispersed phase 
holdup; (iii) the dispersed phase does not alter the interfacial area available for mass 
transfer; (iv) the size of the elements of the dispersed phase is smaller than the thickness 
of the mass transfer film; (v) the microfilms surrounding the dispersed phase droplets or 
particles do not overlap; and (vi) the surface renewal frequency is unaffected by the 
presence of the dispersed phase.  A final common element of all modeling approaches 
formulated thus far is that they have been developed to explain experimental data 
obtained in dispersed phases with particle or droplet size on the order of 1 µm to 1 mm 
(generally termed microphases.) 
2.2.4.1 Homogeneous models  
The central feature that distinguishes a homogenous model from a heterogeneous model 
is the assumption that the dispersed phase is equally distributed through the liquid film.  
This consideration alone simplifies the mathematical treatment of the problem 
significantly and in many cases allows an analytical solution.  Additionally, 
homogeneous models assume that the dispersed phase does not directly contact the gas 
interface, and concentration gradients inside the dispersed phase are ignored.   
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A general formulation for mass transfer in the presence of a microphase using Higbie’s 
and Danckwerts’ theories has been presented (Mehra, 1988; Mehra et al., 1988).  The 
governing equations for the continuous phase and for the dispersed phase are 
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where A is the concentration of the solute in the continuous phase, φ the dispersed phase 
holdup, AL0  the concentration of solute in the dispersed phase, Dp the diffusivity of a 
dispersed phase droplet, A* the solubility of the solute in the continuous phase, K0 the 
volumetric mass transfer coefficient based on the continuous phase, and m the relative 
distribution coefficient for the solute between the continuous and dispersed phase.  It has 
been shown that for spherically symmetrical droplets of size dp with negligible motion 
relative to the continuous phase, K0 in Eq. 15 can be estimated as 2pLA,0 /12 dDK =  
(Mehra, 1988; Mehra et al., 1988).  From surface renewal theory, the instantaneous rate 
of absorption averaged over a surface renewal time is expressed as: 
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with the surface renewal time LA,
2
L / DkS = .  The base rate in the absence of dispersed 
phase can be expressed as 
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Under the assumption that ( )mSKDD φφ −<< 1// 0LA,p , an analytical expression for the 
enhanced absorption rate in the presence of a dispersed phase is obtained 
[ ] ( ) 1LA,*A,enhanced 1 IDAR φ−=         (19) 
where the term I1 is  
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The enhancement in the absorption rate due to the presence of the dispersed phase can be 
calculated as the ratio of Eq. 19 and Eq. 18.  Figure 2-2 illustrates the effect of a 
homogeneously dispersed phase in the liquid film; droplets or particles solubilize 
preferentially the solute in the medium and locally deplete their surroundings.  The 
decreased local concentrations in the surrounding medium translate into steeper 
concentration gradients at the interface and therefore a higher solute flux. 
 
 
 
 
 
 
 
 
Figure 2-2.  Illustration of the Effect of a Homogeneously Dispersed Phase on Mass 
Transfer 
Using homogeneous models, reasonable predictions of enhanced mass transfer in 
dispersions have been obtained for cases in which the particle or droplet size is smaller 
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than the film thickness (Bruining et al., 1986; Mehra et al., 1988; Cents et al., 2001).  
Droplets larger than the film thickness do not show enhancement, possibly because they 
can not penetrate into the film.  A simple expression for the absorption enhancement, E, 
has been proposed (Bruining et al., 1986) 
( )( ) 2111 /mE −+= φ          (21) 
where φ is the volume fraction of the droplet phase and m is the partition coefficient of 
oxygen between the droplet phase and the surrounding phase.  Bruining makes the case 
that two conditions must be met to obtain an enhancement of the absorption rate: (i) the 
particle size must be smaller than the film thickness; (ii) an interaction between the 
particle and the solute is necessary because inert particles show no enhancement of mass 
transfer.   
2.2.4.2 Heterogeneous models 
Heterogeneous approaches model the solute diffusion alternately through the bulk and 
particle phases; in some cases, these models also account for the effect of dispersed phase 
droplets near the interface.  Mass transfer enhancement data obtained for aqueous 
solutions of activated carbon particles suggest that it would be required to have higher 
particle holdups at the interface than in the bulk to predict theoretically the observations 
(Holstvoogd et al., 1988); data show an initial linear increase of absorption enhancement 
as a function of the dispersed phase holdup, followed by a transition to a plateau at solids 
concentrations on the order of 1kg/m3.  Holtsvoogd et al.  hypothesized that this change 
in regime corresponded to the formation of a close packing of solids at the interface.  
There is experimental evidence of this phenomenon; the adhesion of small metal and 
activated carbon particles to bubbles was investigated with a bubble pick-up method 
which yields an estimation of the fraction of the bubble interfacial area covered by 
particles (Wimmers et al., 1988a, 1988b; Vinke et al., 1991).  The authors proposed that 
the concentration of particles at the gas-liquid interface could be expressed as a function 
of the bulk concentration through an adsorption isotherm.  Subsequent work proposed a 
Langmuir isotherm to relate the interfacial coverage to the bulk concentration (Vinke et 
al., 1993); a model to express the initial enhancement in gas absorption as a function of 
the fractional coverage of the gas-liquid interface by particles was formulated.  In this 
model, two parameters, k (the adsorption constant) and ξmax (the maximum possible 
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coverage of the interface), where determined from a fit to experimental data.  This model 
proposes an analytical expression for the enhancement factor  
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where ξ is the fraction of the interface covered by solids, dp the droplet size, and tp/ts is 
the quotient of the residence time of the particle at the interface and the time it takes for 
the particle to saturate with solute.  These two times scales can be expressed as 
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A version of Vinke et al.’s model that accounts for unsteady mass transfer of solute into 
the particles has been derived (Demmink et al., 1998); the authors also used an 
expression with the form of a Langmuir isotherm but noted that the two fitted parameters 
initially proposed by Vinke et al.  were dependent on the agitation conditions.  Recently, 
a heterogenous model that accounts for the possibility of formation of several layers of 
solids on the gas-liquid interface has been proposed (Nagy, 2003). 
Other heterogeneous models have not considered particle attachment at the interface, but 
rather focused on the local geometry of the interface.  These models predict that the 
proximity to the gas-liquid interface of the closest droplet has a strong influence on the 
enhancement (Brilman et al., 1998; Brilman et al., 2000).  An analytical 1-D transient 
model for one particle in the film with one adjustable parameter, which is valid for 
situations in which the dispersed phase elements and the liquid film have a comparable 
size was developed (Junker et al., 1990; McMillan et al., 1990b).  Models in 2-D and 3-D 
that take into account the spherical shape of the dispersed phase have also been 
developed (Karve et al., 1990); these models can only be solved with a numerical 
approach.  Using a unit cell approach, Karve et al.  showed that absorption enhancement 
is dominated by the closest particle to the interface.  A mechanism of enhancement based 
on the enhanced solute permeability of the film, which takes into account the effects of 
both different diffusivity and solubility of the solute in the dispersed phase has been 
proposed (McMillan et al., 1990b); comparison with experimental data shows good 
agreement at dispersed phase holdups below 0.3. 
      35 
2.2.4.3 Effect of the Dispersed Phase on Interfacial Area 
While the effect of a dispersed phase on the mass transfer flux of a solute has been 
researched in detail both experimentally and theoretically, the effects on gas-liquid 
interfacial area have received less attention.  Most studies have been performed in stirred 
cells precisely to isolate flux effects by having a fixed, known interfacial area.  
Accordingly, mechanisms for enhanced or decreased interfacial area in the presence of a 
dispersed phase have not been proposed.  A recent review of experimental studies on the 
effect of a dispersed phase on mass transfer points out that the literature contains 
contradictory results with regard to the effect of interfacial area and lacks systematic 
studies (Dumont et al., 2003).  Photographic methods have been used to measure bubble 
size distributions in the presence of emulsions (McMillan et al., 1990a; Rols et al., 1990).  
Rols et al.  showed that the size distribution is not affected by the addition of emulsified 
n-dodecane, and measured a modest 15% increase of interfacial area.  McMillan et al.  
showed no measurable increase in interfacial area upon dispersion of PFCs.  The gas-
liquid specific interfacial area in slurries of activated carbon, kieselghur, and aluminum 
oxide has been measured using the sodium sulfite method (Quicker et al., 1984); for all 
materials studied, at low solid loadings, no significant changes were reported in area; at 
higher solid loadings, interfacial areas decreased by up to a factor of 3 for kieselguhr.  
The authors correlated the decrease in interfacial area with the effective viscosity of the 
medium.  According to a recent report, carbon particles adhere to gas-liquid interfaces 
because of their hydrophobic nature, and promote bubble coalescence and therefore 
reduce interfacial area (Van Der Zon et al., 2002).  Bubble coalescence has been studied 
in solutions of alcohols and fatty acids; results show that coalescence times are 
proportional to the surface excess concentration of the molecular solute, and that 
coalescence times increase with polarity of the hydrophilic group of the solute and its 
chain length (Drogaris et al., 1983); longer coalescence times increase interfacial area.  
This research is of relevance to the present thesis because the nanoparticles used in this 
thesis are coated with a first layer of a fatty acid and a second layer of charged, 
hydrophilic polymer.  While nanoparticles are approximately 2 orders of magnitude 
larger in size than the molecular solutes used by Drogaris, they also exhibit surface active 
behavior (Section 4.3).   
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Bubble size in an agitated, sparged vessel is determined by a balance of disruptive forces 
and stabilizing forces (Calderbank, 1958); disruptive forces are a function of the energy 
dissipation rate and stabilizing forces are a function of surface tension.  An expression to 
calculate the size of bubbles (dB) in stirred tank reactors based on isotropic turbulence 
theory has been proposed (Metkin et al., 1985) 
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where σ is surface tension, ρ and ρG are the densities of gas and liquid respectively, and 
εH is he gas holdup.  The interfacial area can be expressed as a function of bubble size 
and gas holdup εH 
B
H6
d
a ε=           (25) 
Interfacial area exhibits a σ-0.6 dependence on surface tension.  Eq. 24 shows that bubble 
size can be altered by a dispersed phase if (i) the surface tension of the dispersion is 
different from that of the base fluid, (ii) the effective density of the solution is altered.  
Altered bubble sizes in turn affect gas holdup through the dependence of the latter on the 
superficial gas velocity VS  
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2.2.5 Limitations of the Available Models 
The models reviewed in Section 2.2.4 are primarily based on film theories.  Therefore, 
convective motion in the film around gas bubbles is neglected, and simple diffusive mass 
transfer is assumed.  Clearly this has been a successful approach, judging by the body of 
mass transfer data in the presence of dispersions that has been correctly predicted.  Since 
the diffusivity of a micron-sized droplet generally does not promote its capacity to 
enhance mass transfer (Mehra, 1988), it is not surprising that ignoring flow-enhanced 
particle diffusivity has a negligible impact on the accuracy of the models.  In the context 
of microphase-enhanced mass transfer, it has been mentioned that coupling of shear 
fields and droplet diffusivity would yield droplet diffusivities higher than the Stokes-
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Einstein value (Mehra, 1988).  However, this mention is made in the context of film 
theory; it is apparently inconsistent to consider a shear-induced diffusivity in a stagnant 
film.   
The dispersed phases reviewed in this section have sizes on the order of a few µm to 
several hundred µm.  The characteristic length scale of a dispersed phase element is 2 to 
3 orders of magnitude larger than that of a nanoparticle.  No experimental research has 
been published that bridges the gap between the two length scales.   
 
2.3 Magnetic Fluids 
Magnetic fluids are colloidal dispersions of magnetic nanoparticles that have a size that 
can range from around 10 nm – if they are single domains – to several hundred 
nanometers – if they are clustered.  The smallest particle sizes are preferably greater than 
10 nm.  Below this size, magnetic forces cannot be used to direct particle behavior 
because Brownian forces prevail.  At the other end of the range, as particles approach  
1 µm, it becomes increasingly difficult to prevent aggregation.  Magnetic nanoparticles 
can be stabilized against unbounded aggregation by applying surface coatings.  These 
coatings are usually surfactants (Shen et al., 1998, 1999) or polymers  (Moeser et al., 
2002a; Olle et al., 2005; Ditsch et al., 2005a) that provide colloidal stability to the 
particle and at the same time can be tailored for a specific application; some of the 
applications explored to date include separation of organic contaminants from water 
(Moeser et al., 2002a), ion-exchange purifications of proteins (Ditsch et al., 2004), and 
enhanced oxygen mass transfer.  The common aspect in the applications is the 
exploitation of the large surface area per unit volume of the nanoparticle dispersions; 
mass transfer of a chemical contaminant, a protein, or a solubilized gas from a water 
phase to the nanoparticle phase occurs on times scales on the order of micro to 
nanoseconds.   
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2.3.1 Hydrocarbon-Coated Magnetic Nanoparticles 
This thesis deals primarily with hydrocarbon-coated magnetic nanoparticles in aqueous 
media.  Methods for preparation of magnetic particles coated with organic layers 
consisting of anionic surfactants with one or several polar groups and a hydrocarbon 
chain, such as unsaturated fatty acids and sulfonates, have been described in the literature 
(Meguro et al., 1987); such magnetic particles are only stable in organic solvents and 
would aggregate in an aqueous fermentation broth.  Hydrocarbon-coated particles that 
retain stability in aqueous media have been synthesized (Shimoiizaka, 1977) by attaching 
an unsaturated fatty acid to a magnetite (Fe3O4) core, and then adsorbing a second 
coating of an anionic surfactant.  This approach has the disadvantage that the second 
layer, which provides stability in water, is physically adsorbed – and not chemically 
bound – to the first layer, and therefore tends to detach upon dilution or addition of ions.  
A synthesis method for magnetic nanoparticles coated with two layers of chemically 
bound oleic acid has been developed (Shen et al., 2000).  However, these particles retain 
their stability due to the ionization of carboxyl groups, and do not remain stable below 
pH 7.4.  Typical conditions of ionic strength and pH in cell culture media place severe 
restrictions on particle stability.  Cell culture media generally have ionic strengths on the 
order 1 M and a pH that can vary widely depending on the organism being grown.  
Escherichia coli, for instance, grows best at a pH around 7.  Only formulations that 
produce particles that retain stability at high ionic strength and in a wide range of pH are 
suitable for application in bioprocesses. 
2.3.2 Synthesis for Stability in Fermentation Media 
The hydrocarbon-coated magnetic nanoparticles used in the present work are synthesized 
by attaching a first layer of oleic acid to an Fe3O4-core, to which a second layer of a 
polyethylene-oxide (PEO) based surfactant (Hitenol BC) is covalently attached.  The 
outer surfactant layer contains negatively-charged sulfonate groups that confer 
electrostatic stabilization and long PEO chains that confer steric stabilization in aqueous 
media.  As a result, particle stability is guaranteed at typical fermentation ionic strengths 
and in a wide range of pH from at least 2 to 10.  The synthesis method followed is 
described in detail in Section 3.1. 
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2.3.3 Recovery and Size Control of Magnetic Nanoparticles 
It has been shown that 26 nm particles with a magnetite core of 7.5 nm can only be 
successfully recovered at low flow velocities of up to 0.1 cm/s through an HGMS column 
(Moeser et al., 2004).  At industrially relevant column velocities above 1 cm/s, 100% 
recovery of the particles is not possible.  Moeser et al.  calculated that a minimum cluster 
size of around 50 nm is necessary for successful particle recovery.  While the particles 
used in the present work have sizes around 20 nm, the basic synthesis method can be 
modified to tune the size to larger values.  A general method to synthesize size-controlled 
nanoparticle clusters in the range of 50 to 150 nm has been developed (Ditsch et al., 
2005a); this method has been successfully applied in this work to obtain hydrocarbon-
coated clusters of varying sizes (Section 4.1.3). 
2.3.4 Advantages over Existing Technologies 
Magnetic nanoparticles have a number of advantages over conventional dispersions of 
organic oils as previously discussed in Section 2.1.3.  First, they can be separated from a 
fermentation broth and recovered by magnetic filtration.  Second, they form colloidal 
dispersions with a large interfacial area.  As a result, mass transfer of a solute between 
the surrounding liquid media and the particle can occur in a fraction of a microsecond.  
Third, the particles are non-volatile and therefore are not lost due to entrainment in a 
fermentor.  Furthermore, they are synthesized with benign chemicals and could be 
disposed of safely if needed; therefore, their use does not pose environmental concerns.  
Finally, small loadings of particles, below 1% in mass fraction, are sufficient to obtain 
large mass transfer enhancements (Section 4.2).  The loadings needed per fold-
enhancement of oxygen transfer are two orders of magnitude smaller for magnetic 
nanoparticles than for pure hydrocarbons or PFCs.  Furthermore, the nanoparticles used 
in this work are produced from cheap raw materials (iron chlorides, ammonia, oleic acid, 
and Hitenol BC), and their manufacture does not pose any challenge, since they are 
produced through an easily scalable laboratory process that does not require temperatures 
above 80oC or pressurization.   
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2.4 Nanoparticles for Heat Transfer Enhancement 
Recent research has shown that nanoparticles made of metals, metal oxides, and multi-
walled carbon nanotubes greatly enhance heat transfer in liquids.  It is expected that these 
findings will have important repercussions in the microelectronics and transportation 
industry (Eastman et al., 2004), where cooling of devices frequently limits performance.  
While the anomalous magnetic, electrical, and optical properties of solid and liquid 
dispersions of nanosized materials have been observed previously, the discovery and 
exploitation of their capacity to modify heat transfer have occurred only during the last 
decade; during this time, research done at the Argonne National Laboratory has led the 
way in the development of nanoparticle-based heat transfer fluids (Choi, 1995; Lee et al., 
1999; Choi et al., 2001; Eastman et al., 2001; Keblinski et al., 2002).  Rather 
surprisingly, given the straightforward analogy of heat and mass transfer, applications of 
nanofluids in mass transfer have been largely ignored, perhaps because the excitement 
has not spread far from the mechanical engineering community where the research 
originally started and has stayed.  To the best of the author’s knowledge, only one 
experimental study has been published (Wen et al., 2005), where it was reported that 
TiO2 nanometer-sized particles reduced the volumetric mass transfer coefficient in a 
three-phase airlift reactor, and two theoretical studies were published (Ali et al., 2004a; 
Ali et al., 2004b) that predicted that the presence of nanoparticles in a falling film 
exposed to air would enhance mass transfer but the improvements would not be 
significant. 
2.4.1 Experimental Studies 
The first attempt at measuring increased heat transfer in nanoparticle solutions showed 
that a dispersion of 4% γ-Al2O3 in water enhanced effective thermal conductivity of the 
base medium by 30% (Masuda et al., 1993).  A decade ago, a pioneering theoretical work 
first proposed that nanoparticle solutions, thereafter termed nanofluids, could enhance the 
thermal conductivity of fluids and reduce pumping power in heat exchange operations 
(Choi, 1995).  Although the author mentioned that the large surface area of nanoparticles 
would be beneficial to heat transfer, his initial expectation apparently was that 
nanoparticles of conducting materials would enhance thermal conductivity of base fluids 
in accordance with the predictions of effective property models; these models only take 
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into account the volume fraction and shape of the inclusions, but not their size or surface 
area (Hamilton et al., 1962).  Subsequently, many studies have shown that the actual 
enhancement that can be obtained is one order of magnitude larger than the predictions of 
effective property models.  The dependence of the enhancement on material type, 
temperature, particle size, and volume fraction has been studied and will be discussed in 
the following section.  The results obtained have established nanoparticles as a promising 
candidate in cooling applications and pool boiling.   
2.4.1.1 Influence of Material Type 
Early research concentrated on dispersions of metal oxide nanoparticles.  Following 
Masuda et al.’s work, measurements of the thermal conductivity of Al2O3 nanoparticles 
and CuO nanoparticles in aqueous media were made (Lee et al., 1999); the latter showed 
larger thermal conductivity enhancement at a given volume fraction.   
Metal nanoparticles have also been the focus of research.  Using ethylene glycol as a base 
fluid, it was shown that dispersions of copper nanoparticles provided a greater thermal 
conductivity enhancement than oxide nanoparticles at the same volume fraction (Eastman 
et al., 2001).   
Recently, reports have shown that carbon nanotubes can yield larger enhancements than 
spherical nanoparticles.  Apparently this is because heat can be transferred more 
efficiently along high-aspect ratio fibers than across a medium of spherical nanoparticles 
for an equivalent distance; furthermore, carbon has a large thermal conductivity.  A  
2.5-fold thermal conductivity enhancement was obtained with 1% volume fraction of 
nanotubes which was attributed to ballistic heat transport along nanotubes (Choi et al., 
2001).  Similar observations have been carried out by other authors (Xie et al., 2003; 
Wen et al., 2004b). 
2.4.1.2 Influence of Particle Size 
The thermal conductivity in aqueous media of nanoparticles of the same material (Al2O3) 
as those used by Masuda et al.  but twice the diameter has been measured and half the 
enhancement in thermal conductivity has been obtained (Lee et al., 1999).  A lower 
thermal conductivity enhancement has been measured for 100 nm copper nanoparticles 
(Xuan et al., 2000a) than for 10 nm copper nanoparticles (Eastman et al., 2001); the 
      42 
discrepancy has been attributed to the difference in nanoparticle size.  Thermal 
conductivity enhancement by Al2O3 dispersions with varying particle size has been 
measured and found to be dependent on particle size and pH (Xie et al., 2002b).  
Nanofluids containing CuO particles smaller than Al2O3 particles have been shown to 
yield larger thermal conductivity enhancement (Das et al., 2003c); however this study 
has the limitation that the base materials of the nanoparticles being compared are 
different.  In a subsequent paper by the same authors (Patel et al., 2003), the thermal 
conductivities of Au and Ag nanoparticles have been compared.  Despite Ag having a 
thermal conductivity an order of magnitude higher than Au, larger Ag nanoparticles (60-
80 nm) show lower enhancement than Au (10-20 nm) particles.   
2.4.1.3 Influence of Temperature 
Several studies have addressed the influence of temperature in heat transfer enhancement 
caused by nanofluids (Lee et al., 1999; Das et al., 2003c; Patel et al., 2003; Jang et al., 
2004; Kumar et al., 2004).  Das et al.  observed the thermal conductivity enhancement 
increased from 2% to 4% over a temperature range from 21oC to 51oC.   
2.4.1.4 Convective Heat Transfer 
Early research on nanofluids concentrated on characterization of enhanced thermal 
conductivity.  Recently, systems in which fluid flow plays a role have also been explored.  
Several studies have looked at forced convection.  Convective heat transfer of nanofluids 
under laminar flow in a tube has been studied (Wen et al., 2004c).; with 1.6% volume 
fraction of nanoparticles, a 40% enhancement in heat flux at the entrance region and a 
smaller (14%) enhancement in the developed region have been measured.  Heat transfer 
in the laminar flow of graphite nanofluids with particle aspect ratios lower than one has 
been studied (Yang et al., 2005); results show that nanoparticles increase heat transfer 
coefficients, but that the increase is less than the increase in the static thermal 
conductivity.  Other studies have explored the application of nanofluids to increase the 
critical flux in pool boiling (Das et al., 2003b, 2003a; Vassallo et al., 2004; Bang et al., 
2005); several-fold higher critical heat fluxes in the presence of nanoparticles as 
compared to base fluids have been reported. 
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2.4.2 Modeling Studies 
In most instances in the literature, the thermal performance of nanofluids has not been 
successfully predicted by available macroscopic theories.  According to a review by 
(Eastman et al., 2004), “to date, … understanding how heat is transferred in nanofluids 
remains the greatest challenge that must be overcome in order to realize the full 
potential of this new class of heat transfer fluids”.  The disconnection between 
experimental data and modeling appears to be a general trend in the nanosciences.  
According to a 2002 report conducted by the Basic Energy Sciences and Advanced 
Scientific Computing Advisory Committees to the Department of Energy (Mccurdy et 
al., 2002), one of the fundamental challenges facing the nanosciences is to determine the 
essential science of transport mechanisms at the nanoscale.  The report also warns that 
the rapid progress in experimental studies calls for a theoretical understanding, the lack 
of which is slowing down future advancements.  The central challenge emerging from the 
report is that “within 5 to 10 years, there must be robust tools for understanding … 
dynamics at the nanoscale, without which the scientific community will have missed 
many opportunities.” 
This section reviews several models of enhanced heat transfer that have been proposed 
for nanoparticle dispersions in stationary systems and in flow systems.  Special attention 
is given to stationary systems because the absence of flow simplifies the theoretical 
treatment of the heat transfer problem and makes them a good basis for further modeling 
efforts.  It must be noted that there exists general dispute over the validity of the models 
that will be discussed and that the nature of the theoretical research being published is 
highly speculative. 
2.4.2.1 Models of Stationary Nanoparticle Dispersions 
The first theoretical studies of the effective thermal conductivity (and by analogy of heat 
and mass transfer, the effective mass diffusivity of solutes) of suspensions were 
undertaken over a century ago (Maxwell, 1873).  A theoretical form for the effective 
conductivity of a suspension of spheres initially developed by Maxwell remained 
successful until recently for predicting the effective transport properties of suspensions of 
all particle sizes, down to the micrometer scale, with minor modifications proposed by 
other authors, e.g.  to account for non-sphericity (Hamilton et al., 1962).  Following the 
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initial application of nanoparticle solutions to heat transfer (Choi, 1995), it became 
obvious that macroscopic effective property models failed dramatically at predicting the 
heat transfer properties of nanofluids; specially in terms of not accounting for particle 
size.  In a comprehensive 2004 review, various heat transfer mechanisms potentially 
responsible for the anomalous behavior of nanofluids were examined (Eastman et al., 
2004).  Two of them have received attention in the literature: 
The formation of interfacial liquid layers around the nanoparticle has been given 
consideration, on the basis that liquid molecules can organize into layers in the vicinity of 
a solid surface (Xue et al., 2003, 2004; Xue et al., 2005).  If the arguable assumption is 
made that the thermal conductivity of such layers is similar to that of the solid, it is found 
that, for a typical 10 nm nanoparticle, a 3 nm liquid layer shell has to be assumed (Xue et 
al., 2005) to explain experimentally reported enhancements.  It has been found by 
experiment and simulation that this liquid layer actually has a thickness below 1 nm.  As 
pointed out by (Yu et al., 2003, 2004), measurable increases in heat transfer can only be 
obtained for particle diameters below 10 nm, which excludes practically all the 
experimental data gathered in the literature. 
Brownian motion was initially ruled out (Eastman et al., 2004), (Keblinski et al., 2002) 
as a possible mechanism of enhancement on the basis that the characteristic diffusion 
time of even the smallest-sized (10 nm) nanoparticles is much longer than the 
characteristic time for conductive heat transfer.  This scaling was done using a typical 
diffusion coefficient for the nanoparticle estimated with the Stokes-Einstein equation; if, 
however, the translation velocity of each Brownian jump in a given direction – as 
opposed to the particle diffusion coefficient obtained from the mean squared 
displacement over a longer period of time – is used as a scale for the particle velocity, 
Brownian motion can no longer be ignored. 
Several attempts have been made at estimating the increase of the thermal conductivity 
due to the Brownian motion of nanoparticles in the context of nanofluids.  Using 
expressions for the increased thermal conductivity of a medium due to the rotational 
(Leal, 1973) and translational (Gupte et al., 1995) motion of a sphere contained in it, it 
was estimated that Brownian motion in 10% volume fraction of 28 nm sized Al2O3 
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particles accounted for less than 0.5% of the thermal conductivity increase and therefore 
was not significant (Wang et al., 1999). 
Considering that particles would drag some of the surrounding fluid to create convection 
at the nanoscale, an expression was proposed for the velocity of the nanoparticle for an 
idealized 1-D system, as a function of its kinetic energy and imposed bulk temperature 
gradient (Yu, 2003).  The expression showed a weak, square root dependence of velocity 
on temperature because it did not take into account the drag on the particle and therefore 
the exponential effect of temperature on the viscosity of the surrounding fluid.  The 
expression for velocity was not incorporated into a model for enhanced thermal 
conductivity and therefore no comparison was made with literature data.   
Brownian dynamics simulations have been used to calculate the thermal conductivity of 
nanofluids (Bhattacharya et al., 2004).  The Fluctuation Dissipation theorem was used to 
calculate the thermal conductivity by relation to the time-autocorrelation function of the 
heat flux.  The model did not explicitly take into account the motion of the surrounding 
fluid caused by the particle displacements, and two adjustable parameters, namely a time 
step and a potential energy function to account for interparticle repulsions at close 
approach distances were used to fit simulation results to experimental data.  Nonetheless, 
to the authors’ credit, this was the first effort to account for the colloidal nature of 
nanofluids, a relevant aspect that had been overlooked by previous work.   
A model was presented that accounted for Brownian motion of particles but instead of 
addressing the convective flows due to the relative motion between particle and fluid, 
focused on the convective heat transfer from particles to the surrounding fluid (Jang et 
al., 2004).  It was implicitly assumed that this convective heat transfer occurs in parallel 
mode to the bulk conduction when in fact it occurs in series; having a fast convective 
transfer between particles and liquid would only shift the heat transfer limiting resistance 
to the bulk conduction but not necessarily increase overall heat flux.   
A model was proposed with two independent contributions to the thermal conductivity, 
namely a static term due to unequal properties of the fluid phase and the nanoparticle 
phase and a dynamic term due to particle motion (Kumar et al., 2004).  For the static 
term, it was explicitly assumed that there are two parallel paths for heat flow, one 
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through the nanoparticles and one through the surrounding liquid, which, for the reasons 
stated above, is a flawed assumption.  For the dynamic term, Kumar et al.  explored 
microconvection caused by the Brownian motion of nanoparticles as a way to explain the 
experimental dependence of heat transfer enhancement with temperature.  A mean 
particle velocity was defined using kinetic theory and it was assumed that the 
enhancement could be expressed as a linear function of this velocity; one adjustable 
parameter with no clear physical significance was used to fit the model with experimental 
data.   
A model with a static and a dynamic contribution to thermal conductivity that does not 
assume parallel heat transfer has been proposed (Koo et al., 2004).  The static term was 
expressed according to Maxwell’s (1873) expression for the effective conductivity of a 
suspension; the dynamic term was expressed as a function of (i) a translational particle 
velocity calculated from the kinetic theory of gases; (ii) the volume of a region of 
influence around a creeping sphere, and (iii) two adjustable functions to account for 
interparticle forces and for the fact that, as particle concentration increases, the fraction 
of liquid that travels with the particle decreases because of interactions with other 
moving particles.  While it seems appropriate to include electrostatic and hydrodynamic 
interactions in a model of nanoparticle motion, the functions that the authors proposed to 
account for it are not independent of each other and can only be determined by adjusting 
parameters to fit experimental data.  Furthermore, the volume of liquid dragged by a 
particle was calculated with the criterion of 99% vanishing impact of the velocity 
disturbance, which was estimated to be roughly equal to 105 times the particle volume; 
this is a dubious claim because it assumes that each particle carries with it its whole 
region of influence, when only the regions immediately adjacent, one or a few diameters 
away from the particle are strongly affected (1 diameter away from the particle, the 
velocity of the fluid is 90% of the velocity of the particle, 10 diameters away is only 
10%). 
Prasher (Prasher et al., 2005) proposed a semi-empirical heat transfer correlation to 
account for convection due to the motion of nanoparticles and was able to predict 
experimental data at different volume fractions and temperature by adjusting two 
parameters.   
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2.4.2.2 Models of Nanoparticle Dispersions in Flow Systems 
Several publications have addressed the topic of heat transfer enhancement under 
convective flow conditions.  It has been proposed that dispersion of nanoparticles under 
bulk fluid flow can flatten transverse temperature gradients in the fluid and thus enhance 
mass transfer (Xuan et al., 2000a),(Xuan et al., 2000b).  The authors proposed a 
correlation to calculate the Nusselt number in the presence of nanoparticles experiencing 
dispersion but did not validate it with experimental results.  The dispersion coefficient of 
the nanoparticles was calculated by using an expression obtained for flow through porous 
media in packed beds that contained an adjustable parameter.  The expression was 
derived from experimental data in packed beds, where particle size is at least two orders 
of magnitude larger. 
Possible mechanisms of nanoparticle migration (dispersion) in a solution have been 
studied; a flow model was proposed which includes shear-induced migration, shear-
induced viscosity gradients, and nanoparticle Brownian motion (Wen et al., 2004a).  The 
authors proposed that shear and viscosity effects disturb the suspension from its 
equilibrium state and Brownian diffusion tends to restore uniformity.  The authors did not 
validate their model with experimental data, but had this been done, they would have 
realized that since shear induced dispersion is proportional to a2 (a being the particle 
diameter), and typical particles diameters are ~O(10 nm), shear effects vanish for 
nanoscale sized particles.  Particle Peclet numbers based on reasonable flow velocities 
are smaller than unity and no significant enhancement is possible; therefore Wen et al.’s 
model is only useful for larger, micron-sized particles.   
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3 MATERIALS AND METHODS 
This chapter describes, first, the methods used to synthesize, purify and characterize 
hydrocarbon-coated magnetic nanoparticles.  Subsequently, the methods used to quantify 
the mass transfer enhancement in model systems and in biological systems are described.  
Finally, the techniques to measure the surface tension and viscosity of nanoparticle 
solutions are described. 
3.1  Nanoparticle Synthesis and Purification 
A solution of 94 g of ferric chloride hexahydrate (97% FeCl3⋅6H2O, Sigma-Aldrich) and 
34.4 g ferrous chloride tetrahydrate (99% FeCl2⋅4H2O, Sigma-Aldrich) in 100 g of water 
was stirred at 80 oC under nitrogen sparging for 30 min in a round bottom flask.  Next, 
100 g of potassium oleate (40 wt% paste in water, CH3(CH2)7CH=CH(CH2)7COOK, 
Sigma-Aldrich) was added, and the mixture was stirred for an additional 30 min.  A 100 
mL of an aqueous solution containing 28% ammonium hydroxide (NH4OH, 
Mallinckrodt) was added to the mixture, after which the solution immediately turned 
black because of the formation of magnetite.  The reaction continued at 80 oC under 
stirring and nitrogen sparging for 30 min, after which it is assumed that oleic acid had 
completely coated the magnetite aggregates.  Following the coating of the magnetite 
aggregates, 100 g of Hitenol–BC (Daiichi Kogyo Seiyaki) and 5 g of ammonium 
persulfate (>98% (NH4)2S2O8, Sigma-Aldrich) were added to the reaction mixture.  The 
reaction continued at 80 oC, under nitrogen sparging and vigorous stirring for 30 min to 
allow for the formation of covalent bonds between the propenyl group of Hitenol–BC and 
the double bond in the alkyl chain of the oleic acid.  Hitenol–BC is a polyoxyethylene 
alkylphenyl ether ammonium sulfate that contains a reactive propenyl group; the long 
PEO chains and the sulfate group confer stability in water when attached to the surface of 
oleic-acid coated magnetite particles.  The solution was cooled to room temperature and 
remained in the oven at 80 oC overnight, after which most of the residual ammonium 
hydroxide evaporated.  The dispersion was dialyzed against distilled water (14,000 kDa 
MWCO dialysis membrane, Pals) in a 20 L container under mild stirring for 2 days to 
remove unreacted potassium oleate, Hitenol–BC, ammonium persulfate, and other salts 
and metal ions.  Finally, the dialyzed solution was kept in the oven overnight at 80 oC, 
after which its solids contents were measured.  The final solid contents were typically 
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between 15 to 25% in weight.  This synthetic procedure yielded magnetic nanoparticles 
with an average number diameter between 20 and 25 nanometers (nm). 
Larger particles can be obtained by varying the relative amounts of potassium oleate and 
iron chlorides present at nucleation, i.e. before formation of the magnetite cores.   
Nanoparticles with an average number diameter of 40 to 45 nm are obtained by (i) 
initially adding 33 g of potassium oleate (instead of 100 g) to the iron chloride mixture, 
(ii) adding ammonium hydroxide as previously described and waiting for 15 min (iii) 
adding the remaining 67 g of potassium oleate (iv) carrying out the rest of the synthesis 
steps as previously outlined.   Nanoparticles with an average number diameter of 55 to 60 
nm are obtained by initially adding 10 g of potassium oleate and adding the remaining 90 
g after nucleation.    
3.2 Nanoparticle Characterization 
The size of the magnetic nanoparticles was characterized by Dynamic Light Scattering 
(DLS) using a Brookhaven BI-200SM instrument at a measurement angle of 90o. 
Samples were first passed through a 0.45 µm filter to remove dust particles before the 
measurements were taken.  A value of the diffusion coefficient is extracted from the 
autocorrelation function measured by DLS, and a hydrodynamic diameter is calculated 
using the Stokes-Einstein equation.  Number-averaged and volume-averaged size 
distributions are recorded.  The particle sizes cited in this work correspond to number 
averages.  All measurements were recorded in quadruplicate and reported as average 
values. 
Zeta potential measurements were recorded using a Brookhaven ZetaPals Zeta Potential 
Analyzer.  The built-in software uses the Smoluchowski potential model to convert 
electrophoretic mobility to zeta potential.  Measurements were recorded in quadruplicate 
and reported as average values.  Measurements for both DLS and zeta potential were 
conducted in 1000 ppm nanoparticle suspensions in fermentation media, the composition 
of which is described in Section 3.4.2, with an ionic strength of approximately 1 M.  The 
pH was adjusted with acetic acid or NaOH.  
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3.3 Experimental Determination of kLa 
Mass transfer characterization experiments are made using a physical method and a 
chemical method.  In the physical method, oxygen absorption from a gas phase to the 
liquid takes place after the system has been purged with an inert gas, and the change in 
dissolved oxygen is measured over time.  In the chemical method, the rate of oxidation of 
sodium sulfite in a water solution as measured with a mass spectrometer allows 
calculation of oxygen transfer rates. 
3.3.1 Physical Method: Stirred Beaker 
Dynamic measurements of dissolved oxygen via surface aeration were used to determine 
kL.  Experiments were conducted in a cylindrical, 10.3 cm diameter beaker, filled with 
500 mL of liquid, to a liquid height of approximately 6 cm.  The liquid was circulated 
slowly by a 4.5 cm diameter, 4-bladed, axial-flow impeller (pitched-blade with each 
blade measuring 3 cm wide and 1.5 cm long), placed centrally in the beaker.  The free 
surface of the liquid remained flat, i.e. it did not exhibit a vortex or appear broken at the 
agitation speeds studied (300 rpm and 500 rpm).  Dissolved oxygen was measured using 
a dissolved oxygen polarographic sensor (YSI 5010) connected to a data acquisition 
meter (YSI 5100).  A built-in barometer compensated for slight atmospheric pressure 
variations between runs.  The temperature was regulated at 37±0.5 oC with a water bath 
and the pH of the solution was adjusted to 7.0 before the start of the experiment.  Oxygen 
response curves were obtained by first sparging nitrogen until the dissolved oxygen 
concentration fell to zero and then monitoring the increase in dissolved oxygen 
concentration due to exposure of the liquid free surface to the room air.  To ensure a 
constant gas-liquid interfacial area (83.3 cm2), no air sparging was used during the 
second step.  The relatively long duration of the experiments (~1 hour) guaranteed that 
the time constant of the probe did not affect the response curves.  The dissolved oxygen 
data can be analyzed by constructing a mass balance of oxygen in the liquid phase as 
follows 
( ) ( )bulkO*OLbulkO*OLbulk,O 2,22,22 PPaHkCCakdtdC −=−=      (27) 
where kL is the liquid-side mass transfer coefficient (it is assumed that the gas-side 
coefficient is much larger), a is the specific interfacial area, bulkO2,P and 
*P
2,O
 are the partial 
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pressures of oxygen in the well-mixed bulk and at saturation respectively, bulkO2,C and 
*C
2,O
are the equivalent liquid phase partial pressures, H is the Henry’s law constant, and t 
is the elapsed time.  With 0bulkO2, =C  at t = 0, the integrated form of this expression is  
( ) RatkCC +−=− Lbulk,O*O 2,2,ln         (28) 
where R is an integration constant. The negative slope of a plot of the left hand side of 
the equation against time corresponds to the value of kLa.  
The rationale for characterizing mass transfer by a physical method in an agitated beaker 
is to avoid problems associated with interfacial area and gas holdup.  By conducting 
experiments in a system that has a fixed and known gas-liquid contact area, we obtained 
information on the value of kL. 
3.3.2 Chemical Method: Sodium Sulfite Oxidation 
Oxygen mass transfer was characterized via a chemical reaction in a laboratory scale 
aerated and agitated fermentor by using the sodium sulfite oxidation method, which is a 
well-known approach in the fermentation community.  The method is conducted using a 
sodium sulfite solution, which in the presence of Cu2+ catalyst, is oxidized following the 
reaction 
42
CoorCu
232 SONaO2
1SONa
22 ⎯⎯⎯ →⎯+ ++       (29) 
 
3.3.2.1 Volumetric mass transfer coefficient (kLa) determination  
The reaction rate of the sodium sulfite oxidation is independent of the sulfite 
concentration.  The reaction rate can be adjusted with temperature or with the catalyst 
concentration so that oxygen transport from the gas to the liquid, rather than the chemical 
reaction, is the limiting step.  The reaction rate should be fast enough to guarantee a mass 
transfer-limited regime, but not so fast that the reaction occurs mainly in the liquid film 
around bubbles.  The volumetric mass transfer coefficient kLa can be calculated by 
measuring the rate of reaction.  In the present work, this is done by measuring the 
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effluent gas composition with a mass spectrometer (Perkin-Elmer MGA 1600) and 
performing a mass balance on oxygen of the gas phase through the reactor 
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where OUR is the oxygen uptake rate, FN2,in is the flowrate of nitrogen entering the 
reactor, CO2 and CN2 are the concentrations of oxygen and nitrogen entering or exiting the 
reactor, and V is the working volume.   
The volumetric mass transfer coefficient can then be determined by rearranging Eq. 2 
bulk,O
*
O
L
22
CC
OURak −=          (31) 
where C*O2 corresponds to the equilibrium oxygen reading for the gas outlet; by using 
this value, it is assumed that the tank is perfectly mixed.  Alternatively, an average of the 
inlet and outlet gas concentrations or a mean-logarithmic value can be used for C*O2. 
Experiments were performed in a 20 L (5.5 L working volume) stirred tank reactor 
(Biolafitte fermentor system, model BL 20.2).  The tank was equipped with an Ingold 
type pH electrode, a Biolafitte dissolved oxygen electrode, a temperature probe, a bottom 
aeration system consisting of a 4-branded rotating sparger, and an agitator with 2 
Rushton 4-bladed turbine impellers.  A 0.67 M sodium sulfite solution was loaded into 
the reactor, and then a 1⋅10-3M solution of copper sulfate catalyst was added.  At this 
catalyst concentration the mass transfer is not chemically enhanced (Linek, 1966).  The 
pH was initially adjusted around 8.0 with sulfuric acid to avoid the accelerated reaction 
regime typical of sodium sulfite solutions at higher pH.  Temperature was maintained at 
37±0.5 oC, except when specified otherwise.   
3.3.2.2 Interfacial area determination 
Experiments to determine the gas-liquid interfacial area were conducted with the 
experimental system previously described.  The catalyst used was Co2+ instead of Cu2+ 
because the former permits operation in a regime where absorption is kinetically 
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enhanced (Section 4.2.2.2).  Experiments were run in a 0.67 M sodium sulfite solution, at 
37±0.5 oC, and at a pH of 8.5. 
 
3.4 Cell Culture Experiments 
3.4.1 Organism 
Escherichia coli BL21(DE3) [pUC18] 
Bacteria are a convenient choice for the purpose of this thesis because oxygen transfer is 
of great importance in their cultivation.  E. coli was chosen because it is an industrially 
relevant, thoroughly studied organism and it has a fast growth rate compared to other 
bacteria (its doubling time ranges from 20 to 40 min depending on the medium).  
Because of its fast growth rate, E. coli has a specific oxygen demand higher than most 
organisms; this makes attaining high cell densities particularly challenging.  High oxygen 
transfer rates are required to obtain such high cell densities and to avoid the accumulation 
of acetate, which is produced by E. coli under conditions of hypoxia and inhibits cell 
growth.   
3.4.2 Shake Flask Studies 
Shake flask experiments were conducted to test the biocompatibility of hydrocarbon-
coated magnetic nanoparticles.  Initially, Luria-Bertani (LB) medium was used for seed 
culture, with the following composition (in per Liter): 10 g NaCL, 10 g tryptone, 5 g 
yeast extract.  E. coli cells were grown in 100 mL of LB medium in a 500 mL shake flask 
overnight at 37 oC and 220 rpm without pH control.  Subsequently, the seed culture was 
pipetted into 500 mL shake flasks contaning chemically defined MR medium for 
fermentation culture.  The MR medium had the following composition (/L): 13.5 g 
KH2PO4 , 4.0 g (NH4)2HPO4, 0.7 g MgSO4·7H2O, 0.85 g Citric acid, 10 mL of 10 g/L 
FeSO4·7H2O, 10.0 mL of trace metal solution and 1.0 mL 20 g/L CaCl2·2H2O.  The trace 
metal solution had the following composition (in per Liter): 2.2 g ZnSO4·7H2O, 0.5 g 
MnCl2·4H2O, 1.0 g CuSO4·5H2O, 0.1 g Na2MoO4·2H2O, 0.02g Na2B4O7·10H2O, adjusted 
to pH 2.0 by HCl.  Flasks contained 100 mL of MR medium with 15 g/L of glucose and 
10% (v/v) of inoculated seed culture.  Cultures were performed at 37 oC and 220 rpm.  
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The optical density at 600 nm, which provides a measure of cell growth, was measured 
with a UV spectrophotometer (Hewlett Packard 8452A).   
 
3.4.3 Fermentation Experiments 
Fermentations were carried out in a 20 L Biolafitte fermentor system, at a 5.5 L working 
volume.  This was the same equipment used for the experimental determination of kLa 
through a chemical method (Section 3.3.2).  The inoculation volume was 10% (v/v); the 
seed culture for a fermentation was grown in 5, 500 mL shake flasks, containing 100 mL 
of LB medium each, cultured for 9 hours at 37 oC and 220 rpm, to an OD (600 nm) of 10 
units.  The temperature, pH, aeration rate, and agitation in the bioreactor were controlled 
at 37±0.5 oC, 7.0±0.1, 5.0 slpm, and 300±5 rpm respectively.  Phosphoric acid 2 M and 
NH4OH:NaOH:KOH 6 M 3:1.5:1.5 were used to control the pH.  The medium was the 
same used in the shake flask experiments (Section 3.4.2, MR medium), with the addition 
of 50 µg/mL of ampicillin.  Fed-batch fermentations were carried out starting with a 
glucose concentration of 50 g/L and proceeding until this concentration decreased to 
zero; after this point, glucose was fed in manual injections, each 55 mL of a solution of 
500 g/L glucose and 10 g/L MgSO4·7H2O, that brought the glucose concentration in the 
fermentation medium up to 5 g/L.  Dissolved oxygen was not controlled during the 
fermentation and therefore fell down to approximately zero with time; this was a 
deliberate strategy to bring the culture to an oxygen limited regime of growth.  Under this 
condition, exponential growth of the cells slows down and becomes linear.  Dissolved 
oxygen increased to values higher than zero when the glucose was consumed, and this 
was used as a criterion for a new glucose injection.  Throughout the experiment, foaming 
due to extracellular products generated by E. coli metabolism and also due to the 
presence of magnetic nanoparticles, when applicable, was controlled using antifoam Q7-
2243 DOW Corning and antifoam SIGMA 204.  Inlet and outlet gas compositions were 
measured by a Perkin Elmer MGA1600 spectrometer.  These data were used to calculate 
oxygen uptake rate history curves.  Samples for measurement of optical density (600 
nm), dry cell weight, glucose concentration, and ammonia concentrations were taken 
every hour.  Optical density at 600 nm was measured with a UV spectrophotometer 
(Hewlett Packard 8452A); measurements were repeated 3 times and averaged.  Dry cell 
weight measurements were carried out in triplicate; 1.5 mL samples were centrifuged at 
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6,000 rpm for 10 min.  The supernatant was removed and stored at -20 oC for glucose and 
ammonia analysis.  The pellet was resuspended with 0.9% NaCl solution and 
recentrifuged.  The supernatant was discarded and samples were dried to constant weight 
in a 70 oC oven.   
3.4.4 Cell Binding Experiments 
Cell binding experiments were conducted to determine the amount of cells bound to other 
cells via interactions with nanoparticles.  To measure cell binding, 4mL of E. coli grown 
on shake flasks in defined chemical media were mixed with 1 mL of nanoparticle 
solution for a final concentration of 0.5%w/v of nanoparticles in the mixture; pH was 
adjusted by HCl or  NaOH.  The mixture samples were left sitting for one hour before 
being tested for cell binding.  The mixture was passed through an HGMS column that 
captured the magnetic nanoparticles and cells bound to the particles, while the unbound 
cells flowed through the magnetic column and were collected at the bottom.  Cell binding 
was quantified by measuring the optical density at 600 nm of the feed and comparing it to 
that of the circulated samples with unbound cells. 
3.5 Dynamic Surface Tension Measurements 
Dynamic Surface Tension measurements were carried out to establish the surface activity 
of the nanoparticle solutions used.  The apparatus used was a Kruss DSA10 instrument.  
Measurements were conducted by first creating a fresh interface using a pendant drop or 
bubble at the end of a syringe; a light source placed behind the bubble (or drop) 
illuminated it; an image of the drop profile was captured using a CCD camera with edge 
detection software, and the Young-Laplace equation was used to fit a value of interfacial 
tension from the resulting profile.  A more complete explanation of the instrument and 
technique used has been presented (Faour et al., 1996; Song et al., 1996; Eastoe et al., 
2002). 
Sample preparation required elimination of trace impurities present in the nanoparticle 
solutions.  Several components used in the synthesis of the nanoparticles are surface 
active, especially Hitenol BC (a polymerizable surfactant) and oleic acid, and need to be 
washed away.  A 48 hour dialysis process used to clean the particle solutions eliminated 
most of the unreacted free molecules of components that were not attached to 
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nanoparticles, but left traces in solution.  Even concentrations on the ppm level of surface 
active compounds are enough to alter a surface tension measurement and therefore it was 
necessary to achieve a more thorough cleaning.  This was done by means of centrifugal 
filtration.  A 20 mL sample of dialyzed magnetic nanoparticles, 1% in weight, was loaded 
into a Centricon Plus-80 Millipore filter with a molecular weight cutoff of 100,000 
Daltons, and centrifuged at 14,000 rpm (20,800xG) for 20 min at room temperature in a 
5810 R Eppendorf Centrifuge.  Particles were retained in the filter and the solution 
containing the impurities permeated through the filter.  The surface tension of the 
permeated liquid was then measured.  If its equilibrium value was lower than 72 mN/m 
(the surface tension of deionized water), the retained fraction of particles was 
resuspended in deionized water and the ultracentrifugation cycle was repeated.  If, 
otherwise, the equilibrium surface tension of the permeated fraction was that of water, 
this was taken as an indication that the sample of particles had been completely cleaned.  
Typically 10 ultracentrifugation cycles were necessary for an adequate cleaning.   
3.6 Viscosity Measurement 
Rheological measurements were carried out in order to establish whether viscosity of 
nanoparticle solutions played a role in their mechanism of mass transfer enhancement.  
Measurements were made using a U-tube Canon-Fenske viscometer.   
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4 RESULTS 
 
4.1 Particle Characterization Results 
This section presents characterization data that establish that the colloidal stability of the 
particles used in this research is satisfactory in the range of conditions typically used in 
fermentation and beyond them.  Additionally, it is shown that it is possible to synthesize 
both charged and non-charged particles and particles of different size with minor 
modifications to the reaction protocol presented in Section 3.1.  Mass transfer 
characterization results presented in subsequent sections are obtained using only the 
particles synthesized according to the base recipe in 3.1, that is, Hitenol BC – coated 
nanoparticles with an approximate hydrodynamic diameter of 20 nm.   
4.1.1 Zeta Potential 
Stability in high ionic strength media is a crucial requirement for magnetic nanoparticles 
to be of use in a bioprocess.  Zeta Potential, which gives a measure of the surface charge 
on a particle, is a good indicator of the colloidal stability of a solution of particles.  
Generally, the greater the charge, the better the stability.   
Particles in solution tend to aggregate because of van der Waals forces acting between 
the bare particle surfaces;  this behavior can, however, be prevented by electrostatic and 
steric interactions.  The nanoparticles synthesized according to the protocol detailed in 
Section 3.1 acquire stability in aqueous media by both electrostatic and steric 
interactions.  Their exterior coating of Hitenol BC (polyoxyethylene alkylphenyl ether 
ammonium sulfate) contains a sulfonate group that confers a negative charge to the 
particle surface.  In addition, the 8-unit PEO chains in the Hitenol BC molecule can be 
highly solvated by water molecules, and in this form, two steric contributions are 
introduced; first, a repulsive osmotic contribution: as two surfaces approach, there is an 
increase in polymer concentration in the gap between the surfaces; second, there is an 
elastic contribution that accounts for the reduction in free energy on compression of the 
extended chains (Jeon et al., 1991).  As result of electrostatic and steric interactions, the 
nanoparticles synthesized remain colloidally stable at high ionic strength over a wide 
range of pH, as shown in Figure 4-1.  Hitenol BC – coated particles suspended in 
fermentation medium (see composition in Section 3.4.2) have a Zeta Potential of 
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approximately -30 mV in a pH range of 1.6 to 7.5; this indicates that the sulfonate groups 
on the surface remain deprotonated.  Figure 4-1 also shows the Zeta Potential of particles 
coated with Polyoxyethylene alkylphenyl ether (Noigen – RN, Dai-Ichi Kogyo Seiyaku), 
which do not have charged surface groups; accordingly, their Zeta Potential is 
approximaterly zero over the pH range studied.  Despite this, they remain colloidally 
stable over a wide range of pH as confirmed by Dynamic Light Scattering measurements 
shown in Figure 4-2.  The Noigen molecule has a PEO chain of 50 to 65 PEO units per 8 
units of the original Hitenol BC coating, which confers stability in water.  Stability in this 
case is obtained solely from steric interactions.  Both types of particle are synthesized 
using the same protocol with the only difference being the exterior coating.   
 
 
 
 
 
 
 
 
 
Figure 4-1.  Zeta potential of Hitenol BC – and Noigen RN – coated nanoparticles as 
a function of pH 
The results in Figures 4-1 and 4-2 show that following the synthesis procedure outlined 
in Section 3.1, both charged and non-charged particles stable over a wide range of pH 
can be synthesized.  The range of pH studied covers most practical biological 
applications.   
4.1.2 Dynamic Light Scattering 
Dynamic Light Scattering (DLS) measurements yield the diffusion coefficient of 
particles, from which, using the Stokes Einstein equation, the hydrodynamic diameter of 
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the particles can be calculated.  In addition to Zeta Potential measurements, 
hydrodynamic diameter data calculated from DLS measurements is a good indicator of 
the colloidal stability of a solution of particles.  The hydrodynamic diameter of  
Hitenol BC – coated magnetic nanoparticles has an average value (number average) of 20 
nm over the range of pH relevant to fermentation (around 7), as shown in Figure 4-2.  
The stability of the particles is still remarkable at a pH of 1.6, at which particles 
experience some minor aggregation to form clusters of approximately 40 nm in diameter.  
Also shown is the hydrodynamic diameter of Noigen RN – coated nanoparticles, which 
remains around 40 nm over a pH range of 5 to 9.   
 
 
 
 
 
 
 
 
Figure 4-2.  Hydrodynamic diameter of Hitenol BC – and Noigen RN – coated 
nanoparticles as a function of pH. 
 
4.1.3 Synthesis of Particles of Different Size  
Nanoparticles with a diameter below 50 nm are difficult to recover by HGMS (Moeser et 
al., 2004); however, smaller particles potentially yield larger mass transfer enhancement.  
Flexibility to synthesize nanoparticles of different size is therefore desirable.  A proof of 
principle that particles of size above 50 nm can be synthesized is imperative to guarantee 
that nanoparticles can be fully recovered. 
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Particle clusters of different size can be synthesized following a general method which 
consists of varying the ratio of attachment groups in the primary coating (COO- in the 
oleic acid molecule) to iron atoms in the surface of the magnetite cores  (Ditsch et al., 
2005a).  The appropriate ratio to obtain a desired particle size can be established by trial 
and error.  Larger particle clusters can be obtained by reducing the amount of primary 
coating (potassium oleate) at nucleation, i.e. before ammonia is added to the reaction 
mixture to cause nucleation of magnetite cores.  Subsequently, the rest of the primary 
coating typically used in the synthesis of single particles can be added to stabilize the 
clusters.  Table 4-1 shows the molar ratio of attachment groups to surface iron groups 
[ ] [ ]surfFeCOO /−  needed to obtain particle clusters of different sizes.  The clusters 
obtained are colloidally stable over a pH range of 3 to 9 at least, according to Zeta 
Potential and DLS measurements (not shown). 
Table 4-1.  Molar ratio of attachment groups to surface iron groups needed for 
obtention of particle clusters of different size 
Molar ratio [ ] [ ]surfFeCOO /−  Hydrodynamic diameter (nm) at pH 7 
3.1 20 ± 3 (single particle) 
1.0 42 ± 1 (cluster) 
0.31 58 ± 1 (cluster) 
 
4.2 Mass Transfer Characterization 
This section presents experimental findings of enhanced mass transfer in the presence of 
nanoparticle dispersions.  Systematic mass transfer studies are carried out using a 
physical method and a chemical method.   
4.2.1 Physical Method: Mass Transfer in an Agitated Beaker 
The rationale for characterizing mass transfer by a physical method in an agitated beaker 
is to avoid problems associated with interfacial area and gas holdup.  By conducting 
experiments in a system that has a fixed, known, gas-liquid contact area, the results 
obtained yield information on the value of the mass transfer coefficient, kL.  Details of the 
experimental setup used are outlined in Section 3.3.1.   
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Oxygen mass transfer into an aqueous liquid phase is enhanced in the presence of 
nanoparticles, as shown in Figure 4-3.  The time required to reach saturation is reduced 
by approximately 25% in the presence of a nanoparticle mass fraction of φ = 0.005  
(0.5% w/w).  Further reductions are attained at a larger particle holdup.  The reduction is 
less significant above φ = 0.01 (this effect is shown more clearly in Figure 4-5).  
Experimental points corresponding to each reading by the dissolved oxygen probe are not 
shown for clarity; instead, trend lines are presented. 
 
 
 
 
 
 
 
 
Figure 4-3.  Response curves of dissolved oxygen in a stirred beaker at increasing 
nanoparticle holdup. 
The first order curves shown in Figure 4-3 can be linearized making use of Eq. 28.  The 
absolute value of the slope calculated from the logarithm of the driving force as a 
function of time corresponds to kLa.  The driving force is defined as the saturation 
concentration of oxygen (C*) minus the concentration of oxygen in the bulk (Cbulk), 
which changes with time.  Inspection of the slopes in Figure 4-4 illustrates the increase of 
kL in the presence of nanoparticles.  The absolute enhancement in kL , defined as 
L,control
lesnanoparticL,
k
k
E =          (32) 
is plotted in Figure 4-5 as a function of the nanoparticle holdup for different agitation 
rates.  It can be observed that (i) enhancement increases linearly at particle holdups 
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below φ = 0.01, and plateaus above this value and (ii) enhancement is greater at a lower 
agitation rate because the ratio of kL values in water at the two agitation speeds studied, 
rpmL,300rpmL,500 kk , is larger than the equivalent ratio of kL values in the presence of 
particles.  Data points are the average of 3 experiments. 
 
 
 
 
 
 
 
 
Figure 4-4.  Linearized response curves of dissolved oxygen in a stirred beaker at 
increasing nanoparticle holdup.  The absolute value of the slope corresponds to the 
value of kLa 
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Figure 4-5.  Absolute enhancement in kL as a function of nanoparticle holdup in a 
stirred beaker at different agitation rates 
The experimental values of kL for the base case (φ = 0) can be compared with theoretical 
predictions from available models to gain an understanding of the underlying mechanism 
of mass transfer in the absence of nanoparticles.  The experimental value of kL can be 
estimated from inspection of Figure 4-4.  The line corresponding to the water control  
(φ = 0) has a negative slope of 4.49⋅10-4 s-1.  Since the specific interfacial area of the 
system is 16.7 m-1, an experimental value of kL of 2.69⋅10-5 m/s is obtained.  Film 
theories alone cannot be used to obtain a theoretical prediction of kL without resorting to 
experimental data to estimate its hydrodynamic parameters (residence time of liquid 
elements at the interface or surface renewal frequency).  Lamont’s model (Eq. 6), based 
on isotropic turbulence theory, yields a prediction for kL from easily measurable physical 
quantities (kinematic viscosity, diffusivity, and power input per unit volume).  The power 
input into the beaker can be estimated as (Rushton et al., 1950) 
c
6
5
i
3
pi
0 106.7
60
g
DNNN
P ⋅
⎟⎠
⎞⎜⎝
⎛
=
ρ
         (33) 
where P0 is power input in HP, Ni is the number of impellers, Np is the power number, Di 
is the impeller diameter in cm, ρ is the liquid density in g/cm3, and gc has a value  
980 cm/s.  With the parameters listed in Table 4-2, a value of kL = 3.06⋅10-4 m/s is 
estimated using Eq. 6. This value overestimates the experimental value of kL by one order 
of magnitude. This suggests that energy dissipation in the beaker is nonhomogenous and 
therefore the basic premise of isotropic turbulence does not apply to this system.   
Table 4-2.  Parameters used to calculate kLa in the agitated beaker 
Ni (number of impellers) 1 
Np (power number) 1 (Figure18-17 in (Perry et al., 1997)) 
N (agitation rate) 300 rpm 
Di (impeller diameter) 4.5 cm 
ν  (kinematic viscosity of water at 37 oC) 6.95⋅10-7 m2/s 
DO2,L (oxygen diffusivity  at 37oC) 3.22⋅10-9 m2/s 
P0 (calculated power input, Eq. 33) 3.1⋅10-5 HP 
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ε (calculated power input per unit mass) 0.023 m2/s3 
kL (calculated kL, Eq. 6) 3.06⋅10-4 m/s 
A hydrodynamic model of mass transfer in a stirred vessel that does not need to postulate 
a turbulent transport mechanism has been proposed (Olander, 1963, 1964).  The 
mathematical treatment takes into account two regions in the stirred vessel.  The first is a 
core region that contains the liquid swept by the agitator, which rotates like a solid body 
at ω∞ rad/s.  The second is an annular region between the core and the vessel walls; ω∞ is 
a fraction of the agitator disk speed (ω∞/ωdisk <1).  Olander proposes the following 
expression for kL 
     (34) 
where α is a parameter with a value of 0.94,  Γ(4/3) is the complete gamma function of 
4/3, with a value of 0.893, Ac/At is the ratio of the interfacial area of the core region and 
the total interfacial area, which for the experimental setup used in the present work has a 
value of 0.2.  The surface of the liquid rotates at ¼ th of the angular velocity of the 
agitator shaft (therefore ω∞/ωdisk = 0.25), as measured experimentally.  Olander’s 
expression predicts a value of kL = 3.46⋅10-5 m/s.  This value is 30% higher than the 
value determined experimentally.  Therefore, Olander’s expression gives a reasonable 
description of the base mass transfer coefficient in the experimental system in the 
absence of nanoparticles.   
The mechanism of mass transfer in the presence of nanoparticles will be discussed in 
more detail in chapter 5.  The experimental data presented in this section show that the 
mass transfer coefficient kL is altered in the presence of nanoparticles regardless of area 
effects.   
4.2.2 Chemical Method: Sodium Sulfite Oxidation 
The purpose of the experiments presented in this section is to characterize mass transfer 
enhancement by nanoparticles in the same equipment in which fermentations are 
conducted.  Mass transfer data is obtained by a chemical method in a cell-free system, 
which is significantly less laborious than conducting fermentations.   
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Oxidation of sodium sulfite has frequently been used as a model system for 
characterization of gas-liquid absorption.  A comprehensive review of the method, in 
which the experimental data gathered to date are systematically organized and guidelines 
are set for the determination of absorption characteristics of mass transfer equipment has 
been presented (Linek et al., 1981).  A convenient feature of the method is that separate 
determinations of the volumetric mass transfer coefficient kLa and the gas-liquid 
interfacial area a can be made by manipulating the relative magnitude of the rate of 
chemical reaction and the rate of mass transfer.   
4.2.2.1 Determination of the volumetric mass transfer coefficient 
(kLa) 
The absorption flux of oxygen undergoing a pseudo-n-order reaction with sulfite ions in 
an aqueous phase can be expressed as  (Danckwerts, 1970) 
( ) 2LO1*Onbulk,O*O L2,222 12 kDCknCCaaN n ++−=⋅ −      (35) 
where N is the absorption rate, a the interfacial area, and n is the reaction order.  The 
relative magnitudes of the rate of oxygen consumption by reaction and the rate of mass 
transfer can be compared through the Hatta number 
L
O
1*
O L2,21
2
k
DCk
nHa
n
n
−
+=         (36) 
If the following conditions are met 
0bulk,O2 =C           (37a) 
30.Ha <           (37b) 
( )*OSO 223 zC/CHa −<<          (37c) 
where z is a stoichiometric coefficient (moles of sulfite reacted per mole of oxygen), then 
the reaction is limited by mass transfer and kLa can be obtained from oxygen absorption 
rates according to 
akCaN O L
*
2
=⋅          (38) 
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The left hand side of Eq. 38 corresponds to the OUR as defined by Eq. 30, which is 
experimentally measured.  The concentration of oxygen at the gas-liquid interface, CO2*, 
can be calculated from the inlet and outlet concentrations of oxygen and nitrogen in the 
absorption equipment.  The physical dimensions of the absorption equipment and the 
fluid properties used for the determination of kLa are summarized in Table 4-3.   
Table 4-3.  Physical dimensions and properties of the system used for the 
determination of kLa by the sodium sulfite method 
Tank Diameter 21.7 cm 
Impeller Diameter 9.8 cm 
Impeller Type 2 Rushton Turbines, 4-bladed 
Liquid Volume 5.5 L 
Liquid Height 17 cm (approx.) 
Oxygen Diffusivity (37 oC) 3.22⋅10-9 m2/s 
Oxygen Solubility in 0.67 M sulfite (37 oC) 0.124 mol/m3 
Viscosity (37 oC) 6.95⋅10-4 (Pa⋅s) 
Surface Tension (37 oC) 70 mN/m (40 mN/m with nanoparticles) 
 
 Measurements of OUR at a set of operating conditions have been obtained by means of a 
mass spectrometer and are summarized in Table 4-4.  Details of the experimental 
procedure followed are outlined in Section 3.3.2.  Correct estimation of the value of CO2* 
requires accounting for the decreased solubility of oxygen in a sodium sulfite solution.  
The following expression has been proposed to estimate the solubility H of pure oxygen 
in a solution of sodium sulfite (Linek et al., 1981)  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+−⋅= −
−−
2
3
2
3
SO
SO6
193301
9407011602109095
C.
C.
T
.exp.H      (39) 
where H has units of M/atm, T has units of K, and C has units of M.  Using this 
expression, H = 5.89⋅10-4 M/atm for a 0.67 M sodium sulfite solution at 37 oC.  For a 
partial pressure of 0.21 of oxygen in air, a value of CO2*= 1.24⋅10-4 M/atm is obtained.   
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In the presence of 1⋅10-3 M of Cu2+ catalyst, the rate of reaction is fast enough to maintain 
the dissolved oxygen levels in the bulk at zero, 0bulk,O2 =C  (except for a brief induction 
time at the beginning of the experiments, during which the cuprous ions are being 
formed), according to the readings of a dissolved oxygen probe.  Yet the chemical 
enhancement effect of the absorption rate caused by the catalyst is not enough to obtain a 
fast-reaction regime (Linek et al., 1978), in which absorption rates would depend solely 
on reaction kinetics and not on mass transfer.  Using a value of the kinetic constant kn of 
3.5 s-1 (Augenstein, 1967), a diffusion coefficient of oxygen at 37 oC of 3.2⋅10-9 m2/s, and 
typical values of kLa in the absorption equipment calculated from Eq. 6 and Eqs.  24 to 
26, which range from 5⋅10-4 m/s to 8.3⋅10-4 m/s, it is found that the values of the Hatta 
number calculated from Eq. 36 range from 0.21 to 0.13.  Additionally, the term 
( )*OSO 223 zC/C −  has a value of 2700 for a 0.67 M sodium sulfite solution.  Therefore, the 
constraints placed by Eqs.  37a, 37b and 37c are satisfied.   
The results presented in Figures 4-6 and 4-7 show that a 3 to 4 fold enhancement of kLa 
can be obtained at a particle mass fraction as low as φ = 0.0025 (0.25% w/v).  At higher 
particle concentrations kLa can still be further enhanced, but diminishing returns are 
obtained as the particle fraction approaches φ = 0.01.  The results illustrate that several-
fold enhancement can be obtained over a broad range of operating conditions of power 
input per unit volume and superficial velocity which are representative of most 
industrially relevant conditions.   
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Table 4-4.  Operating conditions and experimental measurements of absorption rate 
for the determination of kLa by the sodium sulfite method 
key: φ = particle fraction, N = agitation rate, Q = air flow rate, PG/VL = Power input per unit volume 
calculated from the aeration number correlation (Oyama et al., 1955), with P0 (ungassed power input) 
calculated by Eq. 33, Vs = superficial velocity based on cross-sectional vessel area ( )2Ts R/VQV π⋅= ,  
V = tank volume, RT = tank radius, OUR = oxygen uptake rate, ( ) 2/CCC *outlet*inlet*ave += , kLa as defined by  
Eq. 2,  Ha as defined by Eq. 36, E defined by Eq. 32. 
φ N       
(rpm) 
Q         
(L⋅L-1 
⋅min-1) 
PG/VL 
(HP/1000L) 
Vs     
(cm⋅min-1) 
OUR 
(mmol⋅L-1 
⋅h-1) 
Cave*     
(atm) 
kLa 
(mmol⋅L-
1⋅h-1⋅ atm-1) 
Ha E 
0.0 300 1.0 2.8 14.5 20.6 0.208 111.8 0.20 1.0 
0.0 400 1.0 6.9 14.5 37.8 0.206 186.1 0.17 1.0 
0.0 500 1.0 14.7 14.5 64.4 0.204 325.4 0.14 1.0 
0.0 600 1.0 25.5 14.5 96.0 0.201 499.8 0.12 1.0 
0.0 288 0.5 2.8 7.2 14.1 0.205 68.7 0.20 1.0 
0.0 300 1.0 2.8 14.5 20.6 0.206 99.9 0.20 1.0 
0.0 320 1.5 2.8 21.7 27.3 0.207 132.2 0.20 1.0 
0.0 325 2.0 2.8 28.9 30.8 0.207 148.7 0.20 1.0 
0.0 350 3.63 2.8 52.5 39.4 0.208 189.2 0.20 1.0 
0.0025 250 1.0 1.5 14.5 45.5 0.202 225.3  3.1
0.0025 300 1.0 2.8 14.5 73.7 0.196 375.6  3.4
0.0025 400 1.0 6.9 14.5 143.0 0.183 804.0  4.3
0.0025 500 1.0 14.7 14.5 192.3 0.174 1104.5  3.4
0.0025 288 0.5 2.8 7.2 53.4 0.190 281.0  4.1
0.0025 300 1.0 2.8 14.5 73.7 0.196 375.6  3.8
0.0025 320 1.5 2.8 21.7 107.4 0.197 546.2  4.1
0.0025 325 2.0 2.8 28.9 128.3 0.198 647.9  4.4
0.0025 350 3.63 2.8 52.5 153.2 0.202 758.0  4.0
0.005 250 1.0 1.5 14.5 48.6 0.201 241.9  3.3
0.005 300 1.0 2.8 14.5 88.1 0.194 455.2  4.1
0.005 400 1.0 6.9 14.5 149.8 0.182 822.9  4.4
0.005 500 1.0 14.7 14.5 233.3 0.167 1401.6  4.3
0.005 288 0.5 2.8 7.2 65.3 0.186 351.8  5.1
0.005 300 1.0 2.8 14.5 88.1 0.194 455.2  4.6
0.005 320 1.5 2.8 21.7 131.6 0.194 679.7  5.1
0.005 325 2.0 2.8 28.9 139.2 0.197 706.6  4.8
0.005 350 3.63 2.8 52.5 192.3 0.200 961.0  5.1
0.01 250 1.0 1.5 14.5 48.0 0.201 238.8  3.3
0.01 300 1.0 2.8 14.5 100.6 0.191 526.1  4.7
0.01 400 1.0 6.9 14.5 171.8 0.178 965.5  5.2
0.01 500 1.0 14.7 14.5 251.4 0.163 1541.7  4.7
0.01 288 0.5 2.8 7.2 73.6 0.183 403.2  5.9
0.01 300 1.0 2.8 14.5 100.6 0.191 526.1  5.3
0.01 320 1.5 2.8 21.7 177.3 0.188 943.4  7.1
0.01 325 2.0 2.8 28.9 182.6 0.193 946.5  6.4
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Figure 4-6.  kLa measured by the sodium sulfite method as a function of power input 
per unit volume at several nanoparticle mass fractions.  Operating conditions are 
T=37 oC, pH = 8.0, Vs= 14.5 cm/min 
 
 
 
 
 
 
 
 
Figur
e 4-7.  kLa measured by the sodium sulfite method as a function of superficial 
velocity at several nanoparticle mass fractions.  Operating conditions are T=37 oC, 
pH = 8.0, PG/VL= 2.8 HP/1000 L 
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Figure 4-8.  Absolute enhancement in kLa measured by the sodium sulfite method as 
a function of power input per unit volume at several nanoparticle holdups.  
Operating conditions are T=37oC, pH = 8.0, Vs= 14.5 cm/min 
 
 
 
 
 
 
 
 
 
Figur
e 4-9.  Absolute enhancement in kLa measured by the sodium sulfite method as a 
function of superficial velocity per unit volume at several nanoparticle holdups.  
Operating conditions are T=37oC, pH = 8.0, PG/VL= 2.8 HP/1000L 
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Figures 4-8 and 4-9 show the influence of power input per unit volume and superficial 
velocity on the absolute enhancement in kLa as defined by Eq. 32.  It is apparent from 
Figure 4-8 that enhancement initially increases with power input, reaches a maximum 
and subsequently decreases.  As shown in Figure 4-9, superficial velocity does not have 
noticeable effect on enhancement, possibly because the bubble rise velocity does not 
determine the typical exposure time of the liquid elements at the gas-liquid interface.  As 
shown in Figure 4-11, a time scale based on isotropic turbulence prediction well kL. 
Through a non-linear least squares fit of all data presented in Table 4-4, an empirical 
correlation for kLa as a function of particle mass fraction, power input per unit volume, 
and superficial velocity is obtained 
( ) ( )eSd
L
Gc
L 1 VV
Pbaak ⎟⎟⎠
⎞
⎜⎜⎝
⎛+= φ         (40) 
where the values of the estimated parameters are a = 12.9±5.1, b = 4.0±1.0, 
c = 0.34±0.09, d = 0.63±0.05, and e = 0.57±0.09 (95% confidence intervals).  As shown 
in Figure 4-10, Eq. 40 gives a satisfactory correlation of all data.  This correlation can be 
used for scale-up purposes but does not contain physical insight into the mechanism of 
mass transfer enhancement by nanoparticles.   
 
 
 
 
 
 
 
 
 
Figure 4-10.  Comparison of calculated kLa values (Eq. 40) with experimental data 
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The first step towards understanding the mechanism of enhanced mass transfer – which 
will be dealt with in detail in Chapter 5 – is to identify the physical mechanism of mass 
transfer in the absence of nanoparticles.  The experimental values of kLa for the base case 
(φ=0) can be compared with theoretical predictions using expressions for the mass 
transfer coefficient kL and for the interfacial area a.  A theoretical prediction of kL has 
been obtained by using the Lamont model (Eq. 6), which is based on isotropic turbulence 
theory.  A value of c = 0.448 in Eq. 6 is used, as proposed by (Linek et al., 2005) for data 
obtained in a stirred tank system in the presence of sodium sulfite solutions.  Eqs.  24, 25, 
and 26 are used for the estimation of the bubble diameter, interfacial area, and holdup, 
respectively.  The product of kL (obtained from Eq. 6) and a (obtained from Eq. 25) is 
plotted in Figure 4-11 and compared with experimental data.  The theoretical predictions 
from isotropic turbulence theory agree well with experimental data.  It is apparent that 
power input per unit volume is an appropriate quantity to correlate the mass transfer 
coefficient. 
 
 
 
 
 
 
 
 
 
Figure 4-11.  Comparison of experimental values of kLa obtained in the absence of 
nanoparticles with theoretical predictions of kLa obtained from isotropic turbulence 
theory.  Theoretical values of kL are calculated from Eq. 6 and values of a are 
calculated from Eq. 25 
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4.2.2.2 Determination of the interfacial area (a)  
The purpose of the experiments in this section is to establish whether nanoparticles 
increase the gas-liquid interfacial area for mass transfer and to quantify this effect.   
The reaction rate of the oxidation of sodium sulfite can be manipulated with the catalyst 
concentration so that it becomes several folds greater than the mass transfer rate; 
generally a criterion of Ha ≥ 3 is used.  The absorption rate is then greatly enhanced by 
the reaction and the effect of the hydrodynamic conditions can be ignored.  Under these 
conditions, the absorption rate depends only on the interfacial area and reaction kinetics.  
Eq. 35 reduces to  
L2,22 O
1*
On
*
O 1
2 DCk
n
aCaN n−+=⋅        (41) 
The appropriate experimental conditions for determination of the interfacial area can be 
predicted if information on the kinetic constant of the reaction is available.  Adoption of 
literature data on kinetic constants for the sulfite oxidation is discouraged (Linek et al., 
1981) because the literature data show significant differences between measurements 
made in equivalent conditions by different authors.  Alternatively, an appropriate range 
of catalyst concentrations that permit operation in a regime where absorption is 
kinetically enhanced can be selected.  This is done by performing absorption experiments 
at increasing catalyst concentration, as shown in Figure 4-12.  For this purpose, Co2+ is 
used instead of Cu2+ because it is not possible to attain an enhanced absorption regime 
with Cu2+ (Linek et al., 1981); instead, low Co2+ concentrations generally suffice.  It is 
found that above a concentration of Co2+ of 1⋅10-5 M, the absorption rate increases with 
catalyst concentration.  This observation is equally valid in the presence of nanoparticles 
at mass fractions of φ = 0.0025 and φ = 0.005.  Inspection of Figure 4-12 reveals that 
nanoparticles increase the gas-liquid interfacial area; it also reveals that doubling the 
nanoparticle mass fraction, from φ = 0.0025 to φ = 0.005, does not have a significant 
effect on the interfacial area.  These considerations are made under the assumption that 
the reaction rate is not altered in the presence of nanoparticles. 
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Figure 4-12.  Absorption rate as a function of cobalt ion concentration at pH=8.5, 
T=37 oC, PG/VL=2.8 HP/1000 L, Vs = 14.5 cm/min, and [SO32-] = 0.67 M.  Above 
[Co]2+ = 10-4 M, the absorption rate is enhanced by the chemical reaction 
The interfacial area enhancement can be quantified using Eq. 41, even if an accurate 
measure of the kinetic constant is not available.  Rearranging Eq. 41 and taking a ratio in 
the presence and absence of particles, the following expression for the area enhancement 
is obtained 
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where the values of the kinetic constants and the diffusion coefficient initially present in 
Eq. 41 cancel.  The CO2* terms do not cancel because the average value of the oxygen 
solubility depends on the oxygen partial pressure in the gas phase, which is not constant 
during the bubble residence time in the absorption equipment; instead, it decreases as the 
oxygen in the bubble is depleted.  Inlet and outlet values of oxygen concentration in the 
gas phase are measured by a mass spectrometer and the corresponding concentrations in 
the liquid phase are determined using Henry’s law and Eq. 39.  The concentration of 
oxygen at the gas-liquid interface, CO2*, is calculated as the average of the inlet and outlet 
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saturation concentrations of oxygen in the liquid phase.  There is agreement in the 
literature that the sodium sulfite oxidation under heterogeneous conditions has (i) order 
zero with respect to the sulfite concentration at high concentrations of sulfite (typically 
above 0.3 M) and (ii) order two with respect to dissolved oxygen at oxygen 
concentrations below 3.6⋅10-4M (Reith et al., 1973; Laurent et al., 1974; Sathyamurthy et 
al., 1979; Ogawa et al., 1982).  Therefore, n in Eq. 42 has a value of 2.   
Table 4-5 summarizes the values of area enhancement corresponding to experimental 
data collected above a catalyst concentration of 10-4 M in Figure 4-11 (below this catalyst 
concentration, the mass transfer is not enhanced by the chemical reaction and Eq. 42 does 
not yield the true ratio of interfacial areas). 
 Table 4-5.  Calculated values of interfacial area enhancement as a function of Co2+ 
concentration at pH = 8.5, T = 37 oC, PG/VL=2.8 HP/1000 L, VS = 14.5 cm/min, and 
[SO32-] = 0.67 M 
 
The average value of area enhancement in the presence of φ = 0.0025 mass fraction of 
nanoparticles at PG/VL = 2.8 HP/1000 L and VS = 14.5 cm/min is 3.1±0.5 (average of the 
4 values in column 5, for φ = 0.0025, Table 4-5).  For φ = 0.005, this value is 3.4±0.2.  At 
equivalent conditions of power input and superficial velocity, the corresponding 
enhancement in kLa (Table 4-4) is 3.4 for φ = 0.0025 and 4.1 for φ = 0.005.  Therefore, 
φ                 
(mass fraction) 
[Co]2+               (M) 
OUR     
(mmol⋅L-1 ⋅h-1) 
CO2* average  
(mol/m3) 
Earea         
(Eq. 42) 
0.0 1.30⋅10-4 66.3 0.116 1.0 
0.0 2.40⋅10-4 85.5 0.114 1.0 
0.0 3.40⋅10-4 92.2 0.114 1.0 
0.0 4.46⋅10-4 101.9 0.113 1.0 
0.0 2.55⋅10-3 271.0 0.094 1.0 
0.0025 1.30⋅10-4 155.4 0.107 2.7 
0.0025 2.40⋅10-4 192.8 0.102 2.7 
0.0025 3.40⋅10-4 241.3 0.097 3.3 
0.0025 4.46⋅10-4 276.5 0.093 3.6 
0.005 1.30⋅10-4 203.0 0.101 3.8 
0.005 2.40⋅10-4 226.6 0.099 3.3 
0.005 3.40⋅10-4 245.8 0.097 3.4 
0.005 4.46⋅10-4 260.3 0.095 3.3 
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for this particular experimental condition, most of the enhancement in kLa is due to an 
increase in the interfacial area.  As will be shown in Section 4-3, the nanoparticles used 
in this work reduce the surface tension, σ, of an aqueous solution to approximately  
40 mN/m; which is 30 mN/m below the value for pure water (70 mN/m at 37 oC).  
According to Eqs.  24 and 25, the gas-liquid interfacial area in an agitated, sparged 
absorption vessel exhibits a σ -0.6 dependence.  Therefore, a lower surface tension yields a 
higher interfacial area.  Using the values of surface tension in the presence and in the 
absence of particles previously mentioned, Eqs.  24 to 26 can be used to predict a 
theoretical area enhancement factor of 1.46.  This factor is lower than the experimental 
values in Table 4-5.  This suggests that the mechanism by which nanoparticles increase 
gas-liquid interfacial area is more complex than merely surface tension reduction.  It is 
possible that nanoparticles also affect interfacial area by preventing bubble coalescence.   
A quantitative analysis of the relative contribution of area effects to the total 
enhancement in kLa can only be made by performing interfacial area measurements for 
the range of conditions presented in Table 4-4.  Estimations of area enhancement have 
been made as described previously for a nanoparticle mass fraction of φ = 0.0025 and the 
results are summarized in Table 4-6.   
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Table 4-6 Calculated values of interfacial area enhancement as a function of power 
input and superficial velocity at pH = 8.5, T = 37 oC, [Co2+] = 2.40⋅10-4 M, and 
[SO32-] = 0.67 M 
 
The data in column 8 of Table 4-6 are presented graphically in Figure 4-13.  The shapes 
of the interfacial area enhancement curve and the kLa enhancement curve as a function of 
power input (Figure 4-13a) for φ = 0.0025 closely resemble each other; this indicates that 
the kLa enhancement trend – an initial increase at low power input followed by a decrease 
above approximately 8 HP/1000 L – is caused primarily by a change in interfacial area 
rather than a change in kL.  Figure 4-13a further shows that (i) enhancement in kL also 
contributes to total enhancement and (ii) enhancement in kL decreases with power input; 
therefore, the higher, the base mass transfer coefficient, the lower the enhancement in kL.  
Both these observations are consistent with the data presented in Section 4.2.1.  
Enhancement data as a function of superficial velocity, shown in Figure 4-13b, do not 
show as clear a pattern; while the kLa enhancement remains approximately constant as a 
function of superficial velocity, area enhancement increases above a superficial velocity 
of 20 cm/min. 
 
φ N          
(rpm) 
Q   
(L⋅L-1 ⋅min-1) 
PG/VL 
(HP/1000L) 
Vs     
(cm⋅min-1) 
OUR 
(mmol⋅L-1⋅h-
1) 
CO2* 
average  
(mol/m3) 
Earea      
(Eq. 42) 
0 250 1.0 1.5 14.5 57.9 0.117 1.0 
0 300 1.0 2.8 14.5 85.5 0.114 1.0 
0 400 1.0 6.9 14.5 103.3 0.112 1.0 
0 500 1.0 14.7 14.5 125.0 0.111 1.0 
0 288 0.5 2.8 7.2 54.2 0.118 1.0 
0 300 1.0 2.8 14.5 85.5 0.114 1.0 
0 320 1.5 2.8 21.7 113.0 0.111 1.0 
0 325 2.0 2.8 28.9 115.3 0.111 1.0 
0.0025 250 1.0 1.5 14.5 130.6 0.202 2.5 
0.0025 300 1.0 2.8 14.5 192.8 0.196 2.7 
0.0025 400 1.0 6.9 14.5 300.4 0.183 4.0 
0.0025 500 1.0 14.7 14.5 315.5 0.174 3.5 
0.0025 288 0.5 2.8 7.2 122.7 0.190 2.5 
0.0025 300 1.0 2.8 14.5 192.8 0.196 2.7 
0.0025 320 1.5 2.8 21.7 312.9 0.197 3.9 
0.0025 325 2.0 2.8 28.9 330.0 0.198 4.1 
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Figur
e 4-13.  Enhancement in kLa, a, and kL for φ = 0.0025, pH=8.0, T=37 oC as a function 
of (a) power input per unit volume at Vs= 14.5 cm/min, and (b) superficial velocity 
at PG/VL= 2.1 kW/m3.  The enhancement in kL is calculated as aLL EEE akk =  
The considerations in this section have been made without using kinetic data describing 
the catalyzed sodium sulfite oxidation.  Calculation of the gas-liquid interfacial area is 
only possible if kinetic data are used.  While the goal of this section has been to 
determine interfacial area enhancement rather than interfacial area, an approximate 
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estimate of the latter can be made to verify that the experimental values are on the order 
of theoretical predictions.  A value of kn0 of 1.3⋅103 m3/(mol⋅s) at 20 oC and  
[CoSO4] = 3.56⋅10-4 M can be calculated from published data (Laurent et al., 1974).  This 
value can be used to calculate kn at the experimental conditions of the present work  
(37 oC and [CoSO4] = 2.4⋅10-4 M) using the following expression (Linek et al., 1981) 
⎭⎬
⎫
⎩⎨
⎧ ⎟⎠
⎞⎜⎝
⎛ −−= 0
11
0
4
40
nn exp][CoSO
][CoSO TTR
En
kk        (43) 
Taking the activation energy of the reaction En to be 53.4 kJ/mol (Linek et al., 1971), a 
value of kn of 2.94⋅103 m3/(mol⋅s) is calculated.  The oxygen uptake rate measured at 
PG/VL = 2.8 HP/1000 L, Vs = 14.5 cm/min, and φ = 0 (Table 4-6), its corresponding value 
of CO2*, and the estimation obtained for kn are used in Eq. 41 to obtain an estimate of the 
interfacial area of 245 m-1.  This value is 18% lower than the prediction of 297 m-1 that 
can be obtained using Eqs.  24, 25, and 26.   
4.2.2.3 Effect of Temperature on Enhancement 
This section investigates the effect of temperature on the mass transfer coefficient in 
aqueous solutions of two types of nanoparticles: (i) 20 nm particles synthesized as 
described in Section 3.1 and (ii) 80 nm clusters of magnetite cores coated with random 
copolymers of ethylene oxide (EO) and propylene oxide (PO) repeat units, the synthesis 
method of which has been described elsewhere (Moeser et al., 2002b; Ditsch et al., 
2005a).  Experiments are performed following the procedure outlined in Section 3.3.2.1.  
A range of temperatures from 20 oC to 80 oC is explored.  Oxygen uptake rates measured 
at PG/VL = 2.8 HP/1000 L, Vs = 14.5 cm/min, and a mass fraction φ = 0.0025 for both 
types of particles are shown in Figure 4-14; measurements for a water control are shown 
for comparison.  Oxygen uptake rates for water remain approximately constant in the 
temperature range studied.  Although diffusivity of oxygen increases with temperature, 
its solubility in water decreases and the overall effect is to maintain the oxygen uptake 
rates in water roughly constant.  The solubility of oxygen in hydrocarbons also decreases 
with temperature; however, as opposed to the data for the water control, the oxygen 
uptake rates for both types of particles show a strong positive dependence on 
temperature. 
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Figure 4-14.  Oxygen uptake rate as a function of temperature for 80 nm – PPO–
PEO–coated particles, 20 nm – oleic acid–coated particles, and a water control 
 
 
 
 
 
 
 
 
Figure 4-15.  Enhancement in kLa as a function temperature for 80 nm–PPO–PEO–
coated particles and 20 nm – oleic acid–coated particles. 
 
Enhancement in kLa as a function of temperature is shown in Figure 4-15.  A strong 
temperature dependence is evident for both types of particles; a 3 to 6 fold enhancement 
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of kLa takes place from 25 oC to 80 oC in the presence of φ = 0.0025 oleic acid–coated 
particles, whereas a 1.3 to 2.7 fold enhancement of kLa takes place from 20 oC to 60 oC in 
the presence of φ = 0.0025 PPO–PEO–coated particles. 
The enhancement trends as a function of temperature are not a product of the different 
solubility (or temperature dependence of solubility) of oxygen in water, oleic acid, and 
PPO–PEO copolymers.  Although the solubility of oxygen in oleic acid is 4 times higher 
than in water, a solution with mass fraction φ = 0.0025 of oleic acid–coated nanoparticles  
contains approximately a mass fraction of oleic acid φoleic = 0.2⋅0.0025 = 5⋅10-4, which 
can account for only 5⋅10-4⋅4 = 0.002 (0.2%) of the total amount of oxygen solubilized in 
the media; PPO–PEO copolymers are not reportedly known as oxygen carriers.   
Figures 4-14 and 4-15 show that both nanoparticles coated with oleic acid and 
Hitenol BC (20 nm) and PPO–PEO–coated nanoparticles (80 nm) enhance mass transfer.   
 
4.3 Surface Tension Measurements 
This section investigates the equilibrium surface tension of aqueous solutions of 
nanoparticles.  The experiments test the hypothesis that the nanoparticles used in the 
present work can accumulate at a gas-liquid interface. 
A concentrated solution of nanoparticles (~5% w/v) is thoroughly stripped of free 
surfactant by following the method described in Section 3.5.  Subsequently, the 
equilibrium surface tension of purified samples is measured, starting at 4% w/v and 
successively diluting the samples up to 10 million times.  The equilibrium surface tension 
of the samples exhibits a decrease from 71.9 mN/m at φ = 5⋅10-9 to 45.8 mN/m at  
φ = 4⋅10-5, as shown in Figure 4-16.  Beyond a nanoparticle mass fraction of φ = 4⋅10-5, 
the change in surface tension becomes less pronounced.  The data inside the box marked 
with a discontinuous line can be studied making use of the Gibbs adsorption isotherm, 
which relates the surface coverage Γ of the gas-liquid interface to the rate of change of 
the surface tension with the natural logarithm of concentration ∂γ/∂ln(c)  
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∂−=Γ γ          (44) 
 
 
 
 
 
 
 
 
 
Figure 4-16: Equilibrium surface tension of aqueous solutions of oleic acid–coated 
nanoparticles as a function of nanoparticle mass fraction. 
Values of Γ are computed from the slopes between consecutive points in the marked box 
in Figure 4-16.  The values of Γ conform well to a Langmuir isotherm, as shown in  
Figure 4-17.  A Langmuir isotherm has the form 
φ
φ
a
a
max 1 K
K
+=Γ
Γ          (45) 
where Γmax is the maximum surface coverage of the interface and Ka is the equilibrium 
adsorption constant.  This expression can be rearranged in the form 
maxamax
1
Γ+Γ=Γ
φφ
K
         (46) 
Therefore, a plot of φ/Γ as a function of φ has a slope of 1/Γmax  and crosses the y axis at 
1/(Γmax⋅Ka).  The values of Γmax and Ka estimated from the data in Figure 4-16 are  
1.98⋅10-10 mol/cm2 and 1.38⋅106 mL/g, respectively. 
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Figure 4-17:  Fit of calculated surface coverage data to a Langmuir isotherm 
The molecule used for the exterior coating of the nanoparticles, Hitenol BC, is a 
polymerizable surfactant.  It is likely that the surface activity of the nanoparticles is 
bestowed by this exterior coating.  Alternatively, it is possible that certain regions of the 
oleic acid–coated magnetite cores are not completely coated by Hitenol BC during the 
synthesis process and that some hydrophobic chains of oleic acid remain exposed to the 
surrounding water; a nanoparticle with hydrophobic regions and charged regions on its 
surface could behave as a surfactant. 
 
4.4 Viscosity Measurements 
This section presents the investigation of the dependence of the viscosity of oleic acid–
coated nanoparticles on nanoparticle volume fraction.  The results obtained are used to 
establish that viscosity does not play a role in the mechanism of mass transfer 
enhancement by nanoparticles.  Measurements are made following the procedure outlined 
in Section 3.6. 
Abnormal increases in viscosity in the presence of nanoparticles have been reported for 
alumina in water and titania in water in the range of 1 to 10% volume fraction (Pak et al., 
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1998; Wang et al., 1999); values of viscosity measured by the previous authors are 
several fold larger than the predictions of typical viscosity models such as the Einstein 
model. 
In the present work, viscosity in the range of nanoparticle volume fractions (φV) of 0 to 
0.65 has been studied.  This corresponds to a range of nanoparticle mass fractions (φ) of 0 
to 0.25 (Appendix 8.1).  Viscosity in the range of volume fractions explored in  
Section 4.2 (φV from 0 to 0.026, or φ from 0 to 0.01) has approximately the same value as 
the viscosity of water, as shown in Figure 4-18.  In addition Figure 4-18 shows that the 
viscosity is only significantly increased beyond that of the base fluid (water) above a 
nanoparticle volume fraction of 0.1 (φ = 0.04).  The experimental values are lower than 
the predictions of the Einstein model.  This finding indicates that the viscosity increase 
by nanoparticles is not responsible for the leveling of the kL enhancement curve as a 
function of particle mass fraction reported in Figure 4-5 (Section 4.2.1). 
 
 
 
 
 
 
 
 
Figure 4-18: Reduced viscosity of oleic acid–coated nanoparticles as a function of 
volume fraction at 37 oC 
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4.5 Biocompatibility Studies 
Shake flask tests are conducted to determine the biocompatibility of nanoparticles with 
the host organism chosen.  Shake flask cultures of E. coli are performed in an aqueous 
control and at nanoparticle mass fractions of 0.005, 0.01, and 0.02.  E. coli grows well in 
the presence of nanoparticles, as shown in Figures 4-19 and 4-20; this is evinced by 
optical density and glucose concentration measurements, which are both indicative of cell 
growth.  A slightly prolonged lag phase in shake flask culture is typical of studies 
conducted in the presence of dispersed PFC emulsions (McMillan, 1990); this 
phenomenon is not observed when E. coli is grown in the presence of nanoparticles.  
Results closely similar to those shown in Figure 4-19 and 4-20 are obtained when E. coli 
is grown in the presence of Noigen RN – coated nanoparticles (not shown).   
 
 
 
 
 
 
 
 
 
 
Figure 4-19.  Optical density at 600 nm of E. coli grown in a shake flask as a 
function of culture time at increasing concentrations of oleic acid–coated 
nanoparticles 
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Figure 4-20.  Glucose consumption by E. coli grown in a shake flask as a function of 
culture time at increasing concentrations of oleic acid–coated nanoparticles 
 
4.6 Fermentations 
Fermentations in the presence of nanoparticles are conducted to characterize the 
enhancement of oxygen mass transfer in biological media and to quantify the 
enhancement of cell growth.  The results are compared to a control run conducted in the 
absence of nanoparticles.  The results presented in this section show that oleic acid–
coated nanoparticles enhance oxygen transfer rates and that this enhancement translates 
to corresponding increased cell concentration.  The mass transfer enhancements 
measured are lower than those measured by a chemical method in Section 4.2.2 at 
equivalent conditions of power input per unit volume and superficial velocity  
(2.8 HP/1000 L and 14.5 cm/min); possible causes of this discrepancy are discussed.  
Experiments are conducted as outlined in Section 3.4.3. 
The results presented in Figures 4-21 and 4-22 confirm the capacity of oleic acid–coated 
nanoparticles for enhancing oxygen mass transfer and consequently improving cell 
growth.  Figures 4.21a and 4.21b show, respectively, the dissolved oxygen profiles and 
oxygen uptake rate profiles for 3 fermentations conducted at mass fractions of oleic acid–
coated nanoparticles of φ = 0, φ = 0.0057, and φ = 0.02.  Since no control action is taken 
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to regulate the dissolved oxygen concentration in the bioreactor, oxygen levels decrease 
to zero as cells proliferate.  For the control run, dissolved oxygen falls to zero at 6 hours; 
this happens at 8 hours for φ = 0.0057 and approximately 9 hours for φ = 0.02.  The 
extended period during which dissolved oxygen concentrations remain above zero in the 
presence of nanoparticles is evidence that greater mass transfer rates are maintained as 
compared to the control run.  Figure 4.21b shows that beyond the time at which dissolved 
oxygen levels fall to zero, greater oxygen uptake rates are maintained in the presence of 
nanoparticles; before this time, cell growth is not limited by oxygen mass transfer and 
therefore no differences are manifest between the runs.  The average integrated values of 
the oxygen uptake rate under oxygen transfer–limited growth, defined as 
∫
==−
=
final
0DO
)(1
0DOfinal
average
t
t
dttOUR
tt
OUR       (47) 
are 1.3 greater than the control for φ = 0.0057 and 1.4 greater for φ = 0.02.  Since the 
dissolved oxygen concentration in the medium is zero under the conditions defined in  
Eq. 47, according to Eq. 2, the values of kLa are respectively 1.3 and 1.4 times greater 
than in the control as well. 
Higher cell growth rates are maintained in the presence of nanoparticles when the 
cultures grow under an oxygen transfer–limited regime, e.g., after 6 hours in the control 
run, or after 8 hours for φ = 0.0057.  This is supported by the optical density and dry cell 
weight profiles shown in Figure 4-22.  The enhancement in optical density or dry cell 
weight in the presence of nanoparticles has a value of 1.5 immediately after oxygen 
limitations are encountered; it has a value of 1.3 near the end of the fermentations.  Since 
nanoparticles contribute to the optical density of a sample, data in Figure 4-22a have 
been normalized by substracting the background optical density due to nanoparticles 
from each data point; base values of optical density are measured for samples containing  
φ = 0.0057 and φ = 0.02 and devoid of cells.  Similarly, dry cell weight data in  
Figure 4-22b has been normalized by substracting from each data point the corresponding 
weight of nanoparticles as measured in a sample devoid of cells.  Optical density values 
are linearly related to dry cell weight values (not shown); this supports the use of optical 
density measurements for quantifying cell growth in opaque solutions of nanoparticles. 
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Figure 4-21  (a) Dissolved oxygen profiles and (b) Oxygen uptake rate profiles  
during fed–batch fermentations conducted at mass fractions φ = 0, φ = 0.0057, and  
φ = 0.02 of oleic acid–coated nanoparticles 
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Figure 4-22  (a) Optical density at 600 nm and (b) Dry cell weight during fed-batch 
fermentations conducted at mass fractions φ = 0, φ = 0.0057, and φ = 0.02 of oleic 
acid–coated nanoparticles 
The increase in cell growth does not occur as a result of an alteration of the E. coli 
metabolism by nanoparticles; it is instead a sole consequence of the greater oxygen 
transfer rates.  Although E. coli can metabolize oleic acid, glucose will always be the 
most readily utilized carbon source if both nutrients are available.  Furthermore, only 
traces of free molecules of oleic acid are expected to be present in the nanoparticle 
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solutions; the oleic acid incorporated in the nanoparticles is chemically attached to the 
magnetite cores and therefore cannot be consumed by cells.  These observations are 
supported by Figure 4-23, which shows that the specific oxygen uptake rates (the amount 
of oxygen consumed per g of cell and per unit time) are the same with and without 
nanoparticles.  Therefore, in the presence of nanoparticles, each cell has the same oxygen 
consumption rate on average, although there are more cells per unit volume. 
 
 
 
 
 
 
 
 
Figure 4-23  Specific oxygen uptake rates during fed-batch fermentations conducted 
at mass fractions φ = 0 and φ = 0.0057 of oleic acid–coated nanoparticles 
In summary, the results presented in this section show that: 
The enhancement in mass transfer obtained in fermentations is smaller than that 
measured by the sodium sulfite method (Section 4.1.2).  Several reasons for this 
difference can be speculated: 
• The coalescing behavior of aqueous solutions of sodium sulfite may be different from 
that of fermentation medium due to different salt concentrations and different 
viscosities.  The mechanism by which nanoparticles enhance interfacial depends most 
likely on the coalescing behavior of the media (Section 5).   
• The reaction rate of the sulfite oxidation could be altered in the presence of 
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to traces of heavy metal ions (Linek et al., 1978); these could be present in the 
nanoparticle solutions in the form of Fe2+ and Fe3+.   
• Nanoparticles adhere to the surface of bacteria and cause them to cluster; this could 
create an additional diffusional resistance to oxygen mass transfer.  The phenomenon 
of nanoparticle to cell attachment is studied in the following section.   
A 40% increase in oxygen uptake rate and dry cell weight of E. coli can be obtained 
using a nanoparticle mass fraction of 0.57% in a fed-batch fermentation.  It is expected 
that the increases in the oxygen transfer coefficient and in the cell concentration reported 
in this section would translate to corresponding increased concentration of products 
synthesized by the host organism, such as primary and secondary metabolites.   
The oxygen transfer rate in a biological medium has been increased in a conventional 
agitated and aerated fermentor without any mechanical modification. 
 
4.7 Cell Binding Experiments 
This section first tests the hypothesis that oleic acid-coated nanoparticles attach to  
E. coli; the hypothesis is confirmed and the phenomenon of nanoparticle to cell 
attachment is quantified.  It is shown that both charged and non-charged nanoparticles 
attach to cells to a similar extent.  This suggests that the mechanism of attachment 
involves hydrophobic interactions.  Experiments are performed as outlined in  
Section 3.4.4. 
Attachment of charged nanoparticles to Pichia pastoris as a function of pH has been 
reported (Ditsch, 2004) and hypothesized to be mediated by a protein on the surface of 
the cell.  The two types of nanoparticle described in Section 4.1 are used to test 
attachment to E. coli.  Oleic acid–coated nanoparticles with an exterior coating of  
Hitenol BC (8 PEO units) are stabilized by electrostatic and steric effects.  Oleic acid-
coated nanoparticles with an exterior coating of Noigen RN (60 PEO units) are stabilized 
by steric effects only.  Results in Figure 4-24 show the fraction of bound cells that are 
retained in a HGMS column as a function of pH; magnetic nanoparticles attach to these 
cells and cause them to be retained in the metal mesh of the HGMS column.  Higher cell 
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concentrations result in an increased percentage of bound cells.  The percentage of cells 
attached shows a minimum at a pH around 6 to 7 and increases at lower and higher pH.   
 
 
 
 
 
 
Figure 4-24  Nanoparticle-to-cell binding at φ = 0.005 as a function of pH for (a) 1.05 
g/L E. coli, (b) 5.18 g/L E.coli. 
The binding patterns are similar for both charged and non-charged particles.  At least in 
the case of Noigen RN–oleic acid–coated nanoparticles, electrostatic interactions are not 
responsible for the attachment.  It can be speculated that the attachment process is 
mediated by hydrophobic interactions.  There could be regions on the nanoparticle 
surface not covered by PEO, where the first coating of oleic acid would expose the 
hydrophobic chains.   
According to the literature, adhesion of proteins (free proteins or proteins on the surface 
of a cell) to flat surfaces can be prevented by PEO chains of a minimum length between 
35 and 100 EO units (Nagaoka et al., 1983), although shorter PEO chains can also 
efficiently reject proteins provided that the chain density is high (Prime et al., 1993).  In 
the present study, nanoparticles coated with molecules that contain 8 PEO-unit chains 
and 60 PEO-unit chains both showed strong binding to cells; this observation suggests 
that the packing of the PEO chains on the surface of nanoparticles is imperfect or 
otherwise that the observations by Nagaoka et al.  and Prime et al.  do not apply to highly 
curved surfaces like nanoparticles.   
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5 MODELING 
The experimental data presented in Section 4.2 suggest the existence of two separate 
mechanisms of mass transfer enhancement in the presence of nanoparticles.  According 
to the data, enhancement can take place by an increase in gas-liquid interfacial area or by 
an increase in the mass transfer coefficient. 
This section is organized in three parts.  First, a mechanism by which nanoparticles 
enhance interfacial area is presented.  This mechanism hypothesizes that nanoparticles 
accumulated at the gas-liquid interface stabilize gas bubbles against coalescence, 
therefore maintaining smaller bubble sizes and greater interfacial areas.  Second, a 
mechanism by which nanoparticles enhance the mass transfer coefficient is proposed.  
This mechanism hypothesizes that random motion of the nanoparticles generates 
microconvection in the surrounding fluid.  Third, predictions of the two models are 
compared to the experimental data.   
5.1 Mechanism of Gas-Liquid Interfacial Area Enhancement 
This section first reviews recent literature that shows that colloidal particles can act as 
surfactants by adsorbing at the gas-liquid interface and preventing gas bubble 
coalescence.  The finding that colloidal particles can adsorb to an interface is in 
agreement with the results presented in Section 4.3.  Second, it is shown that the energy 
necessary to remove a nanoparticle from the air-water interface is sufficiently large to 
assume that the adsorption is irreversible.  Third, a scaling analysis is used to justify that 
nanoparticles can adsorb to a bubble interface on a shorter time scale than the typical 
time scale for collisions between bubbles, and therefore collisions take place between 
bubbles that are already protected with a layer of colloid.  Fourth, an expression to 
predict the interfacial area enhancement as a function of the agitation conditions is 
proposed.  Finally, the experimental mass transfer enhancement as a function of 
temperature is discussed qualitatively.   
5.1.1 Literature Review: Colloidal Particles at Interfaces 
5.1.1.1 Particle-Stabilized Emulsions and Foams 
A number of studies have demonstrated the ability of fine solid particles to stabilize 
emulsions and foams.  As early as 1903, a publication reported the formation of a layer of 
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fine solid particles around air bubbles in water (Ramsden, 1903).  Subsequent research 
established that particles could act as emulsifiers (Pickering, 1907) and identified the 
importance of the contact angle, θ, that the particle makes with an oil-water interface in 
determining the type of emulsion, i.e.  oil/water or water/oil (Finkle et al., 1923).  After 
these initial studies, no work was published in this field until recently, when interest in 
the study of particles as stabilizers was revived in the areas of food science (Gibbs et al., 
1999; Rousseau, 2000) and biomedicine (Schutt et al., 2003).  Lately, work by Binks and 
collaborators, has established the role of particles in emulsion stabilization processes 
(Binks et al., 2001; Binks, 2002; Arditty et al., 2003; Aveyard et al., 2003; Du et al., 
2003; Binks et al., 2005a; Binks et al., 2005b).  Fine solid particles have also been shown 
to stabilize aqueous foams (Pugh, 1996); hydrophilic particles enhance foam stability by 
accumulating at the plateau borders of the foam films and delaying the process of film 
drainage.  A review of the foam stabilizing properties of proteins and nanoparticles has 
been presented (Murray et al., 2004).   
This set of observations is consistent with experimental measurements of this thesis and 
with previous work (Olle et al., 2005).  In this thesis, it was observed that nanoparticles 
coated with oleic acid and Hitenol BC increased slightly the foam height in a sparged 
beaker; such foaming could be eliminated by the addition of small amounts of 
antifoaming agents.  In Olle et al.’s patent, Yin conducted fermentations in the presence 
of nanoparticles coated with perfluorocarbons (Zonyl® FSA, Dupont), and observed 
greatly enhanced foaming in a sparged, agitated system.  The severe foaming was very 
difficult to reduce, even with continuous addition of antifoaming agents. 
5.1.1.2 Particles Compared to Surfactants 
The research mentioned previously suggests that particles can act as surfactant molecules 
by accumulating at interfaces between fluids.  However, significant differences exist 
between the two.  First, while surfactant molecules can assemble to form micelles in the 
bulk of a solution, particles – if properly stabilized in water – do not form assemblies.  
Second, while the key parameter in determining at what phase is a surfactant 
preferentially located is the hydrophile-lipophile balance number, the corresponding 
parameter for spherical particles is the contact angle between the particle and the 
interface (Binks, 2002).  This angle is smaller than 90o for hydrophilic particles, e.g., 
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metal oxides (Binks, 2002) (the particle would lie preferentially on the water side of an 
air-water interface) and bigger than 90o for hydrophobic particles (the particle would lie 
preferentially on the air side).  Third, as will be discussed in detail in the following 
section, the energy of adsorption of nanoparticles to an interface is on the order of 1000 
kT, while for surfactants it is typically on the order of 1 to 10 kT (where 1 kT is the 
thermal energy).  As a result, once they have been adsorbed to an interface, nanoparticles 
do not detach (Binks, 2002).  In contrast, surfactant adsorption is a reversible process.   
5.1.1.3 Strong Interfacial Adsorption of Particles 
When a spherical particle of radius R, initially immersed in the water phase, adsorbs at 
the air-water interface, the following areas are created or destroyed: a fraction of the 
interface between the particle and the water is lost (Sp-w), and replaced by a new interface 
between the particle and air (Sp-a); furthermore, an area at the air-water interface (Sa-w), 
which is a function of θ, as illustrated in Figure 5-1, is eliminated by the presence of the 
particle.  The energy of adsorption of the particle to the interface is a function of the 
interfacial tension γaw, R, and θ, and can be expressed as (Binks, 2002; Dong et al., 2003; 
Wang et al., 2005) 
( )2aw2 cos1 θγπ += RE         (48) 
With γaw = 72 mN/m, R = 10 nm, and assuming θ = 90o, an upper bound of E = 5500 kT 
is found.  For angles greater or smaller than 90o, the value of E decreases.  The energy 
necessary to remove a nanoparticle once it has attached to an air-water interface is 
therefore sufficiently large to assume that the adsorption is irreversible.    
 
 
 
 
Figure 5-1  Illustration of the 3-phase contact angle θ between a spherical 
nanoparticle and an air-water interface 
θ
air
water
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Irreversible adsorption of particles to an air-water interface has been demonstrated by a 
Langmuir apparatus (Aveyard et al., 2000).  Partially hydrophobic silica nanoparticles 
with a diameter of 20 nm were shown to stabilize air bubbles (Dickinson et al., 2004); a 
sharp increase in stability occurred when 2 M NaCl was added to the aqueous phase.  The 
authors rationalized that the increased stability was a result of the screening of 
electrostatic repulsions between the particles attached at the interface, which would in 
turn allow a closer packing of particles and a change in the contact angle θ.  The lack of a 
reliable method to measure θ for particles in the nanometer range is a limitation that 
pervades the research reviewed in this section.   
5.1.1.4 Coalescence Prevention 
Coalescence is a two-step process.  First, two air bubbles have to approach and collide.  
Second, the intervening aqueous film has to drain to a critical thickness, which is 
typically on the order of 50 nm (Tobin et al., 1999), to the point of rupture, which allows 
the two drops to merge.  If a layer of nanoparticles surrounds the bubble, particles must 
be forced out of the interface for coalescence to occur.  According to the previous 
estimation of the energy of adsorption, there is a large energy barrier that prevents this 
from happening.   
Prevention of coalescence by addition of surfactants has been widely studied.  Similarly, 
block copolymers have been shown to reduce coalescence in polymer blends,  
Nanoparticles have been shown to reduce coalescence in air-water systems, oil-water 
systems, and polymer blends.  In all three cases, the mechanisms by which coalescence is 
suppressed are not well understood.   
It has been proposed that copolymers reduce coalescence by reducing interfacial tension 
(Vilgis et al., 1990), by inducing repulsive interactions between droplets (Milner et al., 
1996; Lyu et al., 2002), and by creating concentration gradients along the interfaces that 
result in Marangoni stresses, which in turn stabilize droplets (Van Puyvelde et al., 2002).  
Coalescence suppression is more effective with larger amounts of compatibilizer and at 
larger molecular weights of the block copolymer (Van Hemelrijck et al., 2005).  
Recently, a review on coalescence reduction by copolymers has been presented (Van 
Puyvelde et al., 2001).  Addition of diblock copolymers to a polymer blend results in 
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smaller particle sizes and a narrower particle size distribution (Sundararaj et al., 1995).  
Sundararaj et al.  showed that there exists a critical shear rate in polymer systems where a 
minimum drop size is achieved.  They reasoned that at higher shear rates the droplets 
have higher approach velocities and their coalescence probability increases.  
Nanoparticles have also been shown to suppress coalescence.  Silica particles reduce 
coalescence of polymer blends (Vermant et al., 2004), oil-water emulsions (Arditty et al., 
2003), and air bubbles in water (Du et al., 2003) 
5.1.2 Proposed Mechanism of Interfacial Area Enhancement by 
Nanoparticles 
5.1.2.1 Outline  
Nanoparticles can increase interfacial area by (i) inhibiting coalescence and (ii) 
facilitating bubble break-up by reducing surface tension.  As previously shown in Section 
4.2.2.2, facilitated bubble breakage due to a lower interfacial tension can account for an 
area enhancement factor of only 1.5, and therefore cannot be the sole mechanism 
responsible for interfacial area enhancement.  This section shows that nanoparticles 
stabilize gas bubbles by adsorbing on their interface on a time scale smaller than the 
typical collision time between two bubbles.  This yields a stabilized dispersion in which 
bubble size is determined by breakage processes, whereas in the absence of nanoparticles 
bubble size is dominated by coalescence processes and an unstable dispersion exists. 
5.1.2.2 Scaling analysis 
According to Kolmogorov’s theory, the mean size of bubbles in an isotropic turbulent 
flow is determined by the size of the smallest eddies.  An expression to calculate the size 
of bubbles in stirred tank reactors based on a balance of disruptive forces (which are a 
function of turbulence intensity) and stabilizing forces (which are a function of surface 
tension) due to Metkin et al.  was used in Section 4.2.2 to predict kLa as a function of 
power input.  As shown in Figure 4-11, a model that incorporates Eqs.  24 to 26 predicts 
accurately the experimental data in the absence of nanoparticles.   
The average bubble size predicted from the simultaneous solution of Eqs. 24 and 26 is 
shown in Figure 5-2.  It can be observed that the bubble diameter initially decreases 
rapidly with increasing power input and subsequently the decrease is slower.  The 
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asymptote at increasing power inputs shows that the smallest average bubble diameter 
that can be obtained with the experimental equipment used is approximately 300 µm. 
 
 
 
 
 
 
 
 
 
Figure 5-2  Average bubble diameter calculated with Eqs.  24 and 26. 
The theoretical expressions for the average bubble diameter based on Kolmogorov’s 
isotropic turbulence theory (Metkin et al., 1985; Kawase et al., 1987; Kawase et al., 
1988) predict a dependence with surface tension with an exponent of 3/5.  With typical 
values of surface tension of 72 mN/m for an air-water interface and 39 mN/m for an air-
water interface in the presence nanoparticles (Figure 4-16), interfacial area is predicted to 
increase by approximately 50% in the presence of nanoparticles.   
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Considering that experimental measures of area enhancement in the presence of 
nanoparticles were on the order of 4-fold (Figure 4-13), the prediction of Eq. 49 is quite 
inaccurate.  This is not surprising since the ratio in Eq. 49  only considers bubble 
breakage processes, which are affected by surface tension, but does not incorporate 
coalescence processes.   
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To establish whether the processes of bubble breakage and coalescence occur in the 
hydrodynamic flow studied, several characteristic times can be estimated (Tcholakova et 
al., 2003) 
The average residence time, tR, is the time that an air bubble spends in the agitated tank.  
Experiments are performed at a working volume of 5.5 L at typical gas flow rates of 
1 vvm (5.5 L/min).  Therefore, it can be estimated that tR ~ 1 min.   
The deformation time characterizes the process of bubble breakage and deformation and 
is given by the expression (Levich, 1962) 
3/2
B
3/2
m
3/1
C
D
D 5 d
t ερ
η=          (50) 
with typical values of ηD (viscosity of the bubble, air) = 1.7x10-5 N⋅s/m3, ρc (density of 
the continuous phase, water) = 1000 kg/m3, εM (power input per unit mass) = 2 m2/s3, and 
dB (bubble diameter) = 1 mm, a value of tD ~ 0.2 µs is obtained.  Since tD is much smaller 
than tR, bubbles have enough time to deform and break while they rise in the fermentor.  
Furthermore, the lifetime of the eddies of size ~ dB, given by 
3/2
B3/1
m
3/1
C
C dt ε
ρ=           (51) 
takes on values of 2 to 10 ms in the range of εM studied, which is four to five orders of 
magnitude larger than tD; this is a sufficiently long time for the air bubbles to deform and 
break.  The lifetime of turbulent eddies is also a measure of the characteristic duration of 
one collision between bubbles.   
The process of bubble coalescence is characterized by the ratio of the mean collision 
time, tC, to the drainage time, tDR, which characterizes the drainage of the liquid film 
between two bubbles.  The drainage time (for which there is no theoretical expression at 
present) is, in turn, affected by the presence of surface active agents in the medium.  The 
characteristic time for adsorption of the nanoparticles to the bubble interface in turbulent 
regime can be estimated using an expression for surfactant adsorption (Levich, 1962) 
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ηΓ=           (52) 
where CS is the particle concentration in % weight (~0.25 to 1) and Γ is the surface 
concentration corresponding to a monolayer coverage, which is estimated at  
Γ = 2.7 mg/m2 assuming that a surface monolayer of particles forms and that this 
monolayer has a packing density of 0.9 ( ( ) 9060361 .≈π ).  A range of values for tA 
from 1.85 to 18.5 µs is obtained.  Since tA << tC, (the process of nanoparticle adsorption 
to the bubble interface is much faster than the process of bubble collision), collisions take 
place between bubbles that have had sufficient time to get coated with nanoparticles.   
5.1.2.3 Effect of agitation on interfacial area enhancement  
 
Experimental data for gas-liquid dispersions is usually characterized using the Sauter 
mean diameter (d32) of bubbles; d32 is the quotient of the third and second momentum of 
the probability density function of the bubble sizes 
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where ni is the number of bubbles of size i.   
According to Eq. 53, d32 is related to the maximum and minimum stable bubble sizes in 
the dispersion, dmax and dmin.  The maximum stable drop size can be estimated from the 
balance of the turbulent and surface tension forces acting on a bubble.  It has been 
postulated (Hinze, 1955) that a drop breaks when the ratio of the inertial and surface 
tension forces acting on it, given by the Weber number, 
 σ
ρ 3i2C DNWe =          (54) 
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reaches a critical value.  The maximum stable drop size, dmax , above which a drop 
breaks, is a function of the agitation speed, N (Hinze, 1955; Calderbank, 1958; Shinnar, 
1961) 
2.1'
1
5/3
1
max −− == NCWeC
D
d
i
        (55) 
where the constants C1 and C1’ are characteristic of the geometry of the impeller type and 
size.   
The minimum bubble size that can remain stable against coalescence can be estimated 
from the condition that the turbulent energy on a pair of bubbles is insufficient to prevent 
their adhesion (Shinnar et al., 1960) 
75.0'
2
8/3
2
min −− == NCWeC
D
d
i
        (56) 
where C2 and C2’ are constants.   
According to Eqs.  55 and 56, both dmax and dmin decrease with the agitation speed, but 
dmax decreases faster.  In a dispersion maintained by agitation, a dynamic equilibrium will 
be established between breakage and coalescence, such that any bubble larger than dmax 
will break up, and any bubble smaller than dmin will coalesce (Liu et al., 1999). 
Given that d32 can be measured experimentally (by optical microscopy or laser 
diffraction) while neither dmax or dmin can be measured accurately, some authors have 
attempted to establish whether models with the functional form of Eqs.  55 and 56 also 
describe the change of d32 as a function of agitation.  It has been shown experimentally 
(Shinnar, 1961; Sprow, 1967)  that for systems where the bubble size is dominated by the 
breakage process, data for d32 are well represented by Eq. 55 (d32 ~ dmax), while for 
systems where the bubble size is dominated by coalescence processes, data for d32 are 
well represented by Eq. 56 (d32 ~ dmin).  An example of the former would be a dilute 
dispersion of air in water, while an example of the latter would be a concentrated 
dispersion.   
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The values of the d32 corresponding to the experiments shown in Figure 4-13 can be 
calculated from the experimental values of interfacial area by using Eq. 25 and from 
calculated values of gas phase holdup obtained using Eq. 26.  Figure 5-3 presents a log-
log plot of the average bubble size as a function of agitation speed.  The values of the 
slopes for the control and for an experiment at φ = 0.0025 are -0.78 and -0.39.  These are 
in reasonable agreement with the exponent values of -0.75 and -1.20 in Eqs. 55 and 56.  
The exponent of -0.78 indicates that, in the absence of nanoparticles, an unstable 
dispersion dominated by coalescence is obtained.  In contrast, the exponent of -1.39 in 
the presence of nanoparticles indicates that a fully stabilized dispersion dominated by 
breakage is obtained.  Therefore, in the presence of nanoparticles bubbles are stable 
against coalescence.   
 
 
 
 
 
 
 
 
Figure 5-3  Average bubble diameter as a function of agitation speed.  Operating 
conditions are T=37oC, pH = 8.0, Vs= 14.5 cm/min 
Similar results have been published in the literature for stabilization of liquid-liquid 
dispersions in suspension polymerization (Jahanzad et al., 2005).  Jahanzhad et al.  found 
that the exponent for the droplet size as a function of agitation speed changed from -0.74 
to -1.24 upon addition of poly(vinyl alcohol), which acts as a stabilizing agent. 
100
1000
104
100 1000
B
ub
bl
e 
di
am
et
er
, d
32
 (m
m
)
N (rpm)
control
d
32
=-0.78N+11.59, R2 = 0.87
φ = 0.0025
d
32
=-1.39N+14.16, R2 = 0.89
500
      104 
In view of the results shown in Figure 5-3 and the preceding analysis, it is proposed that 
the following equations can be used to predict the interfacial area for experiments in the 
absence and presence of nanoparticles  
78.059.11
controlH,
B
controlH,
control
66
−== Neda
εε
       (57a) 
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Therefore, the interfacial area enhancement can be calculated as 
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It must be noted that the values of the pre-exponential parameters C1’ and C2’ (e11.59 and 
e14.16) are dependent on the geometry of the equipment and should not be used to predict 
interfacial area in different equipment, whereas the values of the exponents  
(-0.78 and -1.39) should be applicable to other experimental systems as long as 
conditions of isotropic turbulence exist.   
It is also proposed that Eq. 57b can apply to nanoparticle fractions above  φ = 0.0025.  
While no experiments measuring interfacial area enhancement as a function of agitation 
speed above this mass fraction have been conducted, data in Figure 4-12 suggest that 
increasing the nanoparticle fraction from φ = 0.0025 to φ = 0.005 does not yield a 
significant interfacial area increase.  Underlying this claim is the assumption that, at a 
nanoparticle fraction of φ = 0.0025, the gas bubble interfaces are already saturated with 
nanoparticles and further addition of nanoparticles does not alter the nature of interface.   
 
5.1.2.4 Effect of temperature on interfacial area enhancement  
It has been shown in Section 4.2.2.3 that mass transfer enhancement by nanoparticles 
depends strongly on temperature.  According to the mechanism of interfacial area 
enhancement presented in the previous section, an increase in temperature causes the 
average bubble diameter to increase because viscosity is reduced and the film drainage 
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process between bubbles becomes faster, which in turn increases the coalescence 
efficiency.  This phenomenon has been demonstrated experimentally elsewhere (Lazrak 
et al., 1998).  While the acceleration of the film drainage process should be the same in 
the control and in the presence of nanoparticles, in the latter case the final coalescence 
event between bubbles is still prevented by the layer of nanoparticles adhered to the 
bubble interface.  Consequently, a more pronounced temperature effect on the average 
bubble diameter can be expected in the control experiments.  This can explain 
qualitatively the increase in mass transfer enhancement as a function of temperature in 
the presence of nanoparticles presented in Figure 4-15.   
 
5.2 Mechanism of Mass Transfer Coefficient Enhancement 
This section first reviews effective property models of enhanced mass transfer in the 
presence of dispersions and it is demonstrated that its application is unsuitable to 
nanoparticle dispersions.  Second, several potential mechanisms of enhancing the mass 
transfer coefficient are discussed based on scaling analysis.  Third, it is proposed that 
microconvection caused by nanoparticle random motion causes the enhancement of the 
mass transfer coefficient.  An empirical expression that relates enhancement to the 
nanoparticle mass fraction is proposed.  Fourth, the effect of nanoparticles on gas-liquid 
interfacial mobility is discussed.  Finally, an expression to predict the mass transfer 
coefficient enhancement as a function of nanoparticle volume fraction and agitation 
conditions is proposed. 
5.2.1 Limitations of Effective Property Models  
Effective property models (Section 2.2.4) have been successfully used to predict 
enhancement of mass transfer in multiphase reactions in the presence of a dispersed 
microphase (Mehra, 1988).  These models are appropriate when the typical dimension of 
a dispersed phase element is much smaller than the dimension of the domain through 
which mass transfer occurs (the liquid film around a gas bubble).  A 20 nm particle is 
typically 100 to 1000 times smaller than the thickness of the liquid boundary layer 
around a gas bubble.  A dispersion of nanoparticles is therefore macroscopically 
homogeneous in spite of its biphasic nature, and the diffusivity and solubility of oxygen 
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in the medium can be expressed as effective properties of the two components of the 
dispersion.  However, the effective property models presented in Section 2.2.4 fail to 
predict accurately the experimental values of kL enhancement obtained in an agitated 
beaker (Section 4.2.1), as shown in Figure 5-4.   
 
 
 
 
 
 
 
 
 
Figure 5-4  Comparison of kL enhancement data obtained in a stirred beaker at 
300 rpm with predictions from models by Mehra (Eqs.  18 and 19, with S = 2 sec-1, m 
= 4) and Bruining et al.  (Eq. 21). 
As discussed in Section 2.4.1, a number of studies have shown that the heat transfer 
enhancement in nanoparticle dispersions is likewise largely underpredicted by effective 
property models, such as the Maxwell-Garnett theory.  Some authors have hypothesized 
that Brownian motion by the nanoparticles is responsible for the large experimental 
enhancements reported (Bhattacharya et al., 2004; Jang et al., 2004; Koo et al., 2004; 
Kumar et al., 2004; Prasher et al., 2005) but there is no agreement in the literature.  
Furthermore, mounting experimental evidence indicates that heat transfer enhancement 
does not only depend on the size and volume fraction of particles, but also on surface 
properties of the particles (which are a function of pH, ionic strength of the medium, and 
nanoparticle composition) (Xie et al., 2002a; Patel et al., 2003; Lee et al., 2006) and 
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temperature (Das et al., 2003c).  In view of this, it is likely that interparticle forces 
(electrostatic repulsions and Van der Waals attractions) play a significant role. 
5.2.2 Potential Mechanisms of Mass Transfer Coefficient Enhancement  
5.2.2.1 Nanoparticle dispersion 
Some authors have proposed that convective heat transfer enhancement is caused by 
nanoparticle dispersion and have fitted an empirical dispersion coefficient to 
experimental data (Pak et al., 1998; Xuan et al., 2000b; Xuan et al., 2003).  However, it 
has been shown through order-of-magnitude estimates of the various terms of the energy 
equation that heat transfer associated with nanoparticle dispersion is negligible compared 
to heat conduction and convection (Buongiorno, 2006) 
5.2.2.2 Nanoparticle Brownian motion 
Random motion of nanoparticles acting as oxygen carriers can contribute to an increase 
in mass transfer in excess of the bulk diffusive flow of oxygen.  The characteristic time 
that describes oxygen diffusion across the length of one nanoparticle is  
2O
2
p
D 2D
d
t =           (59) 
With dP = 20 nm (particle diameter) and DO2 =3.22⋅10-9 m2/s at 37 oC, tD = 6⋅10-8 s.  The 
effect of Brownian motion on the effective diffusivity can be estimated by comparing this 
time to the time required for a particle to travel its diameter by mean displacements, 
which can be obtained from the Stokes-Einstein equation 
Tk
d
t
B
3
p
B 2
3πµ=           (60) 
with µ = 6.95⋅10-4 kg/(m⋅s), T=37 oC, and k = 1.381 x 10-23 J/K (Boltzmann’s constant), 
tD = 6.1⋅10-6 s.  Since tB >> tD , the contribution of the Brownian motion of the particle to 
mass transfer is negligible compared to the bulk diffusive flow of oxygen.   
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5.2.2.3 Thermophoresis  
Nanoparticles can diffuse due to a temperature gradient, with a thermophoretic velocity 
given by 
T
TV ∇⋅−= ρ
µβT          (61) 
where β is a proportionality factor of order 1⋅10-3.  In the mass transfer experiments 
conducted in a stirred beaker, the liquid and gas phases are in thermal equilibrium and 
therefore VT ~ 0.  In the experiments conducted in a fermentor, the gas phase is at most 
10 oC cooler than the liquid phase, and therefore VT ~ 1⋅10-11 m/s.  Therefore, in both 
systems thermophoresis does not contribute to enhanced mass transfer.   
5.2.2.4 Microconvection caused by nanoparticles 
On the nanoparticle diameter length scale, an enhancement of oxygen mass transfer can 
be expected if the time it takes for the particle, and therefore, the fluid surrounding this 
particle, to travel its own diameter is smaller than tD.  This time scale can be estimated as 
thermal
p
C ~ v
d
t           (62) 
The velocity scale vthermal can be obtained by application of kinetic theory to liquids.  A 
nanoparticle of radius dp immersed in a medium, receiving continuous collisions from 
surrounding water molecules, experiences a mean square displacement after a time t that 
can be expressed as (Einstein, 1906) 
t
a
Tk
x ⋅= πµ3
B2           (63) 
Since a particle has a kinetic energy equal to 2/3 BTk  (corresponding to the three degrees 
of freedom, 2/BTk  each), the instantaneous velocity of a particle of mass M is 
M
Tkvthermal B
3=          (64) 
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For a 20 nm oleic acid-coated nanoparticle at 300 K, vthermal ~ 1 m/s.  This value is similar 
to proposed values of thermal velocity for aqueous suspensions of polysterene spheres 
(Pusey, 1991; Nagele, 1996).  In comparison, a typical thermal velocity for a water 
molecule would be 1000 m/sec.  With vthermal = 1 m/s, a value of tC = 2⋅10-8 s is obtained.  
The ratio tD / tC is a Peclet number based on the particle size 
2O
pthermal
p D
dv
Pe
⋅=           (65) 
which expresses the relative importance of convection in the fluid surrounding a 
nanoparticle to bulk diffusion.  This number has an approximate value of 3 for a 20 nm 
particle at T = 37 oC.  Therefore, scaling considerations indicate that the convective flow 
of oxygen in the immediacy of the nanoparticle caused by the relative motion between 
the particle and the surrounding fluid has the same order of magnitude as the diffusive 
flow of oxygen.    
5.2.3 Proposed Mechanism of Mass Transfer Coefficient Enhancement 
5.2.3.1 Microconvection Concept 
Keller (Keller, 1971), while studying blood flow, was the first to suggest that suspended 
particles (blood cells) could be the source of small eddies that could enhance conduction 
of heat and diffusion of molecular species, but presented no rigorous calculation.  A 
precise derivation of this effect was presented later for a dilute suspension of neutrally 
buoyant spherical particles under simple shear flow at small particle Peclet numbers 
(Leal, 1973).  Both Keller’s experiments and Leal’s derivation focused on large particles 
where Brownian effects are negligible.  
Several investigations have proposed the application of a similar mechanism to the 
prediction of enhanced heat transfer by nanofluids (Jang et al., 2004; Koo et al., 2004; 
Prasher et al., 2005).  Brownian effects are no longer negligible in nanofluids. 
The Reynolds number based on the velocity scale given in Eq. 64 can be expressed as 
µ
ρ thermalpRe vd=          (66) 
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and it has an approximate value of 0.03.  This is sufficiently small for the velocity field to 
be well represented by Stokes flow around a sphere (Taylor, 1932).  The radial and 
angular velocity components for Stokes flow past a stationary sphere in an unbounded 
medium can be expressed, with r as the distance from the sphere’s center, as: 
⎥⎥⎦
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The radial component of the velocity has approximately 70% of its maximum value at a 
distance of 1 sphere radius, dp, from the particle surface, and around 15% at 10 radii 
away.  Therefore, the hydrodynamic boundary layer extends further than 10 diameters 
from the particle.   
5.2.3.2 Empirical Fit 
Given the multiplicity of scales of the phenomena involved, a theoretical formulation is 
not attempted.  Instead, experimental data are fitted with an empirical expression.  
According to Figure 4-5, the enhancement in the mass transfer coefficient increases 
linearly with the mass fraction of nanoparticles up to φ ~ 0.01.  Above φ ~ 0.01, the mass 
transfer enhancement plateaus quite rapidly.  The following empirical expression is 
proposed to describe the enhancement of the mass transfer coefficient below  φ ~ 0.01 
( ) 01.01L,controlnpL, <+= φφ forCkk       (68) 
where C is an adjustable parameter with a value of 51.4 for experiments performed at 
300 rpm in an agitated beaker.  It is plausible that at low concentrations of nanoparticles 
(φ << 0.01) the shells of perturbed fluid around a particle do not overlap significantly.  
The flattening of the enhancement curve at φ > 0.01 could be an indication that 
significant overlap between the shells of perturbed fluid exists at this concentration of 
nanoparticles because the interparticle distances are smaller on average (and therefore 
most fluid around the particles is mobilized).  The mean surface-to-surface distance 
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between nanoparticles is a function of the dispersed phase volume fraction1.  As shown in 
Figure 5-5, for a nanoparticle volume fraction of 0.026 of 20 nm sized oleic acid-coated 
nanoparticles (corresponding approximately to a mass fraction of 0.01), the typical 
surface-to-surface distance is roughly 35 nm, just 1.75 times the particle diameter. 
 
 
 
 
 
 
 
 
 
 
Figure 5-5:  Mean surface-to-surface distance between nanoparticles as a function 
of volume fraction 
An investigation published recently has claimed that mass diffusion of a dye is faster in a 
nanofluid than in water (Krishnamurthy et al., 2006).  The authors visualized a dye 
diffusing in a well, and reported a mass diffusion enhancement above 10-fold at a volume 
fraction of Al2O3 nanoparticles of 0.5%.  However, to make their nanoparticle solutions 
stable, Krishnamurthy et al. used Tween 80 surfactant, which must have accumulated at 
the gas-liquid interface.  Since there cannot be a static system in the presence of surface 
tension gradients, Marangoni flows are likely to have developed.  It is therefore likely 
that this work reported erroneous mass transfer enhancements. 
                                                 
1 The relationship between volume fraction and mass fraction for oleic-acid coated nanoparticles is φvolume 
= 2.57φmass, see Appendix 7.1 for detailed calculation. 
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5.2.4 Retardation of Gas-Liquid Surface Mobility by Nanoparticle 
Adsorption  
The presence of surfactants is known to alter the interfacial mobility of gas bubbles and 
retard its motion.  It is likewise expected that the nanoparticles researched in this thesis 
immobilize the gas-liquid interface.  This would have a detrimental effect on the mass 
transfer coefficient, which would partly counteract the enhancement reported in the 
previous section.  This detrimental effect can be ignored in the study of the experiments 
in a stirred beaker that lead to Eq. 68, on grounds that the free liquid surface rotates at a 
constant speed and is not immobilized.  
Immobilization of the gas-liquid interface of bubbles is certain to occur in the 
experiments conducted in an aerated and agitated fermentor (Section 4.2.2).  It is 
generally accepted that contaminants such as surfactants adsorbed on the interface of a 
bubble are dragged by the surrounding liquid towards the rear of the bubble, where they 
build up.  This generates a surface tension gradient that opposes the surface flow and 
increases the drag, which leads to immobilization of the interface and reduction of mass 
transfer effectiveness (Levich, 1962).  The mass transfer coefficient of a bubble is a 
function of the interface mobility.  If a bubble is rigid, its mass transfer coefficient can be 
expressed as (Frossling, 1938) 
6/13/2
B
rise
rigidL,
−= νD
d
vck         (69) 
where vrise is the relative velocity between the bubble and the liquid and C is a constant 
that takes experimental values between 0.42 and 0.95.  The mass transfer coefficient for 
bubbles that have a mobile interface can be expressed as (Bird et al., 1960) 
2/1
B
rise
mobileL, 13.1 Dd
vk =         (70)  
The rise velocity of a bubble with a mobile interface can be calculated as (Clift et al., 
1978) 
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which is an expression valid for bubbles larger than 1.3 mm.  In the experimental system 
used, average bubble diameters calculated from interfacial area measurements for the 
control experiments are in a range that spans above and below 1.3 mm.  Bubbles are 
larger than 1.3 mm at power inputs below 2.5 HP/1000L.  Above this value of power 
input, bubbles are smaller than 1.3 mm and behave as rigid.  The rise velocity of a bubble 
with a rigid interface can be calculated as (Ng et al., 1999) 
1
15.02
Brigidrise, Re02.0Re6
75450
−
⎟⎠
⎞⎜⎝
⎛ +∆= dv ρ       (72)  
where ∆ρ is the density difference between the gas phase and the liquid phase.   
Average bubble sizes calculated from interfacial area measurements in the presence of 
nanoparticles are smaller than 1.3 mm in the entire range of power input conditions 
studied.   
Eqs. 68 and 69 apply to bubbles in free rise.  Turbulence, however, reduces the mean 
bubble rise velocity by up to 50% (Alves et al., 2003).  It has been assumed that 
turbulence reduces bubble rise velocity by a factor equal for rigid and mobile bubbles.   
Using Eqs.  69 to 72 together with Eqs.  57a, 57b, and 68, the following expression for 
the mass transfer coefficient enhancement is proposed 
( )
( )( )
( )( )
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Ek    (73) 
where the bubble diameters dB,np and dB,control are functions of the gas holdup and agitation 
conditions, as given by Eqs.  57a and 57b.  The bubble rise velocity in the presence of 
nanoparticles, vrise, is given by Eq. 71 at agitation conditions in which dB,control is larger 
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than 1.3 mm and by Eq. 72 otherwise.  The value of C’ can be adjusted from 
experiments.   
5.3 Comparison of Model Predictions with Experimental Data 
Model predictions of akE L  have been obtained multiplying Eqs.  73 and 58 ( aL EEk= ) and 
are shown in Figures 5-6 and 5-7.  Figure 5-6 shows model predictions assuming that the 
bubbles are rigid in both the control and in the presence of nanoparticles.  Figure 5-7 
shows predictions assuming that the bubbles are mobile in the control and rigid in the 
presence of nanoparticles.  It would be appropriate to assume that the bubbles in the 
control are mobile below 2.5 HP/1000L and rigid above, but that would generate a 
discontinuous line.  A more complete model could also account for the fact that, at any 
given power input, a size distribution of bubbles exists, some of which are mobile (larger 
than 1.3 mm) and some of which are rigid.  The additional complexity that this would 
introduce is not justified given that the present model already has two adjustable 
parameters.   
The predictions of the model capture the initial rapid increase of  akE L  as a function of 
power input and the subsequent flattening at large values of power input.  Separate 
predictions of 
Lk
E  and akE L  are shown in Figure 5-8 for experiments conducted at 
φ = 0.0025, which is the only experimental data set for which separate measurements of 
interfacial area and volumetric mass transfer coefficient were made.  Figure 5-9 presents 
a step-by-step flowchart of the calculations leading to the model predictions (solid lines) 
in Figures 5-6, 5-7 and 5-8. 
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Figure 5-6:  Comparison of model predictions (solid lines, calculated as akak EEE LL =  
(Eqs. 73, 58), with C = 54.1, C’ = 0.9) with experimental data of kLa enhancement.  
Bubbles are rigid for both the control and in the presence of nanoparticles 
 
 
 
 
 
 
 
 
 
Figure 5-7:  Comparison of model predictions (solid lines, calculated as akak EEE LL =  
(Eqs. 73, 58), with C = 54.1, C’ = 0.9) with experimental data of kLa enhancement.  
Bubbles are mobile for the control and rigid in the presence of nanoparticles 
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Figure 5-8:  Comparison of model predictions (C = 54.1, C’ = 0.9) with experimental 
data of a and kL enhancement.  Values of aE  (open circles) are calculated from 
experimental measures of a.  Values of 
Lk
E  (closed circles) are calculated as 
aakk E/EE LL =  from measures of kLa and a.  Model predictions (solid lines) are 
calculated using Eqs.  72 and 57 and assuming mobile bubbles in the control and 
rigid bubbles in the presence of nanoparticles.
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Figure 5-9:  Step-by-step flowchart for the calculation of
Lk
E  , aE  , and akE L  
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5.4 Discussion 
5.4.1 Critique of the Area Enhancement Model 
The mechanism of interfacial area enhancement by prevention of coalescence is 
consistent with the interfacial area measurements presented in Section 4.3.  This 
mechanism is also consistent with data generated using PFC-coated magnetic 
nanoparticles (Olle et al., 2005).  Yin conducted E.  coli fermentations in the presence of 
magnetic nanoparticles coated with Zonyl® FSA fluoropolymers and reported several-
fold oxygen uptake rate enhancements (data included in Olle et al.’s patent, 2005).  The 
surface tension of these fluoropolymers is 18 mN/m, lower than the surface tension of the 
nanoparticles used in this thesis (40 mN/m).  The lower surface tension of PFC-coated 
nanoparticles could bestow stronger surface adsorption, a more severe reduction of 
coalescence, and a greater mass transfer enhancement.  Furthermore, Yin observed severe 
foaming, which would be consistent with a drastic reduction of coalescence.   
However, the model has several limitations: 
First, while it hypothesizes that coalescence reduction is what causes the enhancement of 
interfacial area, no direct measurement of the coalescence rate has been made.  The 
equipment necessary for performing such measurements was not available.  Nevertheless, 
there appears to be enough evidence of this phenomenon in the literature (reviewed in 
Section 5.1.1) to justify the claim.  Furthermore, a theoretical estimate of the adsorption 
energy of nanoparticles at an interface (Section 5.1.1.3), together with surface tension 
measurements of nanoparticle solutions (Section 4.3) both substantiate the claim that 
particles prevent coalescence (by accumulating and strongly adsorbing at the interface).   
Second, the model assumes that the interfacial area enhancement is not a function of 
nanoparticle concentration above φ = 0.0025.  This claim is made on grounds that data in 
Figure 4-12 suggest that increasing the nanoparticle fraction from φ= 0.0025 to φ= 0.005 
does not yield a significant interfacial area increase.  However, these data are not entirely 
conclusive, and experiments at φ > 0.0025 covering a range of agitation conditions would 
be needed to confirm the claim.   
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Relatively little is known about the exact behavior of nanoparticles at interfaces.  Most 
research to date has been experimental and a theoretical formulation of nanoparticles at 
interfaces is missing.  Conversely, the behavior of surfactants at interfaces has been 
investigated in depth and modeled in detail.  All equations used in Section 5.1 assume 
that the behavior of nanoparticles is the same as that of surfactants, which is most likely 
an incomplete picture.   
5.4.2 Critique of the kL Enhancement Model 
The parameter C in the empirical equation proposed to describe the enhancement in kL as 
a function of nanoparticle fraction (Eq. 68) has been fit from data obtained in a stirred 
beaker and thereafter used to predict kL enhancement in an agitated, aerated fermentor.  
Although the determined parameter appears to fit reasonably well to the data obtained in 
the agitated, aerated system, such an approach is only justified if the parameter relates to 
an effective property of the medium that is independent of the experimental setup (i.e.  
effective oxygen diffusivity).      
Recent publications indicate that heat transfer enhancement in nanofluids does not only 
depend on the size and volume fraction of nanoparticles, but also on their surface 
properties.  It appears that a comprehensive model attempting to describe transfer 
properties would have to include electrostatic repulsions and attractions between particles 
and solvent structuring.  Such a model would involve a broad range of length and time 
scales and would most likely require molecular dynamics or Stokesian dynamics 
simulations.   
5.4.3 Relationship to Fermentation Experiments 
The mechanism presented describes the experimental trends in mass transfer 
enhancement as a function of nanoparticle concentration and agitation conditions.  Given 
the colloidal nature of the system studied, other variables such as electrolyte 
concentration, pH, and temperature are necessarily relevant as well.  However, they have 
not been included for simplicity.   
Different electrolyte concentrations could explain why the mass transfer enhancements 
measured using the sodium sulfite technique are significantly larger than those measured 
in fermentation experiments.  It is plausible that high electrolyte concentrations screen 
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the repulsions between negatively charged nanoparticles adsorbed at the bubble 
interfaces, thereby facilitating a more compact packing.  This, in turn, would reduce 
coalescence further.  It has been observed elsewhere that addition of electrolytes 
increases bubble stability in surfactant solutions (Ghosh, 2004); Ghosh et al.  found that 
NaCl reduced coalescence in the presence of sodium dodecyl sulfate, and LiCl eliminated 
it altogether.  The authors hypothesized that the electrolytes screened the repulsions 
between the head groups of the surfactants adsorbed at the bubble interfaces, thus 
increasing the packing of surfactant molecules and reducing coalescence.  It has also 
been shown that partially hydrophobic silica nanoparticles of 20 nm in size can stabilize 
air bubbles, and a sharp increase in stability occurrs when 2 M NaCl is added to the 
aqueous phase (Dickinson et al., 2004).  The sodium sulfite solutions used in this thesis 
have concentrations of Na+ on the order of 1.4 M.  This concentration of positively 
charged ions is notably higher than that in the fermentation medium used, which is 
approximately 0.2 M of K+ (the concentration of other cations is negligible).     
Finally, all fermentation experiments have been performed in duplicate, and additional 
experiments were conducted to verify the generality of the mass transfer enhancement 
results: (i) experiments were performed in fermentors at a smaller scale (1 and 1.5 L), and 
(ii) experiments were performed with cultures of Pichia pastoris (Lorenzo-Gonzalez, 
2005).  In all cases, the mass transfer enhancements obtained were on the order of 40 to 
60%.   
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6 CONCLUSIONS 
6.1 Experimental Section 
1. Oxygen transfer enhancement has been observed in the presence of colloidal 
dispersions of magnetite (Fe3O4) nanoparticles coated with oleic acid and a 
polymerizable surfactant.  These fluids improve gas-liquid oxygen mass transfer 
up to 6 fold (600%) in an agitated, sparged reactor and show remarkable stability 
in high-ionic strength media over a wide pH range.  These results are relevant to a 
wide range of processes limited by the mass transfer of a solute between a gas 
phase and a liquid phase, including fermentation, hydrogenation reactions, and 
waste treatment.   
2. Through a combination of experiments using physical and chemical methods to 
characterize mass transfer, it has been shown that  
a. Both the mass transfer coefficient (kL) and the gas-liquid interfacial area 
(a) are enhanced in the presence of nanoparticles, the latter accounting for 
a larger fraction of the total enhancement. 
b. The enhancement in kL measured by physical and chemical methods is 
similar and ranges from 20% to 60% approximately. 
c. The enhancement in kL increases linearly below a nanoparticle mass 
fraction of 1% and subsequently plateaus.  
d. The enhancement in kLa shows a strong temperature dependence. 
e. Both particles coated with oleic-acid, which has a higher solubility for 
oxygen than water, and particles coated with polymers not known as 
oxygen carriers enhance mass transfer in an agitated, aerated system.  
Therefore, the oleic acid coating is not essential to obtain mass transfer 
enhancement.   
3. The equilibrium surface tension of an air-water interface is reduced from 
72 mN/m to less than 40 mN/m at mass volume fractions of nanoparticles above 
0.1%.   
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4. A 40% increase in oxygen uptake rate and dry cell weight of E. coli can be 
obtained using a nanoparticle mass fraction of 0.6% in a fed-batch fermentation.  
It is expected that the reported increases in the oxygen transfer coefficient and in 
the cell concentration would translate to corresponding increased concentration of 
products synthesized by the host organism, such as primary and secondary 
metabolites.  The oxygen transfer rate has been increased in a conventional 
agitated and aerated fermentor without any mechanical modification. 
6.2 Modeling Section 
1. Colloidal particles can adsorb to a gas-liquid interface.  The energy necessary to 
remove a nanoparticle from the air-water interface is sufficiently large to assume 
that this adsorption is irreversible.   
2. Nanoparticles can increase interfacial area by (i) inhibiting coalescence and (ii) 
facilitating bubble break-up by reducing surface tension.  Increased bubble 
breakage can account for an area enhancement factor of only 1.5, and therefore 
cannot be the sole area enhancement mechanism.  Nanoparticles stabilize gas 
bubbles by adsorbing on their interface and creating a stabilized dispersion in 
which bubble size is determined by breakage processes.  In contrast, in the 
absence of nanoparticles, bubble size is dominated by coalescence processes and 
an unstable dispersion exists. 
3. Effective property models of enhanced mass or heat transfer in the presence of 
dispersions are unsuitable to predict the transport properties of nanoparticle 
dispersions.   
4. It has been proposed that the mass transfer coefficient is enhanced by the random 
motion of the nanoparticles, which causes convection in the surrounding fluid.  
An empirical expression that relates enhancement to the nanoparticle mass 
fraction, gas-liquid interfacial mobility, and agitation conditions has been 
presented.   
5. The anomalous transfer properties of nanofluids have perplexed researchers for 
almost a decade and, to date, no model has been presented that has been widely 
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accepted as a complete description of the physical mechanisms underlying their 
performance.  It is not at all clear that one mechanism can explain the body of 
data that has been generated already in the field, either.  In addition, the different 
experimental measures of thermal properties presented in the literature have been 
made in systems with broadly different hydrodynamic conditions, from stagnant 
systems to free and forced convection systems. 
6.3 Recommendations for Future Research 
 
Assuming the mechanisms of area and kL enhancement proposed in Section 5 are correct, 
the mass transfer enhancements realized should not be restricted to oxygen mass transfer. 
Instead, it should be possible to generalize them to many other gas-liquid systems.  Many 
gas-liquid reactions in three-phase fluidized-bed reactors could be accelerated. Some 
examples include hydrogenation and hydrodesulfurization of residual oils, hydrogenation 
of unsaturated fats, slurry methanation of CO, waste water treatment, the Fischer-Tropsch 
process, coal liquefaction, and synthesis gas fermentations.  
Synthesis gas fermentations, through which biomass can be converted to bio-based 
products that replace petroleum-based products, are an appealing target for use of 
magnetic nanoparticles.  Gas-liquid mass transfer is a bottleneck that has prevented the 
commercialization of syngas fermentation products.  The mass transfer limitations are a 
consequence of the low solubilities of H2 and CO – the major syngas components – in 
aqueous media.  Since the solubilities of these two gases in water are even lower than the 
solubility of oxygen, the mass transfer limitations are more accentuated than in aerobic 
fermentations.  
Mass transfer limited reactions that require high temperatures can be another attractive 
target for use of magnetic nanoparticles since, as shown in Figure 4-14, the enhancement 
of mass transfer is more pronounced at high temperatures.  Many hydrogenation reactions 
require high temperatures and would therefore be appropriate targets.  For instance, 
production of high trans fatty acids from hydrogenated oils requires temperatures from 
100 oC to 200 oC.   
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A systematic study of the effect of electrolyte concentration and type on kLa 
enhancement would shed light on the observed differences between the enhancements 
measured using the sodium sulfite technique and those measured in fermentation.  Such 
knowledge could be used to target applications in which mass transfer processes occur in 
media where magnetic nanoparticles can be most effective.  
Recovery of the nanoparticles is of crucial importance to the success of the method 
presented in this thesis.  Nanoparticles with a diameter below 50 nm are difficult to 
recover by HGMS.  The nanoparticles used in this thesis have a diameter of 
approximately 20 nm.  While a proof of principle that particles of size above 50 nm can 
be easily synthesized has been presented in section 4.1.3, it would be important to verify 
that the mass transfer enhancements attainable are not significantly affected by the 
particle size.  A systematic study of the effect of particle size on mass transfer at constant 
particle mass fraction would clarify this.  
This thesis’ research has concentrated on characterization of enhanced mass transfer in 
turbulent media.  Convective effects play a role in heat transfer enhancement by 
nanofluids (Yang et al., 2005), i.e. nanofluids increase the heat transfer coefficient by 
less than the static thermal conductivity.  Likewise, it is plausible that nanoparticles 
increase the diffusion coefficient of gas solutes to a greater extent than they increase kL.  
Absorption experiments of oxygen into a stagnant medium would yield values of the 
effective diffusion coefficient of oxygen in the presence of nanoparticles. 
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8 APPENDIX 
8.1 Nanoparticle Volume Fraction and Mass Fraction 
8.1.1 Oleic Acid-Coated Nanoparticles 
The mass fraction of nanoparticles in the experimental samples is determined by drying 5 
samples of nanoparticle solution and measuring the wet and dry weight.  The 
determination of the corresponding volume fraction in aqueous solution is made from 
knowledge of their elemental composition.  A sample of dried particles was sent for 
analysis to Desert Analytics and showed the following elemental composition: 
%C %H %S %Fe 
20.79 3.03 0.05 42.08 
from which it can be estimated that the particle is composed of 58.3% magnetite, 18.74% 
oleic acid and 22.92% Hitenol BC.  The magnetite core has a diameter of 7 nm, the oleic 
acid coating has a thickness of 2.5 nm and the Hitenol BC coating has a thickness of 4 
nm approximately.  The corresponding volume fraction of the magnetite core in one 
nanoparticle is 0.04, with a density of 5.3g/mL.  The remaining volume fraction of 0.96 
corresponds to oleic acid and Hitenol BC.  A single nanoparticle will contain 3.74⋅10-19 g 
of Hitenol BC and 3.05⋅10-19 g of oleic acid, which will give an average density of 
0.389g/mL for the coating around the nanoparticle.  This is a reasonable number 
considering that the PEO chains in the Hitenol BC coating, which occupy most of the 
hydrodynamic volume of the particle, are highly solvated.  Overall, this gives an average 
density for the particle 2.57 times lower than that of water.  Therefore, the relationship 
between volume and mass fraction for oleic acid-coated nanoparticles is 
massvolume 57.2 φφ =  
8.1.2 PPO-PEO-Coated Nanoparticles 
While the 20 nm oleic acid-coated nanoparticles are single domains with one magnetite 
core, the 80 nm PPO-PEO-coated nanoparticles are fractal clusters formed by several 
domains.  The polymer coating around each magnetite domain is 7.5 nm thick, which 
gives a diameter of the fractal core equal to 2a-15, where a is the particle radius.  With a 
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fractal dimension of 2, the fraction of the cluster that is magnetite can be estimated as 
2
fractalmagnetite, 2
152
152
5.7 ⎟⎠
⎞⎜⎝
⎛ −
−= a
a
a
φ  
from which the volume fraction of nanoparticles in the medium can be estimated as the 
ratio of the magnetite volume fraction in the media to the magnetite volume fraction per 
cluster  
fractalmagnetite,
magnetite
volumenp, φ
φφ =  
which renders the following relationship between mass and volume fraction for PPO-
PEO-coated nanoparticles  
massvolume 86.1 φφ =  
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9 PhDCEP CAPSTONE – COMMERCIALIZATION OF A NOVEL 
ANTIMICROBIAL PEPTIDE-DESIGN TOOL 
 
EXECUTIVE SUMMARY 
 
Background: Researchers at the Stephanopoulos laboratory at MIT have developed a 
novel peptide design method that can be used to generate thousands of Antimicrobial 
Peptides (AmPs) with a high probability of having antimicrobial activity at clinically 
relevant concentrations. The method allows exploration of a very large sequence space in 
comparison to current approaches, because it is not limited to natural sequences. Some 
further development could transform this proof of concept into a commercial drug 
discovery tool.  
Unmet Need: There are 2 million cases per year of hospital infections in the US. These 
infections result in 20,000 deaths per year and double the mortality risks for Intensive 
Care Unit patients. Critical care patients are at a very high risk of contracting pneumonia, 
which causes 135,000 infections per year in the US. Most strains of pneumonia and 
Staphylococcus aureus are currently resistant to penicillin and methicillin respectively. 
Consequently, there is a critical need for new antibiotics that do not elicit bacterial 
resistance. This need is especially urgent for antibiotics against Gram-negative infections 
and for multi-drug resistant organisms. AmPs are the most promising compounds 
available that can address the pathogen resistance challenge.  
Commercialization Strategy: An appropriate commercialization strategy for the 
innovation would be a hybrid model whereby initially, a partnership is sought to perform 
contract research on another company’s drug candidates using the existing technology 
platform. The early revenues obtained from the collaboration and from government 
grants are used to fund the validation of the technology platform. The expertise and 
credibility gained through the collaboration is then leveraged to obtain a higher valuation 
in a first round of investment. Once the technology is validated, the focus is shifted 
towards the internal development of drug candidates through the preclinical stage and 
possibly Phase I clinical tests. Thereafter, partnerships with pharmaceutical companies 
are sought. Partners are chosen on the basis of their ability to help navigate the 
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complicated FDA approval process, and provide marketing and sales expertise once a 
drug gets approval.  
Organizational Structure: The technology platform should be validated by the team 
currently managing SteriCoat Inc., a company spun from the Stephanopoulos and Langer 
labs at MIT that develops AmP-coated medical devices. The SteriCoat team has already 
established the proof of principle around the technology platform; with one more year of 
experimentation, several key risks associated with the technology could be mitigated. 
Following this, a first round of investment could be obtained. The current SteriCoat team 
would have the wrong skill set to continue the development at this stage. An expert 
management team in drug development should then be hired and the business should be 
spun off from SteriCoat Inc. This new management team should identify and pursue the 
best therapeutic application for the technology. The downside of this proposed 
organizational structure is that the SteriCoat founders have to surrender the control of the 
technology platform. The upside is avoiding insufficient resources and lack of focus in 
developing the two businesses in parallel, which could lead to doing a poor job at both.  
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9.1 Background 
9.1.1 What Are Antimicrobial Peptides (AmPs)? 
AmPs are one of nature’s most ancient ways of combating bacterial infections. [1] These 
molecules are produced by animals, plants, and certain bacteria. They have a high affinity 
for the bacterial membrane because of its positively charged groups and hydrophobicity. 
This allows these peptides to kill bacteria by disrupting their membrane. Bacteria cannot 
completely change the properties and structure of their cytoplasmic membrane [1], which 
makes them less likely to develop resistance to AmPs.  
Bacteria have evolved resistance mechanisms against some peptides, but not all.  For 
example, bacteriocin-producing bacteria show resistance to the peptides they produce, 
which enables them to out compete other microorganisms. [2] The mechanisms of 
resistance evolved by bacteria include proteolytic cleavage, production of external AmP-
binding molecules, AmP-specific drug exporters, alteration of the electrostatic properties 
of the bacterial cell surface, and biofilm formation, among others. [1] 
Yet, despite these mechanisms of resistance, AmPs have remained a remarkably 
successful strategy for the inhibition of growth of microorganisms. This is intriguing 
given how effective bacteria are at building resistance against modern antibiotics. [1] 
Nature has evolved some ways to circumvent bacterial resistance to AmPs, such as 
protease-resistant AmPs, or the combination of several antimicrobial mechanisms in one 
molecule.  While many bacteria have developed resistance to a specific mechanism, none 
has developed resistance against all mechanisms.  
9.1.2 The Therapeutic Use of AmPs 
The clinical value of AmPs has not been yet fully proven. While they are the most 
innovative new family of antibiotics that has been developed in the last two decades, the 
only clear clinical success to date in the area has been the lipopeptide daptomycin 
(marketed in the US by Cubist Pharmaceuticals under the trade name Cubicin), which 
acts against multidrug resistant Gram-positive organisms. Daptomycin is similar to AmPs 
(it has a pore forming/ion leakage mechanism) but it is not strictly an AmP, but a 
      143 
lipopeptide. Several other peptides are in clinical trials. Table 9-1 shows a list of AmPs in 
commercial development..   
Table 9-1.  Antimicrobial peptides in development [3], [4] 
Compound  Company Stage of development  
Talactofeerin Agennix Phase II 
hlF-1-11 AM-Pharma Phase II 
CSA-13 Ceragenix Preclinical 
Locilex Genaera Complete, rejected by FDA 
HB-50, HB-107 Helix Biomedix, Inc. Preclinical 
IMX942 Inimex Preclinical 
NA Lytix Biopharma AS Preclinical 
MBI-594, MX-226 Migenix Phase IIIb, Phase II 
Mersacidin Novacta Biosystems, Ltd. Preclinical 
NA Novobiotics Preclinical 
Plectasin Novozymes A/S Preclinical 
PAC113 Pacgen IND approved 
113D Par Advance Tech., Inc. Preclinical 
PTX001 to PTX007 PepTx Preclinical 
NA Polymedix Preclinical 
Neuprex Xoma Phase III 
CZEN-002 Zengen Phase IIb 
 
 
The main impediments that have prevented the clinical success of AmPs are their high 
cost of manufacturing, their short half-life in the human body (they get quickly degraded 
by proteases), and more generally, the lack of understanding of the pharmacodynamics 
and pharmacokinetics of these compounds when administered systemically. 
9.1.3 Advantages of AmPs Over Traditional Antibiotics 
Several characteristics of AmPs make them attractive compounds for commercial 
exploitation as antibiotics. First and foremost, bacteria are less likely to develop 
resistance against them.  Second, AmPs exhibit a broad activity spectra against both 
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Gram-positive and Gram-negative bacteria, and can kill multi-drug resistant bacteria at 
concentrations similar to traditional antibiotics. [3] Third, they kill bacteria very rapidly, 
through a mode of action that is bactericidal (as opposed to simple growth inhibition), 
and that can target several bacteria at the same time. Finally, they can be used alone or in 
combination with existing antibiotics to increase their efficacy. 
 
9.2 Description of the Business 
 
9.2.1 The Company. SteriCoat Therapeutics? 
Chris Loose and Kyle Jensen in the Stephanopoulos laboratory at MIT discovered that 
AmPs contain many semi-conserved motifs in their primary sequence.[5] They 
hypothesized that these motifs could be arranged in novel ways to produce active AmPs.   
They then were able to prove that the new, non-natural peptides synthesized by 
manipulation of these motifs were active against a range of Gram positive and Gram 
negative bacteria in vitro. Almost 50% of the newly designed sequences had moderate 
antimicrobial activity at clinically relevant concentrations (256 µg/ml or better), and 2 
out of 40 leads generated had high activity (in the range of 2-16 µg/ml). It is hoped that a 
bigger screen and more optimization would quickly lead to many molecules with activity 
at 4 µg/ml or below. A patent application was filed and the method was recently featured 
in Nature. [5] One of the advantages of this design method is that it allows exploration of 
a very large sequence space in comparison to the space covered by current approaches, 
which is limited to natural sequences.  
This new method can be used to generate thousands of AmPs, which could then be 
screened against clinically relevant bacteria and assayed for toxicity. The inventors 
believe that some further development could transform this proof of concept into a 
commercial drug discovery tool.  
Chris Loose is a co-founder of SteriCoat Inc., a startup from the Stephanopoulos and 
Langer labs that will produce AmP-coated medical devices to treat infections associated 
with implants and catheters. The SteriCoat team, which initially included Chris Loose 
(Chief Technology Officer), David Lucchino (Chief Executive Officer), and Joel Moxley 
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(Chief Operations Officer), and the staff is currently growing, has been involved in 
obtaining a strong IP position around this invention. The next step for the team, and the 
focus of the present study, is to formulate a commercialization strategy for the 
technology.  
The team will also need to decide whether this technology can be pursued best under 
SteriCoat’s roof, as a therapeutics division, or whether it should be pursued as an 
independent business. On the one hand, it is clear that the invention has a direct 
application to SteriCoat’s main line of business: newly synthesized AmPs could be 
tethered to medical devices using SteriCoat’s coating technology. Furthermore, there are 
clear people synergies in having the inventor of both technologies (the coating method 
used by SteriCoat and the peptide-design tool described in this work) work directly on 
their development. On the other hand, the medical device business currently pursued by 
SteriCoat and the drug discovery business are quite different; they require different assets 
and skills. The lack of focus in trying to pursue the two innovations in parallel could be 
detrimental to SteriCoat, which is currently focused on developing medical devices only.   
 
9.2.2 The Need 
During the past 40 years only three new classes of antibiotics have been discovered, and 
all of them targeted Gram-positive bacteria. Because the use of existing antibiotics has 
inevitably lead to the emergence of resistant bacteria, there has been a continuing need 
for new types of antibiotics. The pharmaceutical industry has attempted to meet this need 
by making iterative, synthetic modifications to existing antibiotic families, most of which 
were discovered half a century ago. [6]  
According to the Centers for Disease Control and Prevention, there are 2 million cases 
per year of nosocomial infections in the US. This type of infections results in 20,000 
deaths a year and double the mortality risks for ICU patients. Catheter-related infections 
cause 70,000 deaths per year. Critical care patients are at a very high risk of contracting 
pneumonia, which causes 135,000 infections per year in the US;  unfortunately nearly 
30% of the pneumonia strains are currently resistant to penicillin. [7] Similarly, most 
strains of Staphylococcus aureus are becoming resistant to methicillin.  There is a critical 
need for new antibiotics that do not elicit bacterial resistance. This need is especially 
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urgent for antibiotics against Gram-negative infections and for multi-drug resistant 
organisms. [8] Gram-negative pathogens such as Acetinobacter and Pseudomonas are the 
highest concern among medical specialists because there is no effective treatment against 
them. [9] 
9.2.3 Previous Failures and One Success  
Several failures have influenced heavily the commercial outlook of AmPs, leading to the 
disappearance of a number of startups and a generalized skepticism among investors and 
professionals of the pharmaceutical industry alike. Magainin Pharmaceuticals, founded 
by professor Michael Zasloff,2 did not get approval from the FDA for an AmP for the 
treatment of infected diabetic foot ulcers. In a very controversial ruling, its lead 
compound was found to be no more efficacious than existing treatments. IntraBiotics 
Pharmaceuticals abandoned the clinical trials for its peptide Iseganan and is now facing 
extinction. PPL Therapeutics, which had worked on transgenic methods for production of 
peptides decided to sell its intellectual property. [10] Some industry experts are skeptical 
about the future of AmPs because, although they have shown promise as antimicrobials 
without eliciting resistance, its understanding has not improved significantly.  
The only success story to speak of in the field of AmPs is the market introduction of 
Cubicin (daptomycin) by Cubist Pharmaceuticals. Cubist licensed this molecule from Eli 
Lilly in 2003 and by 2006 had turned it into a business with sales of $190 million a 
year.[10],[11] In December 2005, ziconotide (Prialt) was approved for the treatment of 
severe chronic pain, but limited to the treatment of patients that do not tolerate morphine.  
 
9.3 Opportunity and Market Overview 
9.3.1 The Global Market for Therapeutic Peptides 
Therapeutic peptides have found applications in oncology, cardiovascular diseases, 
infections, metabolic diseases, and central nervous system disorders. The global market 
for therapeutic peptides is currently estimated at $1 billion. [12] The US accounts for 
65% of the market, Europe for 30% (mainly led by Germany and the UK), and Japan 
                                                 
2 Prof. Zasloff,  who is one of the leading experts in AmPs, will be joining the advisory board of SteriCoat 
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accounts for most of the Asian market. It is expected that this market will grow at around 
10.5% a year until 2010. [12] Currently, there are over 40 peptides marketed worldwide, 
270 in clinical phases, and nearly 400 in advanced preclinical phases. The group of 
approved peptide drugs includes vancomycin, oxytocin, and cyclosporine among others.  
Within infectious diseases, the fastest growing segments are antivirals and antimicrobials. 
The proof of concept for the technology analyzed in the present work focused on 
infectious bacterial agents, which constitute a very urgent market need. While not 
necessarily the most lucrative long-term market, this market would likely adopt novel, 
safe and efficacious therapeutic peptides quickly.  
Oncology, which initially would not be a business target, is the largest segment of the 
therapeutic peptide market. It accounts for 60% of the European market (similar data for 
the US is not available), followed by cardiovascular diseases (15%), infections (10%), 
metabolic diseases (10%), and central nervous system disorders (5%). Eli Lilly & Co., 
which has a strong focus on diabetes, and Roche have been very active in the therapeutic 
peptide market 
9.3.2 The US Market for Critical Care Antibiotics 
The US market for critical care antibiotics is $3.14 billion and is growing at 4% per year.  
Nearly 5 million prescriptions for critical care antibiotics are written annually, at an 
overall average daily cost of $62.5 per prescription. [7]  
Four main families of antibiotics account for 75% of the market. These four families 
include the Cephalosporins (a beta-lactam antibiotic),  which account for 29% of the US 
market for critical care, and have grown marginally in recent years.  Their growth, and 
that of Penicillins (another beta-lactam antibiotic), which account for 15% of the market, 
will remain stagnant because there are no new drugs in the respective pipelines. 
Quinolones have taken market share from Cephalosporins and today account for 33% of 
the market. It is estimated that they will continue to grow at 7% since promising products 
are in the pipeline. Carbapenems account for 8% of the US market but are the family that 
is growing fastest, at 11%. [7] AmPs constitute a new family of antibiotics, and their 
market size is largely determined by the sales of Cubicin. Today, they account for less 
than 1% of the critical care antibiotics market.  
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9.3.3 Antibiotics: a Good Business? 
The global market for oral antibiotics is $25 billion, of which the US accounts for $8.5 
billion. [13] The large market size, combined with the growing antibiotic resistance 
problem and the threat of bioterrorism has fueled demand for new antibiotics. However, 
several forces are acting to oppose growth of this market, the most important of which 
are uncertainty around regulations and the inability of incumbents of obtaining good 
margins on their products. A summary of pros and cons of the antibiotics business is 
shown in Table 9-2.  
Table 9-2.  Pros and cons of the antibiotics business 
Market Upside ↑ Market Downside ↓ 
Large market size: oral antibiotics 
market is $25 B 
Success may limit opportunities 
(effective antibiotics may be put in 
restricted drug list) 
Federal Incentives for antibiotic 
research; Bioterrorism grant money 
available, SBIR 
“Me-too” = low returns 
(affects reimbursement policies, limits 
ability to achieve good returns) 
Clear rules for approval (↓ regulatory 
risk) 
Regulatory issues: possible change of 
standards? (retrospective changes to 
superiority trials, scare investors) 
Few marketing/sales partners (Big 
Pharma left) 
Short clinical trials (<10 years), easy 
patient recruiting (non-inferiority 
trials), and  small number of patients 
needed for trials 
Scientific risk known early, minimize 
time to failure (great if seeking VC 
investment) 
Pharma retreated from the market 
(<$1B) 
Low confidence on computational tools 
for new target identification (genomics, 
bioinformatics, high throughput) 
 
On the upside, the main market drivers, along with the large market size, are  
• Government incentives for pursuing research in the area 
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• Clear rules for approval (at least until recently), which provide a clear path for 
developing new compounds. As a result, regulatory risks are lower than with drug 
development in other therapeutic areas.  
• Shorter clinical trials with unambiguous endpoints. As stated by an expert in the 
area “Basically, the drug either kills the bug or not, and subsequent questions deal 
only with safety and the most appropriate dose and treatment schedule”[13]. As a 
result, human clinical trials tend to be shorter than for other types of drugs, and 
the total time for a drug to reach the market is generally under 10 years. 
Furthermore, patient recruiting for trials is easy because the FDA only requires (at 
least until recently) non-inferiority trials.  
• Scientific risk is known early because the clinical trials are shorter. As a result, 
time to failure can be minimized, which makes this type of investment more 
attractive to venture capital.  
• Big pharma retreated from this market because the typical antibiotic product does 
not have the potential to become a blockbuster, i.e., to have more than $1 billion 
in sales. [13] For example, the best selling antibiotic, Pfizer’s Zithromax, had 
revenues of $2.01 billion in 2003. This is far from blockbusters used to treat 
chronic diseases, which are taken for life (e.g., Pfizer’s Lipitor had sales of $9.23 
billion in 2003). Companies that left the market include Sanofi-Aventis and 
Bayer. This opened up the opportunity for small biotech companies to compete 
for lucrative niches.  
On the downside, the key restraints for the development of this market are: 
• The success of an antibiotic may in fact limit its opportunities. If a new antibiotic 
is very effective, hospitals may decide to put it in a restricted drug list and only 
use it as a last line of defense when all else fails. This limited use makes it very 
difficult for a company to make profits on its drug.  
• Possible regulatory changes. The FDA is considering proposing placebo-based 
clinical trials or superiority trials instead of the current standard of non-inferiority 
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trials. This would make it more difficult for an antibiotic to satisfy an efficacy 
endpoint in a clinical trial. [13] 
• Reimbursement policies limit the ability to achieve large returns. Most antibiotics 
are small modifications on existing families of compounds and reimbursement 
agencies tend to place them under “me-too” categories that offer low 
reimbursement rates. [13] 
• Lack of partners for clinical trials, marketing and sales activities. The exodus by 
Pharma companies has opened many opportunities for small biotech firms, but at 
the same time has left a void in expertise in downstream activities such as 
marketing and sales. This makes it difficult for small companies to find partners 
that can give them resources to support costly clinical trials or access to 
distribution channels.  
• Computational tools have underdelivered in drug discovery. Genomics, 
bioinformatics, and high-throughput screening approaches have provided very 
few leads for antibacterial drugs. [13] Some companies are returning to traditional 
approaches involving evaluation of natural products and chemical modifications.   
AmPs have the potential to address two of the main key restraints of the antibiotics 
market. Since they do not elicit significant bacterial resistance, there would be no reason 
for doctors to limit their use by putting them in restricted lists. Furthermore, since they 
would constitute an entirely new class of antibiotics, they would most likely receive a 
more generous reimbursement by the reimbursement agencies.  
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9.4 Product Offering 
9.4.1 Technology Platfrom 
The technology platform3 at the core of this business opportunity is a novel method to 
synthesize peptides with desired properties. One of these properties can be antimicrobial 
activity. The method identifies motifs associated with a certain characteristic of interest, 
such as antimicrobial activity, by applying a pattern recognition procedure to a database 
of peptides. The method can then be used to generate new, non-natural peptide sequences 
that incorporate the patterns associated with the characteristic of interest.[5] The novel 
peptides synthesized by the method have a very high probability (~50%) of being active 
against bacteria, and the number of new peptides that can be synthesized is only limited 
by the available equipment (e.g., peptide synthesizers) and manpower. Since any given 
compound needs to satisfy many criteria to become a drug, having access to an 
essentially unlimited pool of peptides that are likely to have antimicrobial activity 
increases the odds of success.  
This technology platform can be monetized in several ways. First, novel peptide leads 
that show promise can be developed through internal programs or outlicensed to 
pharmaceutical or biotechnology companies. Second, the platform can be used to 
optimize existing peptide-based drugs or drug candidates from other companies. Third, 
the database of old and newly synthesized compounds with known efficacy against 
bacteria could be quickly scanned to respond to a bioterror threat.[11] Lastly, the IP 
around the technology platform could be licensed out to third parties that do not compete 
in the same space.  
 
9.4.2 Stage of Development 
The inventors have established a proof of concept around using the peptide design 
method to impart antimicrobial activity to new sequences. They designed over 40 
sequences, 50% of which were moderately active against both Gram positive and Gram 
                                                 
3 What is usually meant by the term “technology platform” is an IP-protected invention, frequently 
developed  in an academic setting, that makes possible the development of other products. The technology 
platform itself is not a product, but enables discovery of new products.  
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negative bacteria, and 2 out of 40 of which had activity at clinically relevant 
concentrations. Table B in the Appendix summarizes data on the minimum inhibitory 
concentrations of the designed AmPs on different Gram positive and Gram negative 
microorganisms.  
The next stage of development will involve characterization of the toxicity of the new 
peptides. This information will be used to identify patterns associated with toxicity, 
which will then be incorporated into the design method. This will enable the method to 
yield increasingly safer compounds. [11] 
9.4.3 Initial Market 
The antibiotics market will be an appropriate initial market for the following reasons: 
First, the technology platform has already proven effective at generating large numbers of 
effective leads in vitro. The approach, however, does not incorporate yet parameters that 
are essential for in vivo activity. This makes this technology a better fit for antiinfectives 
(as opposed to chronic diseases, for example), because once a compound has proven 
effective against a pathogen, it is likely that it will also be effective against this same 
pathogen in vivo. Once a compound has shown efficacy against pathogens in animal 
models, the path to market is more straightforward than in other therapeutic areas. For 
this reason, companies developing antibacterials can be more attractive to investors, than, 
for example, companies developing cancer drugs. Of course, efficacy alone is not 
enough; the compounds must also be non-toxic and have favorable pharmacokinetics – as 
is the case in any other therapeutic area.  
Second, there is an urgent, unmet need in the antibiotics market. An AmP against 
multidrug resistant pathogens would not be an incremental improvement, but rather a 
must-have breakthrough drug that reimbursement agencies would most likely support.  
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9.5 Customers 
9.5.1 Key End-User Groups 
Users will include hospital in-patients and healthcare providers. Hospital in-patients 
groups will need the product in the Intensive Care Unit, in critical care, dialysis, 
treatment of infections, surgery, and intravenous nutrition. Healthcare providers, 
including specialists, physicians, surgeons, and nurses, will adopt AmP-based drugs 
because bacteria are less susceptible to develop drug resistance against them. AmPs 
would alleviate the pressure on hospitals to monitor infections from resistant pathogens 
and reduce their liability.  
9.5.2 Customer Access 
Critical care antibiotics are generally distributed directly to hospitals. Wholesale 
distribution is done through manufacturers and hospital pharmacies. [7]   
 
9.6 Business Strategy 
9.6.1 Possible Business Models 
The motif discovery technology platform can be commercialized using a variety of 
business models. Figure 9-1 presents a number of the options available, from simply 
licensing the technology upfront to becoming an integrated company that develops, 
manufactures, and sells its own drugs. A multitude of variants of each of the options 
presented in Figure 9-1 exists in the marketplace. At a basic level, the choice of a specific 
business model involves a tradeoff between the risk that the company is willing to bear 
and the amount of value it expects to capture4. The choice of a business model should be 
guided by the existing IP position and by the complementary assets (technological assets, 
people assets, marketing & sales assets, etc) owned by the company. Since most 
companies do not own all the assets necessary to bring a drug to the market, it will 
generally be the case that only a few of the options presented in Figure 9-1 are sensible 
                                                 
4 “Value capture”, as used in business strategy argot, refers to the fraction of the value created that a 
business manages to retain for itself. The remaining portion of the value is captured by the competition and 
by the rest of participants in the value chain. For example, licensing a technology early on bears a much 
lower risk than developing a drug and taking it through the FDA approval process. However, a company 
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choices. It is also often the case that the optimal business model evolves and changes as a 
company grows, since the company can acquire new complementary assets.  
  Licensing: Licensing is typically pursued for innovations developed in academic 
labs, since the complementary assets do not have to be developed or bought. While 
licensing is a component of many hybrid models that are being pursued by companies in 
the AmP and antiinfectives space, it rarely is the case that a company licenses only its 
core technology. In general, licensing is sought on proof of concept products.  
Life Science Technology Company (LSTC): LSTCs in the AmP space can be 
built around IP (IP around technology platforms or IP around compounds), products, and 
services (e.g., contract research). LSTCs built around selling information (e.g., data 
mining) also exist but are less common. An example of an LSTC in the AmP space is 
Polymedix Inc., which has a computational platform licensed from the University of 
Pennsylvania to generate proprietary crystal structures of membrane-bound protein 
receptors.  
Drug Development Company: Becoming an integrated drug development 
company from R&D to marketing and sales is an unrealistic scenario. However, in many 
cases, companies have started by licensing a technology or offering a service and then 
transitioned to a hybrid business model that includes development of their own drug 
candidates. Companies choose to in-license drugs to strengthen their portfolios in certain 
therapeutic areas (e.g., Cutanea Life Sciences), out-license drugs, and in some cases, sell 
option agreements for their IP (e.g., Genaera with Dupont). Partnerships with 
pharmaceutical companies usually provide the startup company with immediate cash, 
access to expertise and resources around the FDA regulatory process, and access to 
distribution channels. Typically, the pharmaceutical company makes an upfront payment 
and attaches further milestone payments to the progress of the technology or product 
developed by the startup. If a product is successfully marketed, the licensor receives 
royalties.  
                                                                                                                                                 
licensing a technology that will yield a marketed drug will have to share the profits generated by the drug 
with its downstream partners (manufacturing, distribution, marketing, and sales). 
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Figure 9-1:  Value capture as a function of the risk incurred for several business 
models 
9.6.2 Recommended Business Model 
A suitable business model would be a hybrid model whereby: 
• Initally, a partnership is seeked to perform contract research on another 
company’s drug candidates using the existing technology platform. 
• The early revenues obtained from the collaboration and from government grants 
are used to perform the additional experiments necessary to validate the 
technology platform, and to jumpstart internal development of 1 or 2 drug 
candidates in the antiinfectives area. The expertise and credibility gained through 
the collaboration is leveraged to validate the technology platform and obtain a 
higher valuation in a first round of venture capital funding or in an equity 
placement by a pharmaceutical company.  
The internal drug candidates could be taken through the preclinical stage, which would 
involve performing absorption, distribution, metabolism, excretion, and toxicity tests in 
animal models. These tests typically last for approximately 1 year. Thereafter, the costs 
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for clinical trials may be prohibitive and it may be best to seek partnerships with 
pharmaceutical companies, at least for Phase III trials and possibly for Phase II as well. 
The partners of choice would help navigate the complicated and bureaucratic FDA 
approval process, and provide marketing and sales expertise once a drug was approved. It 
would also be necessary to seek a manufacturing partner. Peptide manufacturing is a 
relatively competitive business, and therefore it should not be excessively difficult to 
obtain good terms in a partnership. Since the competitive advantage of the technology is 
not related to the manufacturing process of the peptides, granting the manufacturing 
rights to an outside party should not be a major cause of concern.  
The following support the choice of this business model: 
• First, the inventors have already been approached by a pharmaceutical company 
interested in using the technology platform to optimize one of its products. A 
research contract with this company not only would offer early access to cash, but 
would also be an ideal showcase for validating the technology platform. It is 
likely that investors such as venture capitalists would assign more credibility to 
the platform if it were validated using somebody else’s compound (they may be 
suspicious of a platform validated using one’s own compounds, since these could 
have been carefully selected to portray the technology in the best possible light). 
On the downside, exclusivity issues would have to be dealth with carefully, and 
the the two parties would need to agree clearly on what terms would establish the 
termination of the collaboration.  
• Second, the current source of competitive advantage is the IP around the peptide 
design platform. This asset can be leveraged best in the preclinical R&D 
operations. The company does not have the complementary assets needed to bring 
a drug through clinical trials and to the market; it would be necessary to rely on 
other parties. 
9.6.3 Technology Platform vs. Product 
Why not stay purely as a technology platform, as opposed to venturing into drug 
development? It makes sense to start purely as a technology platform doing contract 
research for pharmaceutical clients, since this is the main source of competitive 
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advantage and the team has no expertise in drug development. However, in the long term, 
contract research platforms have rarely worked as a standalone business. [14] 
Furthermore, since early-stage drug development is very risky, investors place very low 
valuations on early stage drug development companies with a technology platform unless 
they have a product in clinical trials. Capital markets, finding it difficult to compare and 
valuate different platforms, have become fixated on clinical trials as a valuation metric 
for progress; as a result, the valuation assigned to enterprises has become largely a 
function of the net present value of its leading drug candidates. [15] Furthermore, 
pharmaceutical companies have, by and large, stopped doing collaborations with startups 
that have technology platforms but no products. 
9.6.4 The First Partnership 
Ideally, the first partnership could be in place this year if the ongoing conversations with 
a pharmaceutical company are formalized. The partner would most likely offer an upfront 
payment to cover the research costs in exchange for services to optimize one of its 
compounds. Although it is unlikely that royalties on the drug could be obtained, [8] the 
partnership would still offer an attractive avenue to validate the technology platform, and 
would constitute most of the company’s operating revenue during the first years of 
operation. PharmOptima is an example of a company in the antiinfectives area that has 
supported its Gram-negative discovery program through contract research contracts with 
partners and also through government funds. 
9.6.5 Future Partnerships 
A successful collaboration with the first partner would open the possibility for further 
partnerships. Possible candidates could be companies in the antiinfectives area that have 
a major patent about to expire or companies that have had to abandon once promising 
peptide compounds because of unwanted side effects. In both cases, development of 
improved variants using the peptide design method could be an attractive option.  
 
      158 
9.7 Competition and Competitive Advantage 
9.7.1 The Competition 
Several companies have peptide therapeutics development programs. Nearly half of them 
have a focus on antimicrobials (shown in boldface in Table 9-3). The rest have programs 
in cancer, inflammation, immune diseases, cardiovascular diseases, osteoporosis, 
artherosclerosis, and HIV. The main competitors with alternative technology platforms 
for the development antimicrobials are:  
Ansata Therapeutics, Inc.: Ansata has an AmP technology platform to develop new 
therapeutics for dermatological applications. The company seeks to develop and 
commercialize technologies that allow drug molecules to effectively penetrate into cells 
and target the drugs specifically to the nucleus. 
Arris Pharmaceutical: Arris develops computer-enhanced peptide therapeutics. It 
follows a structure-based, rational design approach which combines molecular biology, 
x-ray, crystallography, NMR, combinatorial chemistry and artificial intelligence. 
Inimex Pharmaceuticals, Inc.: Inimex has a technology platform for the development of 
drug therapies that control the innate immune response. The company is currently 
validating is platform testing compounds in animal models.  
Migenix, Inc.: Migenix develops and commercializes drugs in the areas of infectious and 
degenerative diseases. Its most advanced clinical program is in Phase III.  
Polymedix: Polymedix’s technology platform generates proprietary crystal structures of 
membrane protein receptors and novel drug designs that mimic proteins. Its leads are 
non-natural peptides that mimic the structure of magainins. Its platform has been 
validated showing activity of the lead compounds and satisfactory pharmacokinetics.  
SelectX Pharmaceuticals, Inc.: Operates a platform technology based on combinatorial 
genetics, directed evolution and target screening.  
Other important competitors developing antimicrobials with less of a focus on a 
technology platform are: 
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Agennix: Develops lactoferrin, a natural human protein with antimicrobial properties. 
The company has core clinical programs in oncology and respiratory disease, and a 
number of additional indications in development. Its most advanced compound is in 
Phase II clinical trials.  
AM-Pharma: Develops lactoferrin-based peptides. The company operates in the 
segments of lipopolysaccharide -mediated diseases and infections of viral, fungal and 
bacterial origin. 
EntoMed SA: Develops insect-derived AmPs.  
Genaera Corporation: Develops therapeutic products for the treatment of infectious 
diseases by isolating therapeutic compounds from animals.  
Novozymes A/S: Has isolated and developed the peptide plectasin from a fungus. This 
peptide has shown promise for the treatment of systemic infections.  
Pacgen Biopharmaceuticals: Develops innovative peptide therapeutics the treatment of 
infectious diseases and immune system diseases.  
Rx3 Pharmaceuticals, Inc: Applies structure-based drug design technologies to 
antimicrobial programs.  
Xoma, Ltd.: Develops and manufactures recombinant proteins and peptides, in 
partnership with large pharma companies. Its most advanced compound is in Phase III. 
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Company Name Country Status Founded
Amount 
Invested         
($ millions)
Agennix, Inc. US Active Investment * 49.6
Alba Therapeutics Corporation US Active Investment 2004 42.5
AM-Pharma Holding BV Netherlands Active Investment 2000 13.0
Ansata Therapeutics, Inc. (FKA: Rubicon Pharm. Inc) US Active Investment 2002 5.5
Aphton Corporation US Went Public 1981 14.8
Arizona Engineered Therapeutics Inc. (aka; AzERx) US Pending Acquisition 2003 0.2
Arris Pharmaceutical US Went Public 1989 35.2
Biointerface Technologies, Inc. US Active Investment 1987 0.2
BioLineRx Ltd.  (FKA: Bioline Therapeutics) Israel Went Public 2003 24.0
Celtrix Pharmaceuticals, Inc. (FKA: BioGrowth) US Went Public 1983 42.8
Chemokine Therapeutics, Inc. (FKA: PTM Mol. Biosys.) Canada Went Public 1998 1.8
Connetics Corp. US Went Public 1993 55.6
COR Therapeutics, Inc. US Acquisition 1988 20.7
Diatide, Inc. (FKA: Diatech, Inc.) US Went Public 1990 41.7
Digilab BioVisioN GmbH (FKA: BioVisioN AG) Germany Acquisition 1997 29.6
Discovery Laboratories, Inc. US Went Public 13.2
EntoMed SA France Defunct 1999 26.0
Genaera Corporation (FKA: Magainin Pharmaceuticals) US Went Public 1987 18.1
Immune Response Corporation (The) US Went Public 1986 26.9
InfiMed Therapeutics, Inc. US Acquisition 1998 32.0
Inimex Pharmaceuticals, Inc. Canada Active Investment 2001 11.6
Migenix, Inc. (FKA: MitoKor) Canada Went Public 1993 0.0
NanoBio Corporation US Active Investment 10.0
Nobex Corporation (FKA: Protein Delivery) US Bankruptcy - Ch.11 1993 90.5
Pacgen Biopharmaceuticals Corporation Canada Went Public 0.0
Pasteur Merieux Serums & Vaccins (AKA: PMs&v) France Acquisition 0.3
Proteolix, Inc. US Active Investment 2003 40.8
RedCell, Inc. US Acquisition 1993 10.1
Rx3 Pharmaceuticals, Inc. US Active Investment 2004 1.4
Schering-Plough Corporation US Went Public
SelectX Pharmaceuticals, Inc. US Active Investment 2002 8.0
Trimeris, Inc. (FKA: SL-1 Pharmaceuticals, Inc.) US Went Public 1993 38.3
Westgate Biological Ltd. Ireland Active Investment 0.0
Xigen SA Switzerland Active Investment 2002 21.2
Xoma, Ltd. UK Went Public
Table 9-3.  Competitors with peptide therapeutic development programs 
(companies in boldface have antimicrobial programs).  
Source: VentureXpert 
The average amount invested in the group of companies presented in Table 9-3 (before 
they went public, or to date if they are private) is $22 million. The average amount 
invested in the subgroup of companies focusing on antimicrobials is slightly lower, at 
$13.5 million. 
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9.7.2 Competitive Advantage 
The main advantages of the technology are: 
Ability to explore a much larger portion of the peptide sequence space than the 
competition. The approaches followed by the competitors are limited to the study of 
peptides encountered in nature or to incremental modifications of existing peptide 
sequences. As a result, the sequence space they can explore is only a minuscule fraction 
of all the possible combinations of aminoacids, most of which are non-natural.  
Less laborious than existing methods. Current methods require laborious screening of 
organisms for the presence of novel AmPs. Instead, large numbers of new peptides with a 
high probability of efficacy can be quickly synthesized with the present method.  
Ability to quickly scan a diverse library of AmPs to respond to the emergence of a 
bioterror threat. Many companies have a library of variants of 1 or 2 molecules, but they  
do not cover a very diverse space, which would be important fighting a new pathogen.  
 
9.8 Development Plan 
9.8.1 Main Risk-Mitigating Steps During Year 1 
Initially, a licensing agreement with the MIT Technology Licensing Office (TLO) will be 
necessary in order to secure the rights to pursue the commercialization of the technology 
platform. The MIT TLO usually takes an equity stake, a deferred payment, and around 
5% on royalties on sales.  
Following the licensing agreement with the TLO, the team will complete a series of 
experiments directed at eliminating the risk associated with the design tool and at 
validating the technology platform before seeking a first round of investment (Figure 9-
2). The following experiments will be funded with research grants in collaboration with 
the Stephanopoulos laboratory at MIT:  
• Characterization of the activity of all known linear AmPs against the most 
clinically relevant bacterial targets. This will allow weighting of the AmPs in the 
motif discovery tool to favor those most likely to offer the desired activity spectra 
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(the work carried out to date has used as a starting point a published list of AmPs 
that did not include information on activity spectrum and toxicity [16] ). 
• Characterization of the in vitro toxicity of the AmPs by performing hemolysis 
tests on red blood cells. This will allow to filter out the motifs associated with 
human toxicity from the motif discovery tool  
A database with increasingly powerful and selective lead sequences will be developed by 
incorporating the outcomes of these experiments to the motif discovery tool.  
 
Figure 9-2:  Proposed development plan for the first year of operations 
 
 
9.8.2 Key Milestones after Year 1 
After the risk mitigation steps proposed in Figure 9-2 are met, an injection of capital of 
around $1 million (500 K in equipment) will be necessary to scale up the technology 
platform. Assuming that at this point the platform has been validated and development on 
one or more drug candidates has started, it may be possible to attract a first round of 
investment. Revenues from a possible research contract with a pharmaceutical company 
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or additional research grants (e.g., SBIR grants) may be a financial alternative to sustain 
the business.  The key milestones through the next round of funding will be: 
• Creating a scaled-up process that integrates all the different design, synthesis, and 
analysis steps, which would be capable of testing tens of thousands of sequences a 
year. 
• Signing 2 to 3 additional corporate partnership agreements to generate leads for 
other companies or optimize their existing compounds.  
• Hiring a management team with the necessary expertise to lead a drug candidate 
through the drug approval process. Hire a strong chemistry group for the internal 
drug development program.  
• Creating a product pipeline that looks appealing to future investors. Have at least 
one drug candidate in clinical trials by the time a second investment round is 
needed. This second round of investment could come from venture capitalists or 
from a partner in the pharmaceutical industry (e.g., Novozymes took its 
compound plectasin through Phase I clinical trials and then sought a partner for 
further development).  
 
9.9 Risks 
The most important risks that the company will be exposed to are:  
Product risk:  there is a risk that a drug product cannot be created. This risk is inherent to 
most biotechnology enterprises and part of doing business in this area.  This risk is 
mainly driven by uncertainty around the technology. It is generally accepted [17] that the 
main hurdles that have prevented the success of AmPs in the past have been 
manufacturing, delivery, low metabolic stability, and in vivo toxicity:  
• Manufacturing by chemical synthesis can be prohibitively expensive for large 
peptides. The company’s technology offers the freedom to keep the peptide 
sequences relatively short (~20 aminoacids). Peptides of size in the vicinity of 20 
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aminoacids would have a cost of goods sold of approximately $400/gram when 
manufactured by chemical synthesis.  [17] 
• Delivery through patient-friendly routes has proven difficult for AmPs. Other 
companies have bypassed this problem by focusing on topical applications instead 
of pursuing a systemic or oral delivery route.  
• Metabolic stability is low because peptides are degraded by a variety of proteases. 
Other competitors seem to be better positioned to address this issue. Lytyx and 
Helix Biomedix are addressing it explicitly by creating small peptides with low 
charge and with chemical groups that protect them from degradation.  
• AmP candidates that have shown promise in vitro could be toxic in vivo. With the 
exception of daptomycin, despite promising in vitro results, AmPs have not 
shown good efficacy in animal models. Transforming the leads obtained with the 
motif discovery method into drugs that work in vivo will be on of the most 
challenging aspects of the business and will require hiring expert personnel and 
partnering. 
Market risk: the market risk for antibiotics is inexistent because there will always be 
consumers that need them. However, it is still unclear what the market acceptance of 
AmPs will be like. It is expected that reimbursement policies for AmP-based antibiotics 
will be more favorable than for existing families of antibiotics, as long as they fulfill their 
promise of not eliciting bacterial resistance. It will most likely be the case that when 
AmPs are widely commercialized no resistance emerges. Experiments have shown that 
resistant mutants are unlikely to emerge, and when they actually emerge, they have 
severely decreased viability that makes them unlikely to survive. [18] However, it is still 
unclear whether mutants will emerge to non-natural peptides. Existing natural peptides 
do not cause new selection pressure, because the resistance mutations that could occur 
already occurred. [18] Slightly modified, or non-natural peptides might entail some new 
selection pressure. However, mutants to combinations of peptides, whether natural or 
non-natural, are very unlikely to emerge.  
Partner risk: the exodus of Big Pharma from the antibiotics space has left a void in 
expertise in downstream activities such as marketing and sales. This will make it difficult 
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for small companies to find partners that can give them resources to support costly 
clinical trials or access to distribution channels.  
Regulatory risk: the FDA is considering proposing placebo-based clinical trials or 
superiority trials instead of the current standard of non-inferiority trials. This would make 
it more difficult for an antibiotic to satisfy an efficacy endpoint in a clinical trial and 
would scare investors. [13] 
People risk: hiring and retaining management with deep expertise in drug development 
will be crucial. Having access through the Scientific Advisory Board to Michael Zasloff, 
one of the world’s experts in development of AmPs, may help establish contacts with 
industry professionals.  
Financial risk:  there is a risk that the company will not be able to secure to funding 
needed to complete the validation of the platform. Platform companies often have 
insufficient resources to develop both a product and a platform, and risk doing a poor job 
at both. [15]  By focusing the efforts during the first year only on validating the platform, 
some of this risk should be mitigated.  
Competitive risk: A blocking patent application on both the methodology and the range 
of compositions within the design space (product by process) has been filed. Still, there is 
an obvious risk that competitors may devise superior methods of developing AmPs.  
 
9.10 Financing 
9.10.1 Financing Strategy 
Research grants will be sought to fund the first year of development at MIT, after which 
the team expects to have convincing data to pitch the start up opportunity to the investor 
community.  
During the first year of operations, financing options include SBIR grants and upfront 
payments from contract research work. The National Institutes of Health (NIH) and the 
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Department of Defense (DoD) are the main supporters of antibacterial development 
programs.5  
Typically, financing for technology platforms has involved the following steps: [15]  
• Raise a Series A of $3 to $5 million (after transferring the technology from the 
academic institution where it was developed, and identifying areas for R&D).  
• Raise a Series B of $15 to $20 million (after securing partnerships and 
collaborations and initiating internal development of drug candidates). 
• Raise a Series C of  $20 to $50 million, which is usually the last round before 
exit.  
Lately, this model has changed because pharmaceutical partners and investors are no 
longer interested in partnering or investing until a platform has been validated. This 
transfers all the early risk before the delayed Series A to the company founders.   
9.10.2 Exit Opportunities 
Companies in the antibiotic space have realized exits both through public offerings and 
through acquisition. A detailed list of valuations of public, private, and acquired 
companies is presented in Figure 9-3 and in Table A in the appendix. Figure 9-3 shows 
that valuations depend strongly on the clinical phase of the company’s leading drug 
candidate (for private companies, the valuation corresponds to the amount invested; for 
public companies, to the current market capitalization; for acquired companies, to the 
acquisition price). Figure 9-3 also shows that acquisitions in the antibiotic space are 
unlikely at an early stage. Possible acquirers consider early stage companies in this area 
too risky an investment. In general, acquirers look for target companies that have 
products in the market, since that can help boost their revenues right away and meet the 
growth expectations from their shareholders. Companies that have promising technology 
platforms but no product in clinical trials (e.g. Polymedix, Helix Biomedix, Ansata) are 
unlikely acquisition targets. The figure also shows that from preclinical studies to Phase 
                                                 
5 Anadys Pharmaceuticals received a $1.2 million NIH SBIR grant in 2004 to develop antibacterials. In 
October 2006, the DoD awarded $24.7 million to Achaogen for a program to develop a treatment for 
anthrax 
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II, with few exceptions, most companies stay private, and that from Phase III onwards 
most companies go public. This can be due to two factors: first, public markets only place 
attractive valuations on companies that have eliminated most of the risk associated with 
clinical trials; second, in order to raise the substantial amounts of cash needed to manage 
Phase III trials and market a drug, companies can no longer rely on private investors and 
look for funding in the public markets.  
Figure 9-3:  Valuations of public, private, and acquired companies in the 
therapeutic peptide and antibiotic spaces as a function of the clinical phase of their 
leading drug candidate 
 
Exits through public offerings: Antibiotic companies that have exited through public 
offerings have, today, a median market capitalization value 3.5 times larger than the 
amount that was invested in the company before it went public (Table A in the 
Appendix). In other words, the most common return for private investors that kept their 
stock when the company went public is x3.5).  
0
1
10
100
1000
10000
100000
clinical phase of the leading drug candidate
va
lu
at
io
n 
($
M
M
)
Public Companies
Private Companies
Acquisitions
preclinical   phase1   phase2     phase3     NDA       approved
Agennix
AM PharmaAnsata
Ceragenix
Genaera
Helix
Biomedix
Migenix
Polymedix
va
lu
at
io
n 
($
M
M
)
      168 
Exits through acquisition: Antibiotic companies that have been the target of acquisitions 
have received acquisition premiums in the range of x2.5 to x52.8. Table 9-4 shows a 
selection of recent acquisitions in the antibiotics space including the acquisition premium 
multiples (ratio of the price paid by the acquirer over the amount invested in the target 
company before being acquired). The multiples range from x2.5 to x52.8. The average 
time to exit for the group of companies presented was 7.8 years, which is on the long end 
for venture capital investments. However, these companies are not ideal comparables 
because they are not purely focused on the AmP space; however, they are the closest 
approximation we can get given the fact that no acquisitions of “pure-play” companies 
focused on AmPs have occurred yet.  
Table 9-4. Selected information on acquisitions in the antibiotics space.  
Target name Acquirer name
Date 
announced
Phase of 
leading 
candidate
Amount 
invested  ($ 
millions)
Deal value   
($ millions)
Deal value / 
Amount 
invested
OraPharma, Inc. Johnson & Johnson 11/14/2002 approved 33.9 85 2.5
Peninsula Pharm., Inc. Johnson & Johnson 6/30/2005 3 88.26 245 2.8
Cerexa, Inc. Forest Laboratories 1/11/2007 2 50 480 9.6
Connetics Corp. Stiefel Laboratories 12/28/2006 approved 55.55 640 11.5
COR Therapeutics, Inc. 
(acquired by Millenium) Millenium 2/12/2002 approved 20.65 1090 52.8  
Source: VentureXpert and Internet research  
Figures 9-4 and 9-5 show box plots of company valuations organized by clinical phase of 
the company’s lead drug candidate, for both companies in the general antibiotics space 
and companies focusing on peptide therapeutics. Table 9-5 summarizes the statistics in 
Figures 9-4 and 9-5. It can be seen that, at each clinical phase, valuations on companies 
focusing on therapeutic peptides are substantially lower than valuations on companies 
focusing on the general category of antibiotics (which includes also all companies 
pursuing traditional, chemistry-based antibiotic discovery). It appears that both the public 
markets and private investors apply a discount factor to companies pursuing therapeutic 
peptide-based approaches, and that this discount factor gets larger as the drugs progress 
through the clinical phases. When the drugs are in preclinical stages, investors do not 
seem to differentiate between the two types and consider both just as risky (compare the 
mean valuations of $15 million vs. $18 million in Table 9-5). In Phase I, valuations on 
peptide-based drug command a 45% discount ($74 million vs. $41 million), in Phase II, a 
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67% discount ($92 million vs. $30 million), and in Phase III an 83% discount ($219 
million vs. $38 million). This is consistent with the general view, held among industry 
professionals, that the investment community is still skeptical about the promise of 
therapeutic peptides – perhaps rightly so, given the lack of successes to date. Some 
industry professionals believe that the outlook for the therapeutic peptide business, and 
more specifically for AmPs, will change drastically once (or if) the compounds currently 
in Phase III get FDA approval. [19]  
Table 9-5. Summary statistics of valuations as a function of the clinical phase of the 
lead drug candidate for companies in the antibiotics space and for companies 
focusing on therapeutic peptides 
Companies in the antibiotic space
Preclinical Phase I Phase II Phase III NDA Approved
Sample size 32 8 19 13 2 13
Mean valuation ($ million) 15 74 92 219 971 535
standard deviations ($ million) 23 45 108 443 1186 645
Companies focusing on therapeutic peptides
Preclinical Phase I Phase II Phase III NDA Approved
Sample size 9 1 6 3 4 3
Mean valuation ($ million) 18 41 30 38 45 191
standard deviations ($ million) 11 NA 20 22 61 170
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Figure 9-4:  Box plots of the valuations of companies in the antibiotics space as a 
function of the clinical phase of their lead candidate 
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Figure 9-5:  Box plots of the valuations of companies in the therapeutic peptides 
space as a function of the clinical phase of their lead candidate.6 
                                                 
6  Connetics and COR Therapeutics, which were acquired respectively for $640 million and $1090 million, 
are not included in the chart since they had multiple other development programs that obscure the 
comparison 
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9.10.3 Who are the Likely Buyers? 
The company could achieve an exit through acquisition by a market leader in the 
antibiotics space looking to strengthen its antibiotics portfolio, or looking to make up for 
lost revenues in mature products with expired patents. The key market players in the 
antibiotics market are Pfizer and GlaxoSmithKline (GSK). Other important players are 
AstraZeneca, Merck, Eli Lilly, Johnson&Johnson, Merck, and Wyeth. Both Pfizer and 
GSK could be potential acquirers; Pfizer dominates the market with strong products like 
Zyvox and Zithromax. Its merger with Pharmacia expanded its hospital antibiotics 
portofolio, and currently it has an important collaboration with Vicuron Pharmaceuticals. 
GSK ranks second in sales but many of its products are mature and facing strong pressure 
from generics. Since GSK’s pipeline does not have any products in advanced clinical 
phases, GSK will be looking for acquisitions if it wants to maintain a presence in this 
market.  Some key patent expirations that might lead to acquisition activity are presented 
in Table 9-6. 
There is also a second tier of smaller companies that are building deep portfolios, 
including Vicuron Pharmaceutica, Basilea Pharmaceutica, and Cubist Pharmaceuticals, 
that could be possible acquirers.  
Table 9-6.  Key patent expirations of antibiotics 
Compound  Company Expiration 
Avelox  Bayer 2009 
Cipro  Bayer 2004 
Levaquin Ortho-McNeil 2010 
Tequin (recalled in 2006) GSK 2007 
Ivanz Merck 2013 
Merrem AstraZeneca 2010 
Zyvox Lytix Biopharma AS 2014 
Zythromax Migenix 2005 
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9.11 Go / No Go 
If the main risk-mitigating development steps outlined in section 9.8 are completed 
satisfactorily, the opportunity to seek investment and start a business should be 
considered. At that point, the essential requirements to make this business successful 
would be in place: an urgent market need, a promising technological innovation with 
adequate IP protection, and a very strong team of people that have the entrepreneurial 
passion needed, that will be able to inspire it in others, and that have surrounded 
themselves with some of the World’s leading experts in the field. Still, the downsides 
merit a sober examination (Figure 9-6):  
Figure 9-6:  Arguments in favor and against of pursuing the business opportunity 
First, a multi-drug resistant superbug epidemic has not yet hit, and thus far 
pharmaceutical companies have managed to tweak the existing families of antibiotics to 
meet the growing resistance problem. However, the specialists predict that this will 
indeed become a real problem, and then there will be no issue as to whether AmPs must 
be developed aggressively. AmPs will not only mitigate the resistance issue, but will also 
enjoy higher margins in the market than conventional antibiotics because they are not 
“me- too” products, and can therefore benefit from higher reimbursements. 
Second, large pharma incumbents have historically had strong advantages over 
newcomers in the antibiotics area. They have the toxicology knowledge and the 
Very strong advisory group and energetic team
Have started industry dialogue
Broad, blocking patent applications on both 
methodology and range of compositions within 
design space (Product by process)
When resistance becomes a real problem, there 
will be no issue
Go
Remaining technological hurdles:
• Manufacturing
• Stability
• Delivery
Incumbents have strong advantages over 
newcomers:
• Ease of development 
• Toxicology knowledge
Reality test: 
• A multi-drug-resistant superbug epidemic has 
not yet hit
• There are still enough traditional antibiotics that 
can be tweaked to meet the growing resistance 
problem. 
No-go
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development skills to turn around new drugs quickly. Large pharma companies have 
gradually abandoned the antibiotics field in order to focus on the more lucrative chronic 
diseases, which fit better their business model. However, competition is still intense 
because there are a large number of smaller companies in the area (Table 9-3). 
Third, several technological hurdles still remain, including high manufacturing costs, low 
metabolic stability of AmPs, and the need for novel delivery techniques that allow 
systemic administration (Figure 9-7). Although no competitor has addressed all these 
hurdles, some competitors have distinctively targeted some. For example, Polymedix has 
addressed the issue of high manufacturing cost of peptides by using cost-effective 
starting materials, and the issue of low metabolic stability by making small AmPs that are 
less prone to protease degradation. AM-Pharma and Inimex have addressed the issue of 
in vivo toxicity by stimulating the host to combat pathogens using small, non-toxic 
fragments of AmP analogs. The technology platform presented in this work would partly 
address the manufacturing issue, since the size of the non-natural peptides synthesized 
can be decided at will (and therefore be kept small enough to make manufacturing by 
chemical synthesis feasible). It is unclear whether the stability issue would be addressed; 
it has been suggested that non-natural sequences may be more stable to degradation. [17] 
It would not address the delivery issue, but this would not be a factor preventing the 
introduction of a product in the market (an oral antibiotic is ideal, but if need be, doctors 
can administer it by injection).  
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Figure 9-7:  Main technological hurdles restraining the progress of AmPs.  
 
9.12 Under What Roof? 
The SteriCoat team will face the decision of whether this technology should be pursued 
under SteriCoat’s organizational structure, as its therapeutics arm, or as an independent 
business.  
I believe the best approach would be to have the SteriCoat team manage the validation of 
the technology platform throughout the first year of experimentation, and then hire an 
expert management team in drug development and spin it off as a separate business.  
Initially, there are benefits in validating the technology at SteriCoat. First, the inventors 
of the technology, currently managing SteriCoat, would work directly on the 
development. Second, the invention has a direct application to SteriCoat’s main line of 
business: newly synthesized AmPs can be tethered to medical devices using SteriCoat’s 
coating technology. The biggest problem with this approach is that working on validating 
the technology will divide the focus of the SteriCoat management team at a time when 
they will have their hands full with the medical device business. The alternative, 
however, is to expect a third party to acquire the technology and develop it, which would 
not bring much value to the SteriCoat founders since acquirers will not be willing to pay 
a good price until it is validated.  
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After the platform is validated, it will be best to hire an expert management team in drug 
development and spin it off as a separate business. This new management team should 
identify the best therapeutic application for the technology and pursue it. The current 
SteriCoat team would have the wrong skill set at this stage. Separation is convenient 
because SteriCoat may have insufficient resources to pursue both the medical device 
business and the drug development business, and risks doing a poor job at both. It is also 
convenient because the very high cost and complexity of developing a drug would force 
the drug development business to focus on one single product, [15] exposed to a high 
likelihood of failure in the clinical trials. If trials did fail and the two businesses had not 
been separated, the next round of financing would be a down round that would wash out 
the SteriCoat founders and put the medical device business in jeopardy as well. The 
drawback of separating the businesses is that the SteriCoat founders have to surrender the 
control of the technology platform, which might in fact have a higher upside market 
potential than the medical device business.   
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9.13 Appendix  
Table A: Valuations of public, private, and acquired companies in the antibiotics 
and therapeutic peptides space as a function of the clinical phase of their leading 
drug candidate.  
Company Name
Phase of 
leading 
candidate Status
Amount 
Invested       
($ millions) 
Market Cap    
(for public 
companies)    
($ millions)
Acquisition   
Price              
($ millions)
Acambis (FKA: OraVax, Inc.) 2 Public 40.3 147.5
Achaogen, Inc. preclinical Private 42.28
Achillion Pharmaceuticals, Inc. preclinical Public 120.86 105.4
ActivBiotics Canada, Inc. 3 Private 10
ActivBiotics, Inc. (FKA: Merlin Technologies, Inc.) 2 Private 53.34
Adaptive Therapeutics, Inc. NA Private 9
Advanced Life Sciences, Inc. 3 Public 11.47 85.06
Advanced Viral Research 3 Public 22.29
Advancis Pharmaceutical Corp.  2 Public 99.76 112.52
Aegis Pharmaceutical, Ltd. NA Private 0.36
Affinity Biotech, Inc. defunct Public 1.4
Affinium Pharmaceuticals (FKA: Integrative Proteomics, Incpreclinical Private 36.15
Agennix, Inc. 2 Private 49.57
AgION Technologies, Inc. NA Private 27.7
Alba Therapeutics Corporation 2 Private 42.45
Allelix Biopharmaceuticals 3 Private
Allergan approved Public 16840
Alpharma Inc. (FKA: A.L. Laboratories, Inc.) NA Public 0.13
Amoebics   preclinical Private 0
AM-Pharma Holding BV 2 Private 12.95
Amura Therapeutics Limited preclinical Private 0
Anamax, Inc. NA Private 0
Ansata Therapeutics, Inc. preclinical Private 5.5
Aphton Corporation 3 Public 14.75 0.154
Ardea Biosciences, Inc. NA Public 86.15
Arizona Engineered Therapeutics Inc. (aka; AzERx) preclinical Private 0.21
Arpida Ltd. 3 Public 99.09 209
Arris Pharmaceutical preclinical Acquisition 35.15
Ash Access Technology, Inc. NA Private 15
Athelas SA (Merge w/ Merlion Pharma) preclinical Merger 2.36
Basilea Pharmaceutical 3 Public 1647
Biointerface Technologies, Inc. NA Private 0.17
BioLineRx Ltd.  (FKA: Bioline Therapeutics) preclinical Public 24
Bionest Company, Ltd. NA Private 0
Biophage Inc. preclinical Acquisition 0.47
BioRelix, Inc. preclinical Private 0.25
Biovertis AG preclinical Private 21.21
Celtrix Pharmaceuticals, Inc. (FKA: BioGrowth) NA Public 42.77
Cempra Pharmaceuticals, Inc. 3 Private 14
Ceragenix approved Public 40.4
Cerexa, Inc. 2 Acquisition 50 480
Chaperone Technologies preclinical Private 0
Chem Tech Research, Inc. NA Private 5.28
Chemokine Therapeutics, Inc. 2 Public 1.8
China Chemical Synthesis Industrial Co. Ltd. NA Private
Confarma S.p.A. NA LBO 0
ConjuGon, Inc. preclinical Private 3.3
Connetics Corp. approved Acquisition 55.55 640
COR Therapeutics, Inc. (acquired by Millenium) approved Acquisition 20.65 1090  
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Appendix (continued) 
 
Company Name
Phase of 
leading 
candidate Status
Amount 
Invested       
($ millions) 
Market Cap    
(for public 
companies)    
($ millions)
Acquisition   
Price              
($ millions)
Crea BioPharma Inc. NA Private 0.75
Cubist Pharmaceuticals, Inc. approved Public 36.28 1210
Cumbre Pharmaceuticals, Inc. (FKA:Cumbre Inc.) 1 Private 38.89
Daiichi Sankyo 3 Private
Demegen, Inc. (FKA: Demeter BioTechnologies, Ltd) preclinical Public 4
Diatide, Inc. (FKA: Diatech, Inc.) 3 Public 41.73
Digilab BioVisioN GmbH (FKA: BioVisioN AG) NA Acquisition 29.6
Discovery Laboratories, Inc. NDA Public 13.21 132.4
Elitra Pharmaceuticals, Inc. (FKA: RajyaBiotics, Inc.) defunct Private 45.85
EluSys Therapeutics, Inc. (FKA: E-Site Therapeutics) 2 Private 70.24
Emergent Biosolutions (FKA: Microscience, Ltd.) approved Public 326.85
Enanta Pharmaceuticals, Inc. 2 Private 107.26
EntoMed SA defunct Defunct 25.98
EntoMed SA defunct Defunct 25.98
Entopharm Company, Ltd. NA Private 0.77
Exponential biotherapies 2 Private 37
FASgen, Inc. preclinical Private 0.5
Genaera Corporation (FKA: Magainin Pharmaceuticals) 2 Public 18.11 47.9
Genetic Systems Diagnostics Partners NA Acquisition 2.8
Glykoz Pty Ltd. preclinical Private 43.34
Great Lakes Pharmaceuticals, Inc.  NA Private 0.3
Hedral Therapeutics, Inc. NA Private 0
Hedral Therapeutics, Inc. NA Private 0.08
Helix Biomedix, Inc preclinical Public 17.09
Imagilin Technology, LLC approved Private 0.08
Immune Response Corporation (The) 2 Public 26.9 11.98
InfiMed Therapeutics, Inc. NA Acquisition 31.97
Infusion Systems Corporation NA Acquisition 7.5
Inimex Pharmaceuticals, Inc. preclinical Private 11.64
Innate Pharmaceuticals AB preclinical Public 2.37
Intralytix approved Private
ioGenetics LLC preclinical Private 0.2
Ipsat Therapies Oy 2 Private 19.11
Ivex Pharmaceuticals, Ltd. NA Acquisition 0
Korea United Pharm, Inc. approved Public 0.24
KOSAN Biosciences, Inc. 2 Public 52.54 212.37
Libragen preclinical Private 0.68
LTB4 AB NA Private 0
Lyphomed, Inc. recalled Acquisition 2.38
Lytix Biopharma AS preclinical Private  
Mayne Pharma, Pty. Ltd. (FKA: Faulding FH & Co.) approved Acquisition 0.04
Medication Delivery Devices NA Merger 6.1
Mediphore-Biotechologie AG NA Bankruptcy - C 2.61
Microban International, Ltd. NA Private 65.88
Microbiotix preclinical Private 5
Microscience Ltd. NA Acquisition 62.4
Midway Pharmaceuticals, Inc. preclinical Private 0.57
Migenix, Inc. (FKA: MitoKor) 3 Public 0 57.29
MithraGen, Inc. (FKA: MithraTech, Inc.) NA Private 3.06  
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Company Name
Phase of 
leading 
candidate Status
Amount 
Invested       
($ millions) 
Market Cap    
(for public 
companies)    
($ millions)
Acquisition   
Price              
($ millions)
Morphochem AG NA Acquisition 91.77
Mpex Pharmaceuticals, Inc. (FKA: Mpex BioScience) 1 Private 19.7
Mutabilis preclinical Private 11.25
Nabriva Therapeutics Forschungs GmbH 1 Private 50.82
NanoBio Corporation preclinical Private 10
Nectar Lifesciences, Ltd. (FKA: Surya Medicare Ltd) NA Private 1.37
Neogen Corporation NA Public 6.15
NeuTec Pharma PLC 3 Public 10.1 35.4
Nobex Corporation (FKA: Protein Delivery) NA Bankruptcy - C 90.49
Novacta Biosystems NA Private
Novexel S.A. 1 Private 135.16
Novobiotics NA Private
Novozymes preclinical Public
Oculus Innovative Sciences, Inc. approved Public 55.48 78.8
Optimer Pharmaceuticals, Inc. approved Public 67.25 200
OraPharma, Inc. approved Acquisition 33.9 85
Oscient Pharmaceuticals 2 Public 59.9
Oxoid Holdings, Ltd. NA Acquisition 0
Pacgen Biopharmaceuticals Corporation 1 Public 0
Par Advance Technologies preclinical Private
Paratek Pharmaceuticals, Inc. 1 Private 76.6
Pasteur Merieux Serums & Vaccins (AKA: PMs&v) NA Acquisition 0.32
Peninsula Pharmaceuticals, Inc. 3 Acquisition 88.26 245
Peptide Technologies NA Private
PepTx, Inc preclinical Private
Pharmoptima none Private
Polymedix preclinical Public 30.41
Prolysis, Ltd. preclinical Private 20.77
Pro-Med AG NA Private 7.49
Proteolix, Inc. 1 Private 40.8
Protez Pharmaceuticals 2 Private 26.86
Receptagen Corp (FKA: VitaMed Inc) defunct Private 1
RedCell, Inc. NA Acquisition 10.05
Remedyne Inc. NA Defunct 3.2
Replidyne, Inc. 1 Public 126.5 141.4
Rib-X Pharmaceuticals, Inc. 2 Private 124.5
RNL Life Science NA Private 0.73 9.9
Rx3 Pharmaceuticals, Inc. preclinical Private 1.37
Sam Chun Dang Pharm Co., Ltd. NA Public 0
Schering-Plough Corporation NA Public
SciClone Pharmaceuticals 2 Public 120.26
SelectX Pharmaceuticals, Inc. preclinical Private 7.95
Siga Technologies 1 Public 92.4
Smart Drug Systems, Inc. NA Private 12.79
SoloPak Pharmaceuticals, Inc. NA Private 78.46
Suntory NA Public
Targanta Therapeutics, Inc. (FKA: PhageTech, Inc.) 3 Private 85
Tetraphase Pharmaceuticals, Inc. preclinical Private 10.04 25
Theravance, Inc. (FKA: Advanced Medicine, Inc.) NDA Public 244.58 1810
Trimeris, Inc. (FKA: SL-1 Pharmaceuticals, Inc.) approved Public 38.28 157.5
Trine Pharmaceuticals, Inc. NA Private 87.48
Triosyn Corporation NA Private 6.21
Ulysses Pharmaceuticals Products Inc. preclinical Private 0.19
Vertex Pharmaceuticals, Inc. approved Public 13.54 5060
ViroPharma, Inc. approved Public 13.99 1030
Westgate Biological Ltd. NA Private 0
Xigen SA preclinical Private 21.17
Xoma, Ltd. 3 Public 375.6
Zengen 2 Private  
Note: Public valuations are given by current market capitalizations (2007). Private 
valuations correspond to the amount invested (Source: VentureXpert and Internet 
research) 
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Table B: Minimum Inhibitory Concentrations of designed peptides against bacterial 
targets.   
Class E. Coli (gram negative) 
MIC≤256µ/ml    MIC ≤ 64µ/ml 
B.Cereus (gram positive) 
MIC≤256µ/ml       MIC ≤ 64µ/ml 
E. Coli or     
B. Cereus  
MIC≤256µ/ml 
Designed 16/40                    4/40 8/40                       4/40 18/40 
Shuffled 1/38                      0/38  2/38                      1/38 2/38 
Source: Loose et al., Nature, 443 (19), 2006 
Note: “Shuffled” peptides were peptides randomly selected from the middle of non-
antimicrobial proteins. They are intended to serve as a negative control.  
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